var title_f27_4_27712="Intentional human bite";
var content_f27_4_27712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69917&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intentional human bite",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panels A and B) A 3-year-old boy with human bites on his back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ludwig S. Bites and stings. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27712=[""].join("\n");
var outline_f27_4_27712=null;
var title_f27_4_27713="Ectopic ureter duplex";
var content_f27_4_27713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ectopic ureter of left duplex system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 620px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure demonstrates an ectopic ureter to the upper pole of the left kidney with a duplicated collecting system.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27713=[""].join("\n");
var outline_f27_4_27713=null;
var title_f27_4_27714="Macular stain - face";
var content_f27_4_27714=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F81729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F81729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Macular stain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous patches are present on the forehead and eyelids of this infant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27714=[""].join("\n");
var outline_f27_4_27714=null;
var title_f27_4_27715="Dyshidrotic eczema foot";
var content_f27_4_27715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dyshidrotic eczema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dyshidrotic eczema can present with vesicles on feet, and should be distinguished from acute tinea pedis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27715=[""].join("\n");
var outline_f27_4_27715=null;
var title_f27_4_27716="Pathogenesis hemangioma";
var content_f27_4_27716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Imbalanced VEGFR1 and VEGFR2 function in hemangioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) In normal endothelial cells (ECs), VEGF binds to VEGFR1 with higher affinity than to VEGFR2. VEGFR1, which is expressed both as soluble and transmembrane forms, acts as a sink for VEGF, thereby decreasing VEGFR2 activity and downstream signals for endothelial cells to proliferate. Panel B) Endothelial cells derived from hemangiomas express aberrant multiprotein complexes - containing integrins and mutated variants of VEGFR2 and TEM8 and possibly also other molecular components (indicated by question mark). These complexes decrease the activity of NFAT, resulting in the downregulation of VEGFR1 expression. As a consequence, more VEGF is available to bind and activate VEGFR2, causing enhanced endothelial cell proliferation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: MacMillan Publishers Ltd. Claesson-Welsh, Lena. Healing hemangiomas. Nature Medicine 2008; 14:1147. Copyright &copy;2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27716=[""].join("\n");
var outline_f27_4_27716=null;
var title_f27_4_27717="Nebulizer and spacer use";
var content_f27_4_27717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nebulizer and spacer use",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 548px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Girl using a nebulizer with a mask.",
"    <br>",
"     (B) Boy using a metered-dose inhaler with spacer.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Klossner NJ, Hatfield NT. Introductory Maternity and Pediatric Nursing, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27717=[""].join("\n");
var outline_f27_4_27717=null;
var title_f27_4_27718="Antiribosomal P protein antibodies";
var content_f27_4_27718=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiribosomal P protein antibodies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/4/27718/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27718/contributors\">",
"     Donald B Bloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/4/27718/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27718/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/4/27718/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27718/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/4/27718/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoantibodies directed against three phosphorylated protein (&ldquo;P protein&rdquo;) components of ribosomes are present in a minority of patients with systemic lupus erythematosus (SLE) and are highly specific for this disease. Some studies have suggested that these antibodies may serve as markers for specific disease manifestations, including central nervous system (CNS) disease and hepatitis, but other studies have not confirmed these associations. (See",
"    <a class=\"local\" href=\"#H5856066\">",
"     'Associations with specific manifestations of SLE'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The specificity, clinical associations, and utility of measuring antiribosomal P protein antibodies are discussed here. An overview of antinuclear antibodies and the approach to the diagnosis of CNS disease in SLE are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5816?source=see_link\">",
"     \"Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIBODIES TO RIBOSOMAL P PROTEINS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17463419\">",
"    <span class=\"h2\">",
"     Antigen specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The targets of antiribosomal antibodies found in the sera of some patients with SLE are three highly conserved phosphorylated proteins (P proteins) located on the 60S subunit of ribosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The P proteins, which exhibit molecular weights of 35, 19, and 17 kD, are designated P0, P1, and P2, respectively. The immunodominant epitope in patients with SLE is a shared sequence at the carboxy (C)-termini of the P proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In their native form, the ribosomal P antigens form a pentamer consisting of one copy of P0 and two copies each of P1 and P2. This complex interacts with the 28S ribosomal ribonucleic acid (RNA) molecule to form the ribosomal stalk, including a guanosine triphosphatase (GTPase) domain involved in the elongation step of protein translation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/6\">",
"     6",
"    </a>",
"    ]. Monoclonal antibodies to P proteins inhibit binding of elongation factor (EF)-1 alpha and EF-2 to ribosomes and inhibit protein synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    P proteins were initially identified on ribosomes in the cytoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/9\">",
"     9",
"    </a>",
"    ]; subsequent studies have also documented epitopes recognized by antiribosomal P protein antibodies on the surface of neuronal, hepatoma, and activated T cells in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The binding of antibodies to these proteins on cell surfaces could have pathogenic significance, given evidence that such antibodies can be internalized, resulting in cellular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/6,12\">",
"     6,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17463426\">",
"    <span class=\"h2\">",
"     Antibody detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies to ribosomal P proteins produce a finely speckled cytoplasmic staining pattern on a human epithelioma cell, type 2 (HEp-2) cell substrate using indirect immunofluorescence (",
"    <a class=\"graphic graphic_picture graphicRef59670 \" href=\"UTD.htm?2/36/2628\">",
"     picture 1",
"    </a>",
"    ). In clinical practice, these antibodies may be detected by immunoblot, by enzyme-linked immunosorbent assay (ELISA), or by addressable laser bead assay. In these assays, antibodies may be detected using purified native or recombinant antigen or synthetic peptides. A 22-amino acid peptide shared by the three ribosomal P proteins is the major autoantigenic epitope; this portion of the protein can be used to replace the full-length protein in screening assays, without losing sensitivity or specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/3\">",
"     3",
"    </a>",
"    ]. Another study suggests that excluding amino (N)-terminal epitopes may result in loss of assay sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DISEASE ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical significance of antiribosomal P protein antibodies is their specificity for the diagnosis of SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. These antibodies have not been found in normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ] and are rare in patients with other autoimmune diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported prevalence of antiribosomal P protein antibodies among patients with SLE is quite variable. They were initially detected in 10 to 20 percent of patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/10,14,15,20\">",
"     10,14,15,20",
"    </a>",
"    ]; however, other studies, including adult SLE patients from China and Japan and children from the United States and Argentina, have reported higher rates of prevalence (35 to 50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/19,21-23\">",
"     19,21-23",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An international study involving 11 centers, 947 patients with SLE, and 1113 controls used a mixture of three recombinant ribosomal P polypeptides as the antigenic target in an enzyme-linked immunosorbent assay (ELISA); the sensitivity and specificity of antiribosomal P protein antibodies for SLE were 21 and 99 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/21\">",
"       21",
"      </a>",
"      ]. The prevalence at each individual center ranged from a high of 35 percent for patients from China to 8 percent for patients from Canada. None of 208 normal sera used as controls tested positive. The disease controls with positive tests included patients with rheumatoid arthritis (RA) (3 of 284 patients), patients with systemic sclerosis (SSc) (2 of 131), and one patient each with hepatitis C, mixed connective tissue disease (MCTD), and polymyositis.",
"     </li>",
"     <li>",
"      Another multicenter study, which employed an ELISA using the C22 epitope as the antigenic target, showed similar sensitivity and specificity for SLE of 23 and 99 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/18\">",
"       18",
"      </a>",
"      ]. Testing was negative in healthy blood donors and in patients with RA or Sj&ouml;gren&rsquo;s syndrome (n = 135, 60, and 26, respectively). One patient each with MCTD, limited cutaneous SSc, ulcerative colitis, and polymyalgia rheumatica tested positive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several factors may be responsible for the variability of the prevalence in different populations, including variable ethnic or genetic composition of populations in different studies and differences in regional practice and in patient selection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5856066\">",
"    <span class=\"h1\">",
"     ASSOCIATIONS WITH SPECIFIC MANIFESTATIONS OF SLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential association between the presence of antiribosomal P protein antibodies and specific manifestations of SLE is highly controversial. Antiribosomal P antibodies have been associated in different studies with SLE involving the central nervous system, liver, kidney, and skin. In contrast, other studies have not demonstrated such associations. Some studies have also suggested that these antibodies are markers for SLE disease activity.",
"   </p>",
"   <p>",
"    The same factors that appear to account for differences in the prevalence of antiribosomal P protein antibodies among different groups of patients with SLE are likely to result in the variability in the associations with different clinical manifestations. Additionally, small sample sizes in many of the positive studies described below and differences in methods for detection of antibody may also be important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     CNS disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiribosomal P protein testing has limited diagnostic value for central nervous system (CNS) SLE and is not helpful in differentiating clinical subtypes of CNS SLE. Some studies have suggested an association between the presence of antiribosomal P protein antibodies and neuropsychiatric manifestations of SLE, particularly psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/15,17,19,24,25\">",
"     15,17,19,24,25",
"    </a>",
"    ]; however, other studies do not support such an association [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/18,20,26,27\">",
"     18,20,26,27",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lack of diagnostic utility of antiribosomal P protein antibodies for CNS SLE is supported by a meta-analysis of observational data from 1537 patients with SLE from 14 centers in Europe, Asia, and South America [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/28\">",
"       28",
"      </a>",
"      ]. The presence of antibodies to ribosomal P protein had an overall sensitivity and specificity for neuropsychiatric lupus of 26 and 80 percent, respectively. The sensitivity and specificity were similar for psychosis, mood disorder, or both (27 and 80 percent) and for other diffuse manifestations (24 and 80 percent). Positive testing did not distinguish between different manifestations of CNS SLE, and results between different centers showed significant heterogeneity.",
"     </li>",
"     <li>",
"      In another study involving 116 patients with SLE, no association of antiribosomal P protein antibodies with neuropsychiatric SLE was observed; the sensitivity and specificity of antiribosomal P protein antibodies for neuropsychiatric disease were 21 and 13 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association of antiribosomal P protein antibodies with liver disease has been suggested in several reports, including two small case control studies, following an initial case report of a patient with lupus in whom antiribosomal P protein antibodies were produced soon after the development of chronic active hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study found a higher number of patients with SLE-related liver disease among 20 patients with SLE and antiribosomal P protein antibodies than among controls with SLE but without such antibodies (7 of 20 patients versus 1 of 20 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/30\">",
"       30",
"      </a>",
"      ]. Antibodies to ribosomal P proteins were not found in the sera of 59 patients with autoimmune liver diseases, including chronic active hepatitis, primary biliary cirrhosis, and sclerosing cholangitis in the absence of lupus, suggesting that the autoantibodies were not the result of immune-related hepatic injury.",
"     </li>",
"     <li>",
"      Another report found a higher number of patients with antiribosomal P protein antibodies among patients with SLE-related hepatitis compared with a control group of SLE patients without liver disease (6 of 6 patients versus 2 of 20 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/31\">",
"       31",
"      </a>",
"      ]. Hepatitis was present in only 3 percent of the patients in the large lupus cohort from which most of the patients for the study were drawn.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several large studies have had too few patients with liver disease to draw any firm conclusions regarding this association, and further studies are required for confirmation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/18,32\">",
"     18,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiribosomal P protein antibodies have been associated with the presence and activity of lupus nephritis in several mostly small studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/30,33-35\">",
"     30,33-35",
"    </a>",
"    ]; however, other reports have failed to confirm these observations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/15,20,27,32\">",
"     15,20,27,32",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An international multicenter study of 333 patients with SLE and 397 controls found no association of antiribosomal P protein antibodies with nephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/18\">",
"       18",
"      </a>",
"      ]. A single center study from North Africa of 200 patients with SLE and 130 controls also found no association with renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One study found a higher number of patients with SLE-related renal disease among 20 patients with SLE and antiribosomal P protein antibodies than among controls with SLE but without such antibodies (14 of 20 patients versus 4 of 20 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/30\">",
"       30",
"      </a>",
"      ]. In other studies, levels of antiribosomal P protein antibodies fluctuated with the activity of renal disease and correlated with the anti-double-stranded deoxyribonucleoprotein (anti-dsDNA) antibody titer [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. In one report, antiribosomal P protein antibodies were primarily associated with membranous lupus [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Skin disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous manifestations of SLE have been associated with antiribosomal P protein antibodies in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/20,27,36\">",
"     20,27,36",
"    </a>",
"    ]. As an example, in an Italian multicenter study of 149 consecutively seen patients with SLE, there was a significantly higher prevalence of both malar and discoid rashes among antibody-positive compared with antibody-negative patients at the time of the evaluation (61 versus 31 percent and 17 versus 2 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/27\">",
"     27",
"    </a>",
"    ]. In contrast, other studies have not found this association [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/18,32\">",
"     18,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H366645511\">",
"    <span class=\"h2\">",
"     Other associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other associations have been reported in some studies but not others [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/6,37\">",
"     6,37",
"    </a>",
"    ], including associations with younger age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/18\">",
"     18",
"    </a>",
"    ], with arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/32\">",
"     32",
"    </a>",
"    ], with increased disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/32,34\">",
"     32,34",
"    </a>",
"    ], with low levels of complement C3 or C4 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/18\">",
"     18",
"    </a>",
"    ], and with increased prevalence of anti-double-stranded DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/3\">",
"     3",
"    </a>",
"    ] and anticardiolipin antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27718/abstract/27,38\">",
"     27,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL UTILITY OF ANTIRIBOSOMAL P ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for antiribosomal P protein antibodies is most useful in helping to establish the diagnosis of SLE in settings in which the diagnosis is uncertain; a role in diagnosis similar to that of anti-double-stranded DNA and anti-Sm antibodies is supported by the high specificity of these antibodies for SLE, while recognizing their mild to moderate sensitivity. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Disease associations'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\", section on 'dsDNA and Sm antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing for antiribosomal P protein antibodies is generally not useful in the diagnosis or management of neuropsychiatric lupus, given the broad range of results for sensitivity and specificity that has been observed between patients in various studies and given the inability of these antibodies to distinguish clinical subsets of neuropsychiatric SLE. (See",
"    <a class=\"local\" href=\"#H5856066\">",
"     'Associations with specific manifestations of SLE'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'CNS disease'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5816?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus\", section on 'Serologic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184887\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main targets of antiribosomal antibodies found in the sera of some patients with SLE are three highly conserved phosphorylated proteins (P proteins) located on the 60S subunit of ribosomes. Epitopes recognized by antiribosomal P protein are also present on the surfaces of some cells. (See",
"      <a class=\"local\" href=\"#H17463419\">",
"       'Antigen specificity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibodies to ribosomal P proteins produce a finely speckled cytoplasmic staining pattern on a HEp-2 cell substrate using indirect immunofluorescence (",
"      <a class=\"graphic graphic_picture graphicRef59670 \" href=\"UTD.htm?2/36/2628\">",
"       picture 1",
"      </a>",
"      ). In clinical practice, these antibodies may be detected by immunoblot, by enzyme-linked immunosorbent assay (ELISA), or by addressable laser bead assay. (See",
"      <a class=\"local\" href=\"#H17463426\">",
"       'Antibody detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical significance of antiribosomal P protein antibodies is their specificity for the diagnosis of SLE. These antibodies have not been found in normal controls and are rare in patients with other autoimmune diseases. The reported prevalence of antiribosomal P protein antibodies among patients with SLE is quite variable. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Disease associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiribosomal P protein testing has limited diagnostic value for central nervous system (CNS) SLE and is not helpful in differentiating clinical subtypes of SLE. Some studies have suggested a strong association between the presence of antiribosomal P protein antibodies and neuropsychiatric manifestations of SLE, while other studies do not support such an association. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'CNS disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various studies have also suggested that these antibodies are markers for SLE disease activity and for various clinical or laboratory manifestations of SLE other than neuropsychiatric disease, but contradictory data have also been reported for these associations. (See",
"      <a class=\"local\" href=\"#H5856066\">",
"       'Associations with specific manifestations of SLE'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Liver disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Renal disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Skin disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H366645511\">",
"       'Other associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Testing for antiribosomal P protein antibodies is most useful in helping to establish the diagnosis of SLE in settings in which the diagnosis is uncertain, given the high specificity but low to moderate sensitivity of these antibodies for SLE. Testing for antiribosomal P protein antibodies is generally not useful in the diagnosis or management of neuropsychiatric lupus. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical utility of antiribosomal P antibodies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/1\">",
"      Elkon KB, Parnassa AP, Foster CL. Lupus autoantibodies target ribosomal P proteins. J Exp Med 1985; 162:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/2\">",
"      Francoeur AM, Peebles CL, Heckman KJ, et al. Identification of ribosomal protein autoantigens. J Immunol 1985; 135:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/3\">",
"      Mahler M, Kessenbrock K, Raats J, et al. Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J Mol Med (Berl) 2003; 81:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/4\">",
"      Elkon K, Skelly S, Parnassa A, et al. Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus. Proc Natl Acad Sci U S A 1986; 83:7419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/5\">",
"      Hasler P, Brot N, Weissbach H, et al. The effect of phosphorylation and site-specific mutations in the immunodominant epitope of the human ribosomal P proteins. Clin Immunol Immunopathol 1994; 72:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/6\">",
"      Gerli R, Caponi L. Anti-ribosomal P protein antibodies. Autoimmunity 2005; 38:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/7\">",
"      Uchiumi T, Traut RR, Kominami R. Monoclonal antibodies against acidic phosphoproteins P0, P1, and P2 of eukaryotic ribosomes as functional probes. J Biol Chem 1990; 265:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/8\">",
"      Stacey DW, Skelly S, Watson T, et al. The inhibition of protein synthesis by IgG containing anti-ribosome P autoantibodies from systemic lupus erythematosus patients. Arch Biochem Biophys 1988; 267:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/9\">",
"      Miyachi K, Tan EM. Antibodies reacting with ribosomal ribonucleoprotein in connective tissue diseases. Arthritis Rheum 1979; 22:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/10\">",
"      Koren E, Reichlin MW, Koscec M, et al. Autoantibodies to the ribosomal P proteins react with a plasma membrane-related target on human cells. J Clin Invest 1992; 89:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/11\">",
"      Hirohata S, Itoh K, Nakanishi K. Antiribosomal P protein antibody in human systemic lupus erythematosus is an antilymphocyte antibody that specifically reacts with activated T cells (abstract). Arthritis Rheum 2000; 43:S240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/12\">",
"      Koscec M, Koren E, Wolfson-Reichlin M, et al. Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J Immunol 1997; 159:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/13\">",
"      Heinlen LD, Ritterhouse LL, McClain MT, et al. Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides. J Mol Med (Berl) 2010; 88:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/14\">",
"      Bonfa E, Elkon KB. Clinical and serologic associations of the antiribosomal P protein antibody. Arthritis Rheum 1986; 29:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/15\">",
"      Schneebaum AB, Singleton JD, West SG, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991; 90:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/16\">",
"      Koffler D, Miller TE, Lahita RG. Studies on the specificity and clinical correlation of antiribosomal antibodies in systemic lupus erythematosus sera. Arthritis Rheum 1979; 22:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/17\">",
"      Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/18\">",
"      Mahler M, Agmon-Levin N, van Liempt M, et al. Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope. Rheumatol Int 2012; 32:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/19\">",
"      Sato T, Uchiumi T, Ozawa T, et al. Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease. J Rheumatol 1991; 18:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/20\">",
"      van Dam A, Nossent H, de Jong J, et al. Diagnostic value of antibodies against ribosomal phosphoproteins. A cross sectional and longitudinal study. J Rheumatol 1991; 18:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/21\">",
"      Mahler M, Kessenbrock K, Szmyrka M, et al. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol 2006; 13:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/22\">",
"      Nojima Y, Minota S, Yamada A, et al. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/23\">",
"      Reichlin M, Broyles TF, Hubscher O, et al. Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum 1999; 42:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/24\">",
"      Hanly JG, Urowitz MB, Siannis F, et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008; 58:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/25\">",
"      Hanly JG, Urowitz MB, Su L, et al. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis 2011; 70:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/26\">",
"      Teh LS, Bedwell AE, Isenberg DA, et al. Antibodies to protein P in systemic lupus erythematosus. Ann Rheum Dis 1992; 51:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/27\">",
"      Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002; 41:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/28\">",
"      Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006; 54:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/29\">",
"      Koren E, Schnitz W, Reichlin M. Concomitant development of chronic active hepatitis and antibodies to ribosomal P proteins in a patient with systemic lupus erythematosus. Arthritis Rheum 1993; 36:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/30\">",
"      Hulsey M, Goldstein R, Scully L, et al. Anti-ribosomal P antibodies in systemic lupus erythematosus: a case-control study correlating hepatic and renal disease. Clin Immunol Immunopathol 1995; 74:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/31\">",
"      Arnett FC, Reichlin M. Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P. Am J Med 1995; 99:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/32\">",
"      Haddouk S, Marzouk S, Jallouli M, et al. Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009; 48:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/33\">",
"      Reichlin M, Wolfson-Reichlin M. Correlations of anti-dsDNA and anti-ribosomal P autoantibodies with lupus nephritis. Clin Immunol 2003; 108:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/34\">",
"      Chindalore V, Neas B, Reichlin M. The association between anti-ribosomal P antibodies and active nephritis in systemic lupus erythematosus. Clin Immunol Immunopathol 1998; 87:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/35\">",
"      do Nascimento AP, Viana Vdos S, Testagrossa Lde A, et al. Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis. Arthritis Rheum 2006; 54:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/36\">",
"      Tzioufas AG, Tzortzakis NG, Panou-Pomonis E, et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis 2000; 59:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/37\">",
"      Toubi E, Shoenfeld Y. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 2007; 6:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27718/abstract/38\">",
"      Ghirardello A, Doria A, Zampieri S, et al. Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann Rheum Dis 2000; 59:975.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1817 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27718=[""].join("\n");
var outline_f27_4_27718=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H184887\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIBODIES TO RIBOSOMAL P PROTEINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17463419\">",
"      Antigen specificity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17463426\">",
"      Antibody detection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DISEASE ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5856066\">",
"      ASSOCIATIONS WITH SPECIFIC MANIFESTATIONS OF SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CNS disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Skin disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H366645511\">",
"      Other associations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL UTILITY OF ANTIRIBOSOMAL P ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184887\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1817\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1817|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/36/2628\" title=\"picture 1\">",
"      Indirect immunofluorescence antiribosomal P autoantibodies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5816?source=related_link\">",
"      Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_4_27719="Naegleria life cycle";
var content_f27_4_27719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Naegleria life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 620px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJsAgQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDgNQ1zxA174uuYdX0TTNG0Gfy3NzpM11JsFpDcO5KXCZ/wBawwFzhR1NUvC3iPxB4pVH0XxFpcsDxedHPN4P1CCGRMgZWSS4VW69ASep7Gr1rbfbV+KFobD+0Vnv/KNn53k/aA2mWYMe/wDhyDjPbNY/wy8N65o3jK6ktrLVNE8Fx6clvb6RqWoi8ZbgMDvjxLII0CgjG7nPT0AO88EarPr3gvQNXvEiS51DT7e7lWIEIHkjViFBJOMk4yTW1XK/Cf8A5JZ4N/7Atl/6ISuqoAKKKKACiiigAoqpqupWek2Ul5qVzFbW0f3pJGwM9gPUnoAOSelcjrPii++xNdlrbw5pGdq32qqTPKT0EduCCCe287v9g0AdzRXh2o6wdSLiC21TUVJyLrWrt4Yz7raw7QR7PtNZP2G4Jyy6IB/cTRocfmct+tS5pHHUx9Cm7OX3H0PRXgVrcX9hgwwQgYwTpt1PYsPcKXkjJ9ioFdZ4c8b6gbiS3KXOqGJDLJZzxJFfrEMAumw+VcKOhC7WGRwSQCKSZpSxVKtpCWp6jRVXS7+11TT4L3T51ntZ13RyL0I/mCOhB5BGDVqqOgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAGTSxwwvLM6xxRqWd3OAoHJJPYVHYXlrqFnDd2FzDdWky745oJA6OvqrDgj6VzXxP0vVNe8Jy6LowVX1KVLW4nfBWC3JzK5XcpYFQV2qQTu7ckcZpPgvxNBe2OhX01wnh631G5uTc6Rdvp6PDLGXWMIkpkUJMWAG48be2aAPX6pXOqWdtqdlp88228vFkaCPaTvEYBfkDAxuHUjrXjkPhX4hWvheJLK/1Qatc6NEL03WptPi8WeMyLHmXCMYvNUFCi9PmBwwgj8LeK9mj3Gq2HibU1tp70+TBqCWl1AskcIjUTG+kcpvVzkzFuoK7cAgHu9FeFy6L8TF1Xw15iXcktmdPF5eQag3lXCgr9oEiNdKmQN44gcvjO4Hgbnwz0XxtYeK5Z/FN1qDw+VMsxZg9tO5kBRkzduUIGcBYIhgkHtQB2d94J0e81O8v2fV4Lm8dZJ/sesXlskjqixhikUqrnaiDOP4RUX/CB6R/z+eJP/Cj1H/4/XCTx+IdU+KevJpT63tsNasP9I/tHbYwW32aB5ojB5o3s4LYxGRls7gc1k6T4Y+JX2DUotRv9Z+3y26Ru8dyFilk+0xM0kUhvHKERiTAWGFSCQRkAUAe4aTp9rpGlWWm6fF5NlZwpbwR7i2yNFCqMkknAA5JJqWK7t5bqe2iuInuIApliVwXjDZ2lh1GcHGeuK8a8R+GPHMMlza6Nc6tLokepyPDH/aEk1y8DW0W0iQ3cMhVZfO+Vph1HykYquvhDxZanWp4o9fuNav8ASbOOHUU1JYAs8aFZBLELgqHxjBAdcliGGTkA9zqGzu7e9t1nsp4riBiQJInDqSCQRkccEEfUV5B4p0DxpH4108eHYdV/sq2vLVzdHVpZBPCZA1wJFkuwBgM4CiB8jAVlwAMdPB3jHTfDdhpuj2ut2yW95cm9Uam0pulZnMMkOL2IqoB+ZS8ZLEEq+DQB77VbUr2DTdPur68fy7a2iaaVsZwqjJP5CqXhGC/tvC+lQavPPcahHbRrPLOirIzgDJcK7ru9cMwz3NUPHWLm10vStof+0dQhidPWND5sn4bYyD9aAMS4kTS9NPjDxdBJPqXyiy08YYWfmEKkMYPHmnIDyHvnkKK4WU3Wp6nJq2tsk2pSZCKpJjtY/wDnnHnt6tgFjyeMAbXxDuJNR8dta3G4W2lwRPBET8pkk3bpcdDwAoJ6YfHU1l1lOXQ8DM8XJy9jHZbhRRRWZ5AVWvbZpjDNbzPbX1s/m21yn3oZAMA+4wSCp4IJB4NWaKCoycXzR3On8E65m+t9Q8pLWHVbhrPUrRchLfUVXcJEz/DKo/EmM9WbPpteBwSPaXGseScLJZxahjHSW1uIirfUiTBPoor3yuiLurn1uGq+2pRqdwrzfUb27N7411LUvGOq6LpGi3axKlrDaFEiFnbykkyQO7MWlbv3AAr0ivLtZ8Lnxpo/xT8PrcC2e91SJUlK7grCwsWXI9MqM0zcs+E4db8R2gux4g8c6baSIskEt9b6Svnq2cFVSFmXjB+cKeR711Hw91C61fwD4a1LUJfOvbzTLa4nk2hd8jxKzHAAAySeAAK4/wCFvgDU/DPifUtYv00nTorqygtTp2kO7QSSoBuuGyiYcnPAU8E5JNdN8J/+SWeDf+wLZf8AohKAOqooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOV+I3iO98MaPYXem2DX8txqdpZtCu3OyWZUbG50G4g4XJwGIz8uSOb0P4hz2+u61beIbDUo7Maytlb3LJB5VnutYZBDIUfcWDGTLAOPmHzYxXe6/othr+nNY6rC0tuXSUbJXidXRgyMroQysGAIIIPFUIfB2hxRGMWbuDeJqDGW4lkZ7hI1jWRmZiWO1FBySDjJySTQBjeAvidoPjfUZrLRzKJkg+1KHlgffFu27sRyOUOSPlkCtyOOtTf8ACwrAa82mvpuqRxDUG0v7cyxeQbhYzJs/1m/lQfm249SK1/DvhbTPDpYaSL2KIp5awSX9xNDGueBHG7lEA7bQMDjpTLrwfoV2kiXNgsiSXrag6tI+GnaMxlyM90JG3p7ZoA5GD4zeH5YNTf7LeCXT/JMsaXFnKMSOUBMsc7RIAVO7e67eCeDVvWPivoujx6TJqNtPFFqKoyFbyycpuk2D5FuCz4OCTGHAB68EDTsfhz4csFkFnHqkDvBHbeYmsXgkWGMkpGr+buVQWPyggc1C3wv8ImNIxps6RhEjdI7+4RZgjs6+aBIBKQ7M2X3HJJzQAvhXxJOfCviLVtZke4TTdR1Nf3aKG8iCeUKoAwCQiAZPXue9ZsfxXszI4n8OeIbaOJLWWeWVLfbDFctthkbbMTgnPABYYOVGK7GHw9pcOk6hpkdrtsr955LmPzGPmNOzNKc5yNxZjwRjPGKqzeD9CmS6WWx3LdQ21vMPOk+ZLdi0I+9xtLE5HJzzmgDHn+Jeh21il5dJew2xub+2aRo1Ow2iyNKxAYnBETbcZJyOBUkvjt4lso5PC+vrfX29rWy/0Xzpo0UM8n+v2qBuUYZg2SAAanf4d+F5NVl1CTTWknkeeRkkupmh3TqyzEQl/LG8M27C85yeeaD8PvD7WcNsyaoyQMWhdtXuzLDldpVJPN3opXgqpCnuKAKFp8TtGvdW0yws7e7ka/t47mOSSS3gAR8/wyyq7lcHcEVsd6s+B/iHpPjDVNQ06wimhvLGNJZUae2nXaxYDDwSyLkFTlSQRkcc1Jf+B/CxisVvbd1srNY4re0e/mW0TaMJ+43+WWHYlSc89as+FfCGgaBcvd6JFN5rW6WfmS301zthQkpGvmO21QWOAMYzTs7XC50tct4quLe28R+GpZZVjeGS5mkLHCpbrbv5jsewDGIZ/wBqukup47W2luLhtkMSGR2xnCgZJ/KvAtS1ybxXrWorcgWkM+xJIZGAme1GHjhUZ4jbcHdh98kIPlXJ58TiIYam6k9kbUKEq81Thuy/428Q2WuXcWs6ZY6na3EUXlpNcRAwXkGSQGVC0kZBJKsU43EMBnIraKdS1yATaRol5dwk482Oe3KA9wT5vB9qv7WPO0/lVZYrmx1JdV0aUWWpoMGTZlJ1/uSrxvX8cjqCO/zuHz7mnavGy7r/ACPQx3C1Gt+8pt835ldLp4r6TTtTiWy1aI4ktHkBbHUMp/jUjncOOo4IIFqu80HVdO8dQ3Om+IdEt/ttoqSSQTBZ4mVtwDxsRnGVYcgEfkTneI/hvDbQyXng0LZXSqCdPyBbXJGeOeY3I43jjgbgcV9DDlqRU6bumfIYnJpU5NRdmuj/AMzlKKzLafVdQ8S22iWenta3UqyLL9uhlX7NIoDDfsVlKlckHdg4AB5FdY/gTW44ZJdZ13S9PsIkLz3NvExdUHLEGQ7U4B5IYD0NNQbPPhl9eeqRleGdOW/8PLd3Mxk1fW7tdJFvGPktI45S06qf4spGzF+M4QYFe4Vw/wAP9Gh/darHbSW2nxQtb6Vby58xYWYM88m7nzJWAY55Chc8lhXcVslZH01OCpwUF0Mi08SaReeJL3QLa8WTV7KNZbi3CtlFbBHzY2n7y8A5G4Z6iq2qeCvCur38t9qvhrRL69lx5lxc2EUsj4AAyzKScAAfQCuCh+GeuwzLq66zHJrV1PePfW0mwWvl3KlXWN1iEpK7LfG4kfuugqg/wWijs5RZWWhw3Y0aytoJVQgx38UjtLcAhMgsCg3j5jjnFMs7bWPBHgLSdIvtRuPBfh5oLOB7iRY9KtyxVFLEDKgZwPWup0Q2raNYHToFtrI28ZghRAgjj2jaoUcAAYGBwMV5BP8ACfWX8Ua5qLXdvN9t+3mG6Nykcm24ikVIpVFqZHRd6jHn4G0MFGAtRr8LdeTTLyK0sfC1ilxHZwS6dERPBP5PmF52aW2ZRMxdfmMT8JySTkAHuFFfPsnwY8RSaJpFnc3ljdraQXEH2cXUcawb7h5EeKR7OXawRlXKJGV2DaccV6n428IjxPD4ZtryO1vLPTtRS7u4r0bxPGsE0eMbcMd0inBAGAfpQB1F7cx2VpNczLM0cSl2EMLyuQP7qICzH2AJqevD7j4NXcPh42ekLpFpez6TqWn3UqF188zSRm23EJlljRCvP3eAoIqtf+GL6f4oRRQaPFcz/wBsT38utvaXCSpA9rIqwGV4RGY1LooCStnA+UEMaAPeapabqtlqU2oRWU3myWFx9luRtZfLl2I+3kc/LIhyMjn614r4l+Dmq3fg3Q9G0uDw6s9tpItrq5kRBKbwRInmrK9vK5T5AML5TAKuGGABa1D4T6pNB4git4dDSfUruG9N8GAmnCrCJLWUNA6+WzxvJuO8FiMxnJNAHsuoXkGnWFze3knl21tE00r4J2ooJJwOTwD0p9rcR3drDcW7b4ZkEiNgjKkZBwfauE8PeBprT4Yap4YvRAr3iXKqjSpcQxGUHG3bBCoUE52iMAdq4+/+FWrXOnwwQ6R4VtX/ALMWwjCTybdNmDszXlvtgXMr7gTwhzGvzsMigD2O+1Wzsb7TrO6m8u51CVobZNrHzHWNpGGQMD5UY846euKg8Na3beIdKGoWSTJCZ57fbKAG3RTPEx4J4LISPbHTpXN/EXwe/iO58N3cenaRqr6TdPK9rqvyxzI8LxkbvLkwQxR8bSCUHTANck/wjvU0/wD4l9xYadq8/wDay3eoW24SyLcyO0ILbQWCgpkHGCDtz1oA9lrM8N61b+INHi1KySZIJXkQLKAGyjshzgkdVPfpXJfCPwZeeD7bUkvUgiN00bCK2uI3hBVSCwSO1t1QnjPDE4GTxzw8nwg1qbS9RtYodA0+4lsdQtTd208jSX7XD7o/tH7pdqoOnL89MCgD3iobO5jvIPNiWZU3MmJYXibKsVPysAcZBwcYIwRkEGvIPG3wt1PUvE1rdeH4NBsrK1ltpoJQiRXKMk3mSln+zvI5b5iCsqcsdwbJyTfCS5vdPu4dSTSbqX+z9UhtDJuYQ3FxdyTQyDKcFVcZYcg5xnrQB7LUIuUN6bXbL5gjEu7yn2YJIxvxtzx93Oe+MVy3i3w5qWp+FtNTTri2TxFpckN1Z3FwWMXnoNrByBuKupdTxnDZrkNQ+GWqw6Z9l0mbSbgNpcFnP/aEYcXEouWmnkIaORAXLMwYo4DH7pxQB69RXFfCXwvqHhHwxNpuqSWzO17NcRJbuGSKNzkIMRxqMHPCoq+gHSu1oAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqlrGq2GjWMl5qt3DaWqD5pJXCj6D1PsOaqMXNqMVdsTaWrLtU9U1Ox0mza61O7gtLZeskzhF+nPf2rxHxX8cLm/vP7L+H+my3dxIdqXMkRZmP/TOIc/i35VS0r4ReKPGF4uqfEHWJod3PkBhJMB6D+CMewz9BXvU8i9jFVcxqKlF9N5P5f57djkli+Z8tFcz/AA+80/iL8Z/DV7pt3o2n6ZJrkdwpjYy5iiPoRxuJBwRwPY18/wBnpOqXGtRadaWV1/aUjAJbhCJORkcdRxzn05r7M8J+AvDfhZVOkaZCtwv/AC8yjzJT/wACPI+gwKs6N4U0zStd1TWYovM1PUJC8txJyyrwAi+i8D6/lj1MFxDgsthOnhKbt0cnu/NbJW7bnPVwdWu1KpJfI5r4TfD5/CFh9o1W8lvNWmXDgys0UAP8KA9T6t+WO8CeH9Fg+Ic+mX+i2ktle24eyt0jSSGMJkySPGeY2LNtBUBSAB1Nel1zEvzfEqEW37tl0tjdkt/rVMv7kAdypExz2345zx8nisVUxdV1qzu2ejTpxpxUYjD8PPCJOT4d03/vyKhufhv4VkjYW+lR2MxGFns2MMiH1BU/ocg9wa7CiuR04tWaNVOS1TPGvATz6X8S/wCzr9zJdJFc6fJLt2iUp5Usb47FoyTgcAk4r2WvINRcQ/HGB4xybuENj1azmU/oF/KvX658HFU4ypx2i3/n+pvipOclOW7S/wAv0CuRls08TeKr2LUC8mk6Q0SJa5/dzXJUSFpB/FsVotqngEkkE4x11c54HXNpq0x5ebVbwsf92Vox+iCus5jo6KKKAPD9L8U+M9Q/4Q+eaKymuZtd1G1WNNReJLlI1vF2TbYQFWPy12nDltgYhWrTT4xT3EtlHYeFb67la1jubuKATzNHvkeMrH5UDq2PLY5dowe3OQPSLXw5odpqD39ro2mw3zymd7mO1RZGkKspcsBkth3GeuGI7mqV34Z8L3t7bWt34c0yeWzj8y3aXTFZIQXJwjlNoO7J2g5745zQBH4u8SXej6hpWm6Xp9ve6hqImeMXN2baFUiUMxLhHOeRgbfU5ABrybUfFuseJr5ZNEa4Sz1a40kC2fU5bXy1kindkWWJWKBjGAWTBIA6549w1rRdL121W21vTbLUbZW3iK7gSZA3rhgRn3oXRdLWVJV02yEqGNlcQJlTGCqEHHG0MwHoCcdaAPMJ/jDDpt7d2sulfaLGG1uZrO7t7id1uPJdEwXmgRTkuNzI8gUg5PQnT1HxN4vtPGnhy1utO0iC0urS9uLi3g1F5g6RG3+cMbYNvUO2EGA27lhgV18HhHw3b3dxdQeHtHiurlXWaZLKJXlD/fDMFyQ3fPXvTbfwb4YtobeK38OaLFFbT/aoESxiVYpuP3igL8r/ACr8w5+UelAHDj4sXUel295ceH4c3tpa39lFb6iJGkhnuYoB5hMYEbjzlOBuU4I3cE1tHxzfW3iOLw9qOjQR63NcQLDDBeNJHJburtJOHMSnEYikBG3khBkbxXR2vhXw9aC5FroOlQC5kWacR2ca+a6sHVmwPmIYBgTyCM9ae2g2r+KV1+RpZL2O0NnErbdkSFtzFeM5Yhc5J4UYxzkAwPG3jHUNB1ePT9L0e31GT+zLnVJGnvTbhY4GjDKMRvlj5gx0/qMbS/inLqvieLT9P8OX81iZoIJrpY52aJpYlk3HbCYgih1yWlU9TtxgnrNO1DR9ftdQ1M6eZPscl5pkrS2wklZY5CkqKF3MyM0YO0ctheM8VOnhnw7PfWeq/wBg6Yb6FEFvcvYos0SqPlCkruXA4A4xQBxEHxWlt/DWjeItd0OOw0XVbR54JY70zSLKsXmLEy+Woy4VwpDEkhQQC2A//hZ2pf8ACTLow8JXss0ElrBf/Z/Pm+zyTRo5wyweWUTeMs8kZwCQpGM+gHRdLOnW2nnTbI2FsUaC2MCeVEUOUKrjC7SARjp2qDUPDOg6lqUOo6jommXeoQ48u6ntI5JUwcja5GRj2NAGL4A8XXfiV76HU9Mi0m9tljdrJpZmnQPu5dZIYwBlSAyF1JDYbjJzI/iBfS+HrrXv7L0yHSjK1vZGbUJTPcSibygjRR27lS2Gwql2zgY5JHYaH4f0bQI5Y9C0nT9MjlIaRbO2SEOR0JCgZrOh8L+FdSN7enw1pbSXxeO6e40tUknw/wA3mB0DMCyBgTkHAYZGDQBymg/Fcak8Udzo5s38rUnmMk7qEazMeVAkjRsMJAfmVSuOVpqfEy9n+yGbRBp1je2Ed1BdzXEoMrvbedshb7O0TMDlcO6sdrHYQOezfwZ4XewhsX8N6K1lBIZYrc2MRjjcjBZV24BwByOafF4R8Nw3wvYfD+jpeLEIROtlGJBGE2BN23O3YAuOmOOlAHD2PxLv9tszaKs2nRtpkFzdyX4E++8WPaRGsIVtrSDdyg7gdhp+G/iBda1r2l2zaRbwabqhvPslx9u3z4t22sZIfLAXJPQOxHfmuvXQ9JWIxrpdgIy0TFRbpgmLHlHGOqbV2/3doxjFc/o/w90nTPGdz4mjeSTUJvNwPs9tCqeYwLcxRI8h4wDIznGeckmgDsaKKy7zW7a18R6bosiTG6v4J7iJ1A2BYTGGDHOcnzVxgHoencA1KKK5jTvHGj3mk2Goubu2gvjCkJmtnwXmlMUablBTcXGCAxwCCcAg0AdPRUFtcx3D3CxrMDBJ5T+ZC6AnaGypYAMMMPmXIzkZyCBPQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUE4HNZPibxFpfhnS31DWrtLa3XgZ5Z2/uqvUn2H8q8A1fxX4u+L2pS6R4VtpLDQwcTMW2gqe8zj1H8A9/vYzXq5flNXGp1G+Smt5PZf5vyOetiI0vd3k+h3HxD+NOmaE8lh4cWPVtUzt3qcwRn3I++fZfz7Vx+jfDfxd8RL6PV/Ht/cWlmfmSFhiXaeyR9Ix9Rn2PWvS/h18K9E8HLHcsgv9XA5u5l+4f+ma9F+vX37V6FXfPNcPl6dPLI69akt36LojFYedZ81d6dlt8zC8KeEtE8KWf2fQ7CK3yMPLjdJJ/vOeT9Og7Vu0UV8/Vqzqyc6jbb6s7YxUVaK0CiiisxhWXrOhWWrvDLcrNHdQAiG5t5WiljBxkBlIODgZB4OBxWpRQBzS6FrFmSNL8STmIjlNRt1utp9VYFG/MtUem63caeuvW/iGdJpdJQXRnih8vzbZoywfbk8hklXg/wD1rqa4f4l6W1xDBcWzCOW8jk0adscGO5XYhP+7L5Z+hb1oA4zwc15rvxDs764i/0hpH1W8VOVtkMJhhiLd2wfx2OcYr2uvG/hVra2viAx3oEC6zDGihuPKu4dyyQn0JGce8beor2SuHLnzUOZv3m3f1vqvkdmOVqvKtklb06BXNeEG+z3/iLTXP7y31B51HrHOBIG+m4yL9VNdLXK+KWOh6vaeJQD9jSP7JqeBnbATuSY+0bk59Fkc9q7jjOqopFYMoZSCpGQQcgiloA8A0f4bazq2j6o6abpujTzprlt9pkaRbq+NxJMkQnXyhtiXcHBDPkBSAMkV1HiP4WtfLNBp0OlwWc9pYwTxtuHmvFepPMz4U7iyKRuPJbrjrVDVfEOqweHIdZTV9TtZNW8UPYy/ZIftT29tHJNCI4oWSQBsQhjtQksT1rI1P4ieK9Nt9MjlGomWwEuo6hnSXea4s/tGyFZ1SMi3d4VmkJOzBQdMkAA6O2+FR0vVI9Q0G20Wwu4damu4ZY4yvl2b20iCAAKPl81wxjBC9TnNc/oXwg1+3nmN6+i29tcTabLNb2TiJGNvc+bKyrDbQhcpkLkM2eC5GCJPEvxF8S2fizxjp2lzi5tJxBb6JKkCstpMbWKZ3YgfMpSSWUbsj9yR3xXXeD9Y1GXWvB013ey3A1/wAOC6uo3b5VniEB8xE6Lu89gwUAHC0AQQeD9nxP8jT7b7L4Vtkt9UktktzFAb1EaGJYyAFICKjFV+60aZ61W+NXw/13xvNGNIOjLElo0cU1yqJPBPuyHWQ28rbcbeEaNgRnca1te8a32l+KL7TbGwN/O11ZWcMU92sMStNHK27KxMwA8vnO/PYDGCax4nutY+DHirWIYpNM1C2sdShIhnLGGaASxlkkAUn5kyGwD04FAGPc/CaC+1tNR1Oy0a7nk15r+5klQu01mbdkEJyvP7wq2w/LxnOeKwNV+Dmt3MGlQ/a7Se3tLRrVIFukh+y4uJJEeGR7WYq2x0XKCMjyx8xGMdBcfFG/0a3FjqegB9XElnBClvczXKSieKV1ZykBkBAhfKrG/JGCRkhmtfGCfStHtL248OyJN5Pn3tjK10lxbJ5zRh9v2YgI20srStFuHYGgDP8A+FU6u+p6pOsOh2sk1xq0w1CGZ2ubtLsSiOGYeUAqKZFY4Z+U4Heuj8K+B73RvFZ1C/0zQdU3+UY9Umlb7ZZKtusZiiUxEFNysRh04dsjPXG0DxJ4mHxBttLtZIbvT7jUNYEyXd0ykJFPAF2ny3I2K52oCA24g7doJq+A/iLrVh4E0f8AtjSjfTJoUeq/ahqDyzTwI8aTPIDHkOFfeAC27GCVNAG346+GP/CUa5r2ozQabLNdW+nw2Ms+7zLcwzO8xBCkpuVlAKnJ5BwOuL4g+Ed/PHPb6SdMi0oatPewaV+7jtxFJbwoPlkt5kVldJGAEZH7wkEGvSNB8Sf27oup6nbQbLGGaeK0nSUN9pSP5TKMrgAuHA+8CFDdDiuI0L4oahPp+nTvoom0/ZpUVzdzX48/fepEVYRrCqNtaUbuUHcD+EAFYfCa5NrLK5spNUii0tLG7uJzNNbG2cGXEoiU5KjaGVRu7gU2b4SXN7p93DqSaTdS/wBn6pDaGTcwhuLi7kmhkGU4Kq4yw5BzjPWq/iH4garcT2+s28DWOkR6brM9utvqGZ7g26ABpI2iMaMCpK58zBPI6g9JcfEd0vJ9HXTXGrx7nKi5XItBb+aLrOwjrhNu3G/2oA43UfC+op8RLCOTSotUvm1WyvG1l7a4MtrDHEgeJZWh8rZlWPEoJL4KE5NTp8IteOkXNnFNpGnXBsPskt7aSu0urSfaIpTLdbo8AlY3U583/WvncPlq5qnjzVNXstEi02E29vDquiQ3t3Jf+XcSNO0EpQRpGA6FJMMSUB+bCkDFdBF8Urc6bpd3cWltaC9tNQunNxeEJb/ZXCYchCcMT1C5GOjGgDD0H4RlBpsOuWem3FhbzXk0llLKlxCGmiiVDGiW0KKAUZiuzgncCSeJfD/w31jT5LRtTg0TVboadaWi6ncTubnTJIofLZrbdE24FvnB3RnJOe2IG+Ieoa7qejQLp91p13Za/HBcW8Uk6C6jewuZVUiaKF8EqOGQDKgjIwa7nwD4rufEy3yahp8WmXlr5Zez8yZpow4JHmLLDFj7pwV3qcHDEdQDyJ/hZrWhaAIpLC21Kaa90yKSCG4Uw3QjukZpJkjs4yowW3SMZWCk5Jxk9NbfCWW5e1/tez0JrKNdUZNNUGS3s2ufI8pIg0YBVfKZidq4ZvlHp7JRQB4gvww8UyeJfDWoXM+iN/ZTaeXu4yq3DrDGizKzG3MrliHwfOVSCAV6mi4+EWpz6daRXSaJfNa2unItvcsxile3vJppFYmM4R45dmdpPLArjr7fRQB4trXwu1S9srtYdP0HzJdRa9t7drgG2tVNpbwhPLktJEkAaJsfKhC4wykkD2HT4Xt7C2hl8rzI4lRvKTYmQADtXsPQdqsUUAFFFFABRRWTqviPSdJnuIdRuxBJBZSajICjHFvGQHfIHOCRwOeRxQBrUVk6V4i0rVrmK3067E8stlFqCBUbBglJEb5IwN21sDrx0qyNUszrLaUJv9PW3F0Ytp4jLFQ2cY6gjGc0AXaKKKACiisvwtrdt4k8OadrVik0drfwJcRJMAHCsMgMASM/QmgDUoqlo2q2Ws2P2zTZvOtvNlh37WX545GjcYIB4ZGHvjjiofEmtW/h/R5dSvUmeCJ40KxAFsu6oMZIHVh36UAadFFRXVxHaWs1xcNshhQyO2CcKBknA9qAJaKo6fqtpqCWr2bSyRXVst3FL5DhGjbGDuIwCcg7SQ3twaZres2WiWk11qTyxW0MEtzLKsEkiRxxrucsVUgcdAeT2BoA0aKrQX0NxceTEJifJScOYXEZViQMORtJ4OVzkDBIAIzZoAKKKKACiiigArg/ib8SdL8D2nluRd6vIuYrNG5Hozn+Ff1PbuRgfF34sQ+GzJo3h0pd68/yMwG9LYnjkfxP6L27+hyPhh8JJprweJPH2671CZvNWznO/B/vS56n/Z6Dv6D6DB5ZSoUljcx0g/hj9qf+S8/+AcdWvKcvZUd+r6IwPC/gfxH8VNUTxF42uZrfSm5hiA2l06hYlP3E/wBo8nrz1r6D0XSLDQ9OisNJtYrW0i+7HGMD6n1J7k8mrwGBxRXFmOa1cc1F+7CO0Vsv835mtHDxpa7t7sKKKK8w3CiiigAooooAKKbLIkUbSSuqRoCzMxwAB3JrlZvEF5r7Pa+DwjQ/dk1iVN1vHzg+UOPOb6fIO7H7pANjWdf03R3ijvrkLcTf6q3jVpZpf92NQWP1ArGKap4nvrNrizk0vRLaZLnZOR9pupEIZAVBIjQMA3J3EgDCjOdfQdAstFWV4BJPeTkG4vbht8859Wb0HZRhR0AArWoA8h+KPhf+z57vWIEf+x7phNfCHiSymXG26QjoMhS2PukB+m6un+H/AIufVFGla08Y1qJNyyINqXsQ/wCWqds8jco6E+hBrtmAYFWAKngg968I8X6M/hnWLix0w+WsKf2ro5zjyGUndEP9kNgY/uS7egrzcRfBz+sQ+Fv3l+HMvPv3O+hbFR9hL4l8L/R/p2PeKR1V0ZXUMrDBBGQRVbSb2PUtLs76EERXUKTID6MoI/nVqvSOA421a48FObSaK4uvDHW2miRpZLAf88nUZYxD+FgDtHytwA1dTp1/aalZx3en3MNzbScrLC4ZT+IqzXNar4bkjvZNV8NTpp2rP80ylc2957TIO/pIPmHuPlIBasPDOnWd1eSiPzo7i9/tBIJ1R47e4xhpIsrlSxyx5PJJGMmtIWFoJbqUWtuJbpQtw/ljMwAwA5/iABI5rI0jxRb3N2unapC+layf+XO4YfvPeJ/uyr9OR3CniugoAoWejaZYwzQ2WnWVvFMixypFAqLIqoEVWAHICAKAegAHSq1j4dsbLWv7SgVlkSzSxt4QFWK2hU52RqoGASFznP3FAwBitiigClLpWnS3f2qWwtHud6Sec0Kl9yAhG3YzlQzAHtk460o0vTxYXFiLG1+w3Hmedb+Svly+YSZNy4wdxZic9cnPWrlcxpHjrRdW1c6XZrq/21du9JtGvIRFuBKl2eIKgIBwWIzjigDUvvD+jX8VxFfaRp1zHcKiTJNbI4lVM7AwI5C5OM9MnFUJfA/hOaO2jm8L6FJHaoY4FbT4iIlJLFUG35QSxOB3J9a6KszxLrVv4e0K81a9SZ7e1Te6wgFyMgcAkDv60ANufDmiXUkL3OjabM8NwbuJpLVGMcxOTKpI4ckA7hzxTbjw7prac9pZ20On/wCiPYxTWkMaSW8LdVjypCjgHGMZA44rXooAo6TpVnpOjWmlWUKpY2sC28cZGRsUYAPrxUcWgaPFb+RFpOnpCDCfLW2QLmLHlHGMfJtXb/d2jGMVcvLlLS3aaVZmRSARFE8rckDhVBJ6+nA5PAqDSdVs9Xhnl0+bzo4LiW1kO1l2yxOUdeQOjKRnoccZoAojwl4bF3d3Q8P6R9pvFdLmX7FHvnVxhw7bcsGBIOeueavtpWntctcNYWhuGg+ymUwruMOc+XnGdmTnb0q5UJuUF6LXbL5hjMu7yn2YBAxvxtzz93Oe+MUAZcnhTw7JfW17JoGkveWyxrBO1nGZIhGQUCtjKhSBjHTAxSJ4S8OJdXNynh/SFubkOJ5RZRh5Q/39x25bd3z171t1yUXxF8LyyMF1GQQBZmF29pMtq4iVmkKTlPLfaFY/Kx+6fSgDSsvCPhuwhENj4f0e2hD+aEhsokXftZd2AvXa7jPoxHc1Z0PQdH0CGSHQtK0/TIpG3ulnbJCrNjGSFAycVht8RfDUdhd3k9zfQQ2yxPIs+mXUUhWVxHGUjaMM4Z2ABUHrW9omrW2s2r3FnHfRxq5jIvLKa0fIAPCSorEcjkDHUZ4NAGhRRWf4h1WDQdA1PV7tJXttPtZbuVYgC7JGhYhQSBnAOMkUAaFFR20y3FvFMgIWRA4B64IzUlABRRRQAUUUUAFcT8RvB914nu9CmsZ7eH7Lc+Xe+bkGWycq0sa4B+ZjHH1wOvoK7auO8deL7vwvd2YTSkl0+VS0+oXEs0cFvhgMMYoZcE5Jy+1ePvZ4oA4m4+F2tx6JqlpC+iXbXOpJ5Ud2isq6dEriGIGWCVFkUuxz5bDBIGOtZ1l8HdYt9LtoGXQnv/7Jm03+0C586yYzStHJCfJ+bCSKhA8vAHHGBXWXvxWgsbFbq60twou9Vt5I4590irYrKzMF2jJbyhxxt3jk949Y13xZJrfg6SPTdOimvJbgpaQ6xI0M8f2YsDK4gGMdQArjPQ96AMbw78Jb22i0+HUYtPFpFqsV7c2i3CPBJGltPEwWOK0gUFjKm4EEMByex6/xT4At9QsIoNLeeMNqNndTRXGoXDQrDDOkjJFGWZYvlUhQgUdBwOlmLxvDL8NrXxZ5EVuLiCORLe5mcLvdgoj3RxuxJY4G1CSccc1y8XxY1CbRWvo/DBQW95cWl9JNLcpBaeUqNvci1MqhhJnLxIF2tuI4yAQR/Cu7tPiQms2X2RNKju4Z7cQSRW8lrGiBTAq/ZXYx8H5VmjUhjwDknDm+EfihrbwzCJtAEmkW1hEl0m1JkaGQNIA5tmlZTg7dskQGTkEE16r4z8SXuh6NZ32l6SdVE8gVzG8pjhQoW8w+VFJIVyAPljP3gTgZNc6nxa0q2mlj1aERosNvdrPZy+fC1tKiH7RuKoRGJH8vOM9CQBnaAcpdfB/UhpCWFjZ+H4IoNTnuyIiijUIpHlaMTrJayorRCQKoKyDGcFOKfdfCbV3treDyNGvylvZQwXWpXjzT6b5Mu51hYQAMGGBkCM+oIxW7D8RdUaeIRaN5l9etp0cdlPfqkUDXMUsh+dYd3y7Pmzuz2AxgxxfFfUY9Jm1HUfDdvBbiz1O4hEWpGRnksSRIjAxLtVirBWGTxyooA2Pi94R1TxfY2Fpp0eky28bSGdL6OMsCVAVo2kgmCkc5woJB4ZcVzel/DDU4oY4NdsPD2vPLpdtYNeX0rPLYtHB5T+SGhberHL9YySTntjUb4k63bXU66j4Ysore1msUupIdVMjKl3IqRlFMC7mBY7gSoGOCc1Vj+JmpQ6ZNJaaONRNtbalqE73d+sTLFbXckRVdkGGJCjaCBxgMxOWIBX074WXh0eKzntdF0p4dGNlG2myMw+2LLFJHdf6pOd8QY9TnjJ60/U/hdqeraH5eo3GmSape22ptqM2GMZurqNVjMYK5KR7EUE4ICKetbFt8SLi81e1S10aD+yJ9UTSftEt9tuBK0XmFhCIyNoHHLgnrjFej0AeK6r8LNYv7GWOzh0PRkawsrY2FjJmCVobmeV1bdb7driVTzG/zZBVhyYLf4Tarb/2M0NppBms5Wcte3cV3FArTbyscP2FFA6keWYSCcZIAr3GigAooooAK8W+MPxRms7o+GPBrNPrUrCKaeEbjExOPLT1f+X16L8afibLp83/CMeE3MusznyppoeWhJ4CJj/loc/h9emt8HPhhF4St11TWFSfxBMvJPzC2B6qp7se7fgOMk/R4PB0cBRWPxyvf4Ifzeb/u/n+fFVqyrS9lS+b7f8Er/B/4VReGlTWfEKrc6++WUM29bbPoe7+rdug9T61RRXj43G1sdVdau7t/cvJeR00qUaUeWIUUUVyGgUUUUAFFFVtSvYdO0+6vbtttvbRNNI3oqgk/oKAKuu63Y6JBG97IxkmbZBBEheWd8Z2og5Y/oBycDmstX8UasNyLa6BbH7olAurkjPcAiNDj3eneEtKlOdd1lN2uXyAtu5+yRHlbdPQDjcR95sk9gOloA5tfB9hO6ya3Pd61KG3AX8m6IH1EKgRj/vnNdGqhVCqAqgYAHAApaKACuF8b+NJbC7k0fw8sU2rKoM88uTFZqeRuA+85HIQEcckgYzofELxJJoGmRQaeEfWL9jFaK3ITAy8rD+6gOT6kqv8AFXmdjaJZwGNGeRmYySSyHLyuxyzue7E8k14+bZl9UjyU/jf4f10PVy3L/rUuefwr8SX7Triv9pj8Saob8HcJJHDRE+hhACbfYAHHcHmrXifWj4hTwjqjwiCWewvRLEDkJIrwq6g9wGVgDUFUF/5A3hL/AK5at/6VJXi4bFVq2GrxqSb0vr6nrYjDUqNejKnG2v6GhfahcXPhjwdoKTSw2R0WG7uvLco0w2qiR7hghfvEgdcKOmQadhDcaLN9o8N3T6fODkxZZreX/Zkizgj3GGHY0L18K/8AYs23/oVW6M1xdali3ySata33XFluFpVML78U73/M9L8F+KIPEtlLmI2upWpCXdozbjEx6EH+JGwSrd+ehBA6OvCjNdaZqFvrGlLu1C1BBizgXMJOXhb64yp7MAemc+0aLqdrrWk2uo6fJ5lrcxiRGxg4PYjsQeCOxBFfQ5bj1jKV3pJbnh4/BPCVLfZew/U9OstVtGtdStILu3bkxzIHXPY4Pf3rDHheexH/ABINc1GxUY2wTt9rhHtiTLgeyuK6aivROE5aXXNW0QFvEenpNZLy2oaaGdUHrJCcuo91Lgd8V0lpcwXltFc2k0c9vKoeOWNgyup6EEcEVLXIm3Xwr4jtms8R6Lq8xiltxwlvdEFlkQfwiTBVh03FSOS2QDrq878W+Br/AFufxKYprVYtUm0p4w0jqVW2nEkmSBwSoO3HfrjrXoleK6D8RdU8P+GppdYsBfwltcuLS4OoM00v2Wad/LdTH8ibVCKwZsYUYGQKANK/+Gdwvi83mlWehwWX26zure8G6O60+KHZvtoI1Tbscq2fmUfvXyrHBrkvDXwu1nUvCin+ztL0KWbS57OQB5FnvneZGDXQMSldixnaMufn6gcV2fiL4pXegywfbNFtJFKwS3EVtdzzTW0c0m1Gk22xiQnk4aRQSpCluCYh8SNUiuL21sNHXUZYDq1w7XmoLDsis7kRFV2QHOdw2gjIwAzNy1AEGp/C6eLVrqTS9O0C50I6gt3FoN0zRWjg2oiZmVY3VXDgsPkYHJJINVl+GOrG+8Nm80zw3fR6VbxgXhmaK6WYE4YMYHZ0iBGxC6glQW7AdX488S6pb+D9A1bw2kKzX+oachS5kCAxTSoChOx8Z3BSQMgEsMkAHIu/iFq+mW97K+im5W3v57e7nluZGtrIRxxMcvDas4TLthnTgKxZhwKAMjTfhXrMGly2oj0Oxk+xW9rI9pLIf7RljuI5Wup8xjEhWNv75y5y2MVV1P4P6lIt1FYWfh+KA6vcX+EKKb2KVpGRJlktZUBh3gLlZBgnGziui8QfFK80T+25LrQYlgsbaW5tvMupka+WNQ26I/Z/KKkHPEhYDkqKs+K/igNF1q60qz0lr+7S6gtYjG8rq5khaUlhFFI4wExhVYnOeBkgAx9L+GmqWGv+GryKDTWXTooIZ7i+u0vZQkZJ2xBrRSrAHAdHjHQlTgCt74jeB77xTqE8tvJaC3l05bNlmdlJIuopT0U8bY2Hrkj6103hXxFHrmm2Ulzbvpupzwmd9NucpPGocoW2MFfbkcMVGQRwM4rdoA5Lwd4SXw6fElrBHa22k39759na2g2LBGYIkYBcAKS6u2FyPmz1JrF0rw/4vs/CUHhae28MXWl21k9gJ5pJmN1EIykavCEATPy7iHbvgDPHo9FAHj978PPEep+H9U0yW4t7C0uTZeVYrrN3eohiuUlkkWWRA8XyJtVEGAcHI616Hc6I9r4U1DTNElZriWCVYG1S4lvV8xlIG8yszMmcZGSMdq5j43eM9V8EeHNNvdDjsXubrUFtG+2RPIgQwyuSArqc5jA69zXl2g/F74ja9qsOm6TZeG7i9m3bI/scqZwpY8tcAdAe9XGEpK6LjTlJXWx0Xhv4QanA8kWtR6I+mzalZ3sljEUMTLFHMkg2R20Mfzb4+NnIBDE901j4RavPo91YRW3h+/ge0v7OyhvpXEem+dcSSRSwjymAZUdFIAXbsG1iOu78EPH+u+NL/wAQ2viCLTUbTktmjNlC8eTIZgwbdI+ceUMYx1Ner1LTTsyWnF2ZBYQtb2NvC5BaONUJHTIGKnoopCCiiigAooooAKy9V8O6JrF3bXWraPpt9dW3ME1zapK8XOflZgSvIzxWpXA+PvC2talrq6poH9nSPLo93pE0d7M8QRZmjYSKVR9xGw/KcdetAHTp4Y0FNWk1RNE0tdTkJL3YtIxMxKlSS+NxypI69CRWVa2Phbw74m0rSNN8P2Fle3sdzeQSWllFGqeUI0ckjBDETKOAcjOSO/HWPwruYNRTUnXSjqkeo6ZcRXY3ebHBb28EU0atsyN3lvwOGBGcdBkf8Kj1x1kSN9FsLr+z76zk1a2kc3d+80kbJJPmIdkZT8z43nHHFAHskui6VLo/9kS6ZYvpW0J9ia3Qw7QcgbMbcZ5xisxvAvhJreG3bwtoJghcyRRnT4dsbEKCyjbgEhVBI/uj0Fee+FfhNcWl7YHWLbTm06O6lnubETxywOGt/KG2KO1gjGTjcCpBxkknirDfDXX/ACpdPj1mBdCbU8CwLOU/s5pzO6Yxjztx2A9BGMZ60Aeg+MbLw9PoVxdeLNPsLzS9Pje7k+2Wq3CxKiks4UqeQuegzVg6Not7bEtpdhNDParakPbIQ9uOViII+4MkhTwM9K8e1P4Sa/q2va3d3j6BFFqFrqNuz28aJ5pnU+S7oturEowRiXllO4Fl29KXUvhJq97f6bcRW2j2EEFtFALOwuo4lsnSRmMsDvZOQXyGO0RHIwWYYIAPZ30nTXuftL6fZtcB0fzTCpbcgIQ5xnKhmAPbJx1rH8TxeH9D8Py3eoaNay2MRaIwx2sbcXMgWQBTgYdny/8Ae5zmsTwN4X1HwxfW0K2OmstxJf3GoaioLSMr3LyW8KEkMMCVmYEFQQcctmsr4gfD3U/EPiO8vYLXRLxLhbMW9zqEjifTvJk3uIVEbDDjuGQ5JzkUAegQ2Gkaglw39mQMGlWOUT2ewu0D/IcOoLBWGUbkdCpxg0y00vRJvtkMOkWyKnm2kyvY+WsiyESSKNygOjF8sRlSxbOSDXnd/wDDLV5opDZ6haW017qGoR37Kz/vNOu7lpSikAYlAwB2BZufW3/wrBbnxGZtTttKutE/tea++xyKXUxNZRQIpQrtJDxk46Ywc54ABvXHw60afxpbeJZC32q2ZXhgjtraNFKx7F/eLEJmAHO1pCuccYAA7Ovm7W/A+r6WNL0m70y31/UnttOt4Lv7PdTHTxFOd/lSmExKpAyd0kbAdQRtB9+0KXVZkvn1mCCD/S5VtY4/veQpwjOdxBZsFuMYDAEAg0AL4k1WLQ9CvtSm27LaIuAzbQzfwjPbJwM+9eJeIfGQ0m2juL/VdQ1K+mJ3Pb3ht4I2wOAqkfL1xtV2wOc9a911Ozj1HT7mznyIp4zGxHUZHUe4ryRLZLyy8R6JrTPe3EaiC7jvCFjlZl+R1A4VXPIAbjjGOBXDjYyfK7tLrbQ6MPFSbXU6D4MeNJ/FekX1tqT79S06RVkfZtMkbgmNj2J4YZXhtoYYDYE/xo8T6n4X8HyXGi2c0tzO3k/aVXctqD/GffsO2evYHA+Hmg/8K8luzbJJqFvepCszGYI8RjDD5VbClSWJ6g5J69a9G03X9P1KQ24dobkdba5Ty3P0B4YcdVyK9DAYqlCrCpNKaT1T6mOIoTScdvM83+CPw2bQ4h4i8RI0mu3QLokvLW6tySc8+Yc8nqM49a9foorpx2Nq46s61Z6v7kuy8jGlSjSjyxCiiiuQ0CiiigAooooAK5rx+BPpFrp5BI1C+t7VgO6eYGkH4ojiulrnNd3XHi/wzajBWI3F8w/3I/KH6z0AdHRRRQAUjEAEkgAckmlrjvitfyWnhCa0t3ZLnU5FsI3XqofPmMPcRiQj3AqZzUIuctkVCLnJRjuzz6fUW8Q61ea65Jhn/c2IP8Nsp+Uj/fOXPsVH8Nc74tsr6C3n1jRdQuLe8tk8x4HYyW86KMlWjPAOM4ZcH61qanq2maFDANQuYrK3b93G0mQgwOAW6Djpkis2+8XeH/IeJr5LhZAUKxKW3A8Hn7vf1r4GVWtXrOvyt3fa6t2PtY06VGkqN7W/PubGj36appVrfRDak8Yfb/dPcfgcimD/AJA3hL/rlq3/AKVJXPfD+5Ww0ZdL1GWKC6tyXRJJF+eJ/mVlOcMMlgSCeQRUlt4gjFrp8kEct5BYLc2x8gbvne5klmYeojijVjj1I611YaHJGvTjrdJLz10ObET5pUZy6Nt+Wh0K9fCo/wCpZtv/AEKpreeK5iEsEiyRkkBlOQcHB/UGsjSr9Lm/0+x3ZuNM0lLR+4ZBK3lSA9CrJg5HfI7Vm6A8+jeKL7RJX8yxuHe8s+OYQ+WZP93d5mPTHuMTmaVbETnF9E/lZDy5ulQjGS6tfO511bfwz1P+zPENzokrYtNQDXlqD0SYf61B/vAhwPUSGsSqepyy2ccOpWy7rnTpVvIwP4tn31/4Ehdf+BVjlmKeGxEZdHo/Rm+Y4f6xQceq1R71RUdtPHdW0VxA4eGVA6MOjKRkGpK++PiQrnfiFG7eDdTmi4mtIxexkdd8LCVf1QV0VRXcCXVrNbyjMcqFGHqCMGgB0MqTQpLGd0bqGU+oPIrzJ9d+Hdjb63qNj4dWUMJ4L+e38PSIlxhykqNO0SxvlgwIL4Jz1rsPh/cNceCtFMmfNjtkgkz13xjY3/jymuKg+GFzF4I1zTxdsdX1Ce6dc6jctaKkty0q/uSdittIBITOc8nJJAO81Lwt4f1S7hutS0LSry6gUJFNcWccjxqOgViCQPYVZTQ9JSSSRNLsVeRZUdhboCyysGlBOOQ7AM394jJzXj+r/DLxNdeMNU1sXek2CzR6ggutPRUnaOaF0iJRLcSM6koTumfJGVAOBWFofgPVPEVtr66dotl4etnOmAW6W8lvBfGATmUOLm1DHPmoSzwuCVA+bBNAHrXjLXvDulwvoetaT9sshaRzm2+zRyQmPz44VXYxA4Z1OMYAHqAKs694b8G2OizXms+H9E/s3TIpLti+nRyLAqoC7KoUnO2NegyQoHYVwVt8LNYi0mK1Se0j22hgEcl15ojY30dxhSkEShNqNgBFwSABgZqjqfwk1/Vte1u7vH0CKLULXUbdnt40TzTOp8l3RbdWJRgjEvLKdwLLt6UAetWnhvw4bi41G20TSluL+Mie4WzjV7hHHzB225YHuD171kXei+DrC7sPDLeGNKEGqiSYQJp8PkEwgHLrjGRv44PfpXns3wk1ebWNPvFtdHsbeFLdVtdPu0iFk0chZmgdrJ2+c/OdhiySwJYfNW/4P+Hup6P4zsNVu7XRP9Ga9M+pQyO15f8AnNlDKDGMFQMY3sPTHSgDq9Ln0ay8V/2FougLHNY2aLLdWtvDFDaRSFmSLO4N8xQnaikA4Jxmuqry7xZ8M21fW/EWq29to7XV+1i0fnoQZ0hbM0MrhCVSQBVON2QBkEDBZovwzlF9pr6xaaP/AGXDc3s76TAWktoEmWIJFGrIodQYyxBVRluF4FAHqlFeMQ/Bi2YWLXmn6HNKLXUkvXaMsZ5ppFa3c5T5vLUMMnlc/Lmr+h/D3V7Dxto+syxaS5t7eCK7u55RczSFLYRHyg1uHiJYdRNtI3EoSxwAUP2p/wDkTdA/7DSf+ktzWF8LbvQtMj8I3dvdaLbMGu/7Wlu5IUuFfaRHgudwTn+Dr3717P4v8J6N4w06Gx8Q2j3VtDMLiNUnkhKyBWUHdGyno7DGcc1yf/CkPAH/AEB7r/wa3n/x2tYzSjys2hUShys4j9mAhvEXjYqQQY7Igjv891X0BXM+DfAvh7wY96/hyxktXvBGJ2e6mnLhN20fvGbGN7dMda6aonLmdzOcuaTYUUUVJIUUUUAFFFFABXGeNfGd1oOpNZadplteyw6dNqlw1ze/ZVWGNgCEOx9z8ng7QOMsM12dZus6Bo+ueR/bWk6fqP2di0P2u2SbyycZK7gcHgdPSgDD8G+LrrxTqGoi20pINMspxA1zLc/vHZoIZlxGE9JcHLDGBjdkhcXUPiJeLe3MNrpNuLQ31zpNtcPe4lN1FE75aHyziMlCNwZjjB24Neg2tnbWjzta28MLXEnmzGNApkfaF3NjqcKoyecADtVNdA0ddZfV10nTxqzrsa9FsgnZcYwZMbsY460AeO6T448WwW2i65fWdrfEeEjqlzCupNGkyL5TmbaIdomOWGwLtGcb8V1dn8T5b/xcNK0/w7f3FilxDbTXaRTs0TSRq+8hYTEEG9clpQep2kYJ7Gx8K+HrCKeKx0HSbaKdHjmSGzjQSI+N6sAOQ2BkHrgZpZfDGgS6pBqcuh6W+pW4VYbtrSMyxhfuhXxkY7YPFAGb4H8S6j4n8H2+vNpENot3arc2tuLzzHfK52udgC88AjdwckA8Vzmn/F7StRh0cWtpKtzftHlJ38tEURGW4IbBLeSFIfIHzYH07PWL7TvB/hea7Fp5OmafENtvZxqoVMgBUXgAc9OKZo1v4evkZtKsbErp9xcWw2WoTyZS375VyoxuP3iOG96APLdQ+LOtagI7TSdMtbS+W80x1laecQXNtcXPlkBprVGw2AN6ow2sWViVweih+Jt9J4ln0weGLmWG0uDZ3Vzb/aJFilEW9ju+ziLywxC7jIrYIbYOldNpfhPwi+n3KWXhfSYLS6zFPC2lJAJQjnh0ZAWXcCQSMHhhkEGrg8I+GxfwXo8PaOL2BFiiuPsUfmRoq7VVW25AC8ADoOKAKXhTxHqOueDIfEEujJB9qskvbW0iuvNklDRBwpJRQpJOBycjBO05UcxY/ErVryXTrKLw/YrrF7eG0+xzX9xCbfFu8+ZfMtVYcRkDarA9QTXoyWFmmmrpyWluunrD9nFsI1EQi27dmzGNuOMYxjiuM1DwX4Hu9X0vRG0jToTZtJqq6ZDYxrbzgoYS0i7NrY8wEdDkKegoAw4fi69zpsuo2uhxm0srOK71Ay3+x0DyyRAQDyyJuYmIJKA5XGScUaz468T3cmnvoWlafBa/8JFLo7tc6gQ1z5TzIRgQPsRvLB3A7gRjBHzH0GfwxoFxLYyz6JpcslgoW0d7SNjbgdBGSPkA9sVJeeH9GvdPlsLzSNOuLGWVp5LeW2R43kZixcqRgsWJJJ5yc0Ac9oHjC/v/ABfc6JqmkRaWU83yDLPMZLoRsAXjBgWN0+YHKyFgCu5QTgc54lt7TxJ42u4r20triHT2RFRoSVlICkmRuclWf5VxgYJOeMegaX4Z0HSL+a90rRNMsb2YES3FtaRxySAnJDMoBPPPNeaa9Pqdn4u1bTNHntIGuL37Ss08Rlxm1DshUMv8SLzngN7c8+Jb5NDfD259TXubKY6fqdpDKsjSQkQLIzHYShVdxJJIyOv1pmm20Gq+HLNL+1mAeNGkjuc+YrgDOSec5B5rGste1GabQ7u40V7a51KzEoi+0IUmjI3KInJGZBkHYwB2sfSrll9rfxLNLfi5sUuFVreM3KsH8v7ylQSBkMDwSeDyK8yUJQ0ejPTjOM9Vsdh4M1aSWSbTLq4Nw0APkTyZDyIrFWV/VkOAW7hlPXNdXXkVnNe2PiHWmATzLeSLULWNM5kQrtkH1baV9M4PevWbeZLi3imibdHIodT6gjIr08PU5467o8zEU+SWmzJKKKK6DAKKKKACiiigArmpc/8ACybbd0/smXZ/3+j3f+y10tc14pzZ634c1NS2EujYygd451wP/IiRUAdLRRRQAV5d8T7n7R4u0my522dpLdkZ43SMI1P5LL+deo1494ukM3xB1liciG3tbce3Dv8A+1K8zOKnJhJ262X4noZXDnxUb9NShIiSRskqK6MMFWGQR7iqcOk6bC2YdOskb1WBAf5Vman4x0LTbx7O4v1e7Q4eCBTK6H0IXofY1TPxA0MI7F7kKn3t8YTH/fRFfGRoV7aRdmfWSrUb6tXJNf0ays7K4vEkFvbRZla3NvHPEW/2EcfKzEgfKQCT0rtvgpo1xPctqWpeW502D7BGUjVEM7Yecqq8AL8iAj0f3rgb+7vtV1OK3itvLlgKyw2zMH8pz92e4K/KoUcrGCSx57ce1fBuAW3w60yESSS+XJcqZJDlnP2iTLH3PX8a97JaXNU5pu7Sv9+n9f8AAPEzapaFoKyen9f1+Z5Z8QdFi8LeK0t7Dz4rIQG6t54I/MawVnIaJk6yQZGQByvsACOUvWL6zBereySyyqdmoRzrbWrkjAiRtsmCMHhsElj16V7/APELwxd6q9tqmimP+1LRGjMMrbUuYjyU3fwsCAVbp1B4bI8ku9JsLy9uLea3utJ1YpmeEqIpGXPJZDlJVzxnDD3qczoOhWdTl9x9V+N+2uvbyuVl9ZVqSp83vLo/0/q5H4X1yW5urnSdV3R6nbHOJAFaRcZzxwSM9RwQQRjkDpCAeGGR3B715hfaNJb65p+l315JazPkabqMAGY2XkIA2fl6/IT8pPynaxA7vRf7aTdDrf2GXavyXNqWTzDn+KMj5TjnhiK8bEUoq04Pfp/l/luj1qFWT9yS2/rU9U+E9yZ/Amnwu257IyWJz1xC7Rrn/gKrXX1wPwgO3TtdhJz5epsw+jQxP/NjXfV95hp+0owm+qX5HxmIhyVZR7NhRRWf4g1EaRoOo6iyhhaW8k+0/wAW1ScfjjFbmJneBMf2HNs/1f8AaF9s/wB37VLiuMufi01nYnUbvRIxptxHdvYtFfBppDA+wiWMoBECe4Z9vfB4rv8AwppraP4b02wkIMsECiVh/FJjLt+LEn8aSLwzoMN5fXcWiaZHdXysl3MtpGHuFb7wkbGWB7g5zQBzk3ivxFFqunaN/YOkHWbyGa7VP7YcW6wRmMZ8z7PuZy0n3QhAAzu5xWVN8UZk8VyaPb6Kt+rC7S3lsppm82e3jZ2hy8CRbiVK/JI+D1rrG8DeE209bBvC+hGxSUzrbnT4fLEhABcLtxuIAGeuAKkPg3wwbye7PhzRftc4cTTfYYt8gdSrBm25OQxBz1BIoA4V/ilLDBBeanYtavbfa3u7G1mkaRFitTOFkSe2jcMQOMbR0O5gcVaf4k6rFdx6bJ4esW1eaWzSKOLVi8Gy5WUozSiHKkeS2V2HgggnIz2+neGdB0yKOLTdE0u0ijZ3RLe0jjCMy7WIAHBK8E9xxSab4Y0DTIlj03Q9Ls41mFwFt7SOMCUAgOAAPmAJGevNAHnGtfGR9M0L7edEhmuLcXBvrOO5neSEQzvCzKUt2UoWjbDSGIcY4qrF4i1mHxdcyWT3eo+Vfas0Vg10yLMI7e2ZI+hAwWbbwQCx6ZNel3/g3wxqOz+0PDmi3Wwuy+fYxPtLsWcjK8bmJJ9SSTV9dH06OYz29lawXOXdZ44EDqzgBmBx1IVcnvtGc4oAyPBXi2Dxel7d6ZB/xKojGkF2Xz57NGruAuOAu5Vzk5YMOMc8QPijqNro81zBow1CKz0+fVLuW51BYpBFHcSxlUCQbWbEeQMKMcE55PpPhjQ7Tw3oNppOn7zb2y4DyYLyMSSzsQACzMSxIA5J4FL/AGBo/kyw/wBk6f5M0LW8ifZk2vEzFmQjHKksxI6EsT3oAwfH2sXlqPDlnYX66WmsX62smoNGrtAvlSSAIHBTe5QICwI+boTgVz2uTeJrO9tdO0zxPeawkclw119hGnJqSYWLy0KyhYiq7nLEKrYZPqfR9R02x1Owey1KytryycAPBcRLJGwHQFSCDWTL4I8KS2MNlL4Y0J7OFi8cDafEY0Y9Sq7cAnHUUAeZW3irXdZ8SafbafrOvz6W2g299JcadbadAQ7Tzo8swuQcDEY4QkfKSBzXtNpcwXlpDdWc0U9tMiyRSxOGSRCMhlI4IIIIIqvHpOnRSF47C0RzbraFlhUHyVzti6fcG44XoMmrFpbQWdpDa2cMUFtCixxRRIFSNAMBVA4AAAAAoAlooooAKKKKACiiigAooooAK4Px14Suta8S6dqQ0rQ9es7e2kgOnaxKyRRuzKwmT91KC2AVOVBxjB6iu8rifHXjW68PX0lnpul299NBps+q3Bur37KiwxkAhSI3LOSemAB3PIoA4HUvhV4mv9d16+aXQYDqNlqdoXtgsPnfaEZYjIqWyv8AKdpYvLKc5Ix0PoPgbwcvhXWtYls4bK1028gtFjt7UbQJo1cSyMuAMtuT5uScc1mWfxJmudQi26PEumG/ttLkma9xOtxNGjjbDs+ZB5ijdvB4JC4GaxNF+KuoyaFb3a6L9rtbfTdPv725uNQVZ8XLug2okAR2Gwk/cB9qAIdX+Ed3ceGLSC3/ALNOqJqlzeXW/YUu4ZJp3jjZ5YJRhBKrbTGy7gxAyd1PsPhjqlnq3hi6it9MdtMSGOWe/ukvWREmZ9sSGzXaQGwrRvD/AA5U7Bno9D+IF3qniLTrT+x7eHS9Ru7y0t7k3xM+623B2eHy8KCUIHzk8jIHSrHiLx+ui33iW2ksFf8AseCynVmuNn2j7RI6YA28bdnvnPagDif+FYeKJdJtdKml0VLXT9JutMtpluZWeYyTwyK7r5QCfLFggFue5zx3PgHwi3hjWPEMv9maNDFf3kt1Fe2pxcSI7bhHIvljAXJxh2+gqpZ/EC7l8SW9jcaNDFp1zq9xo0Nyl6XmMsSO+8w+WAEIjPO8kE8jHNYvxJ8ReJLXVfHGn2DQR6ZaeE2vo5VuTFPBIVugJU2x5Lbo1GN4ChQwOSRQBVm+Elze6fdw6kmk3Uv9n6pDaGTcwhuLi7kmhkGU4Kq4yw5BzjPWuz8ZeGtV1fwtpUOl3sFvr+mzQXEF1NuZFdVMchPGTlHkx6kjOOa5i4+KN/o1uLHU9AD6uJLOCFLe5muUlE8UrqzlIDICBC+VWN+SMEjJHSzeNp7f4X3vi280S5tbi0tpp30643wvmMsMZdAwVtuQSgOCDgdKAOU1X4b+ILi01lWvNM1WW4uIIbY6oBM/2CIyOEZ5YZVEoeVvmMb5CjPJyM3w/wDCPVtNh0z7THoc95DY3lj9sLnzbHzJ2khlgPkgM0auQFAjA52kDiuqf4harFrB0Kbw/Zpr73kdrFEdSP2YhoHn3NN5O4EKjDaEbJxgkZIisvibdXdxoznQ0tdMvmWN764uJTEJfPeFo43jgdGO5Bt8xo9+9cdTgA5rwz8H9Rsjax6iLHyEu7WW5ijukMVykSSqxMcdpD858wZLFywJDMcDPtltbw2ltFb2sUcNvCgjjijUKqKBgKAOAABjArgfhx8RrjxpfKB4evbLTp7U3VtevHPsYBgux2eFEDkNkBHkHDc8c97e3MNlZz3V0/l28EbSyPgnaqjJOBz0FAEWrXTWOl3l2kfmtBC8oQtt3FVJxntnFfMvijXNTtr6+v8AXp0sbnUQSWjKvCw2CM+UQSGAGAeSfXHFeo/8LPtvFMWp2XhbSr/ULb7M4F9EYwoJQ4/dswbrxgjJ7ZrC17TPDnjzT9E02SN/PgVLhLdYWtxmQAsQzKAVAVsgA5xjiuLFx9olFNr0O/A1lQk5OClfv+h6N4ct9N8VfDrSEu7BPsFzZRFYHGfLGwBSp6gjqGHI4PWvL4NU1DXLPV9P+WS40vUzZ2d/HLslcBgizEbSDkFwSOG2tjHbqr6+1Tw74ag8MxSO090yWOm6hDHjy0J+YMBwjRxBip6NsHfgw3Gm2tpqnh2109TBHbh08mMDBgSM4Dd8K5Qg+p9zWeLmpRio7iw9OSbfQxfGmo6nYanPLpoU3MFq/wBnkVA+N5iUIylgM7vmySAAOe5rZ+B2v3rxXfh/XGgS8izdWsazo7+QSAwIVmxtdh3PDjB4p+m6Za3usXmqT20chVzDbtIueAfnYDpywAz1wg7GtHwfcTap471PdbhItHQ24lz98zJE4H1AByO2V9anCSkqnKti8VC8XNv0PRKKKK9M84KKKKACiiigArm/G5LRaLbqMvPq1qF/4A/mn/x2M10lZ+oaYt7qWmXbyuv2CR5VjAGHZo2TJ+gZvzoA0KKKKAOW/t6dPigfD8jD7LLo4voxt5DrMUfn3DJx7GuD8SjHj7xGD3Ns34eSB/Q10HiECH4w6FengR2otWI9JvOwP++o1rK8fQ/Z/H8jjIS80+Jx7tHI6t+jpXlZ1FywcrdLfmellMksVG/W5zspsNFsrm68uC0t03TTNGgXJPJJx1JP4k1ykCah4xmjupt1rpStuiyASfQqDkM/+2flX+EMfmrr9RsLXU7Q21/Cs9uWVzG/3WKsGGR35AOKnkeOGJnldI4kGSzEKqj3PQCvjYVVBXS97v8A11Pq50+Z2fwkOn2Nvp9sILOIRx7izYySzHqzE8sx7k816R8Jv+RDsf8Artdf+lElcBoem6n4qcLo6Pa6a339VlTClf8Apgp++3o33B1y3SvYtH0210fS7XT7CPy7W2jEcak5OB3JPUnqSepOa+myPCVaXNVqq3N33Pns4xNKpy0qbvb7i5XAfGBLY6bozsinUBqMYtnH3lGCZef7pjV8j6e1d/XknxBMknxCC3JbZDpyNaKT8uGkYTMPfKxA+g2+vPp5lV9lhZytfS336HnYCn7TEQje2v5anI+L9FbXNFeC3lEN9C63FpMf+WcyHKn6HkH2JpPCWvpr2ns0sf2bUrZvJvbNvvQSDqP909Qe4rcqsLG1/tD7cLeIXhTyjPtAcpnO0nuK+EVROnyS+X9dv67n2bptT54/M7j4RANa+IJQchtS2/8AfNvCD+ua1/h5rs/iLStQvp3Dxrql5bwYUDEUUzRr0/3c/jWT8P5hpfwyn1hlOZludTOe6ksyf+OBKn+EFn/Z/hE2hGGhu5lYf7W7Lfrmv0HCQdOhCD6JfkfEYmfPWnJdWzt6wPH8JuPBGvRqMt9imYDHUhCQP0rfpk0aTRPFIoZHUqwPcHrXQYCWs6XNtDPCd0cqB1PqCMipKpaJYDStHsdPWV5VtIEgWR8ZYKoUE478VdoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuT8f8AgTTfHEFrDqsskccAcAR29tIx3YzhpYnZDxwYyp568DHWUUAZEPhnQ4dQt9QTR9P/ALQt41hiuzboZ0RRgKJCN2AOOtPi8PaLDbPbxaRpyW7xRwNEtsgVo4yTGhGMFVJJA6DJxWpRQBx9h8PtJs/G0nine8mos0jKPs9tEELjBJaOJZHOMgGRnxk9+a2tU8N6Hq95Fd6ro2m313CuyOa5tY5XRc5wGYEgZJPFa1FAHOaD4L0LRNWvtVtNPt21W8uJbiS9khjM4MhyyCQKG2egzV/U/D2i6tdJc6ppGnXtykTwrLc2ySOsbghkBYEhSGII6EE+talFAGZfeH9Gv4riK+0jTrmO4VEmSa2RxKqZ2BgRyFycZ6ZOKfDoekw6KdHh0uxj0ko0Zslt0EG1iSV8vG3BJORjvWhRQBmal4f0bVI7iPU9I068S5ZGmW4tkkEpQYUsGByR2z0qD/hFPDov7S9Gg6T9ttFVLa4+xx+ZAq/dCNjKgZOAOlbVFAGLa6H4d0S/uNStNL0nTr24BE11FbxwySAkE7nABOSAeT1FF34l8PRpsutZ0sI/yFXuUwfUEZriPHXgrXNf8SpqNvbaAsdtkROS63EylMYkbYRgEnAH1z2rj7/w5rulXKpe6FNMJ0Z2ktIBcLlcDDFVyDg8ZHIB9K2p04z3lYicnHZGr4p0jw94bmtrrwJqlrpl5fzLC9raXSGNyyssTCMkgKJdmQoAKls1Pp1qw1uPX2lu4tMWFtQ3MwIUiMobQqR8gRnlfHBLNjPyGuOu4pCWN7YTxQoNp861lhD+zfIMj9KbZ6jFBJLYq1xDDckzSxxzOFkGckgOoJXLc4OMn3qKmB537klqXTxHKveid3da7YXPgr7RLONUaa4CRFZCHW6LE+WAoDRtGQQB975cdTWf4n1g+GdFN5FO2qa5dIlnayS4RXJDFW+UYCDl2I64+mOTSexkkkt47SFk6h4rgock7jnON3X36sMdcxyWEMzxJq73kxgy8YebcV3YznCsT06/41g8rm3o1Y2+vpRdl73Q9C8A6xZ6joUVra+as+nxRwTRylS2dgw2VJDBsHkHqCOCCK1fh7q6W2i3dy1jqM1zf3styUjtjypISM7jhcFI1Oc9K8u0fQ9GQSPam5tS8m6Ui6DhwOsRU4IjPOVI9+tdQnkQQRLAIEtgu0bNkQAA46daull8qUnIzni3UhGMt1uenjxZpy7VuYtRt5jx5UljMW/NVIP4E1OPE2j4AkvUhk7xzAxuPqrAEV5zZarYScfuCeB5VtctISfdUwD+VdR4d0/WLy1iujK+kwOCVtpN8ki845DYC+vetZQ5dzNO519te2t1j7NcwTZGf3cgb+VWKyNK0Cz0+8lvObi+k4NxKq7lXAG1cAbV4zgdTWvWZQUUUUAFFFFABRRRQB554zR21jXr2BfMl0uxsL0L3JiuJpWA9yqEfjR8UrV7i00bXrCOW6htWZZvIQyEwSqPnAXJIDLGTgdMntXV6ZpUkGta3fXLI4vniWNRziJIwMHI67jIfoRVDwMzWVteaBKxMmkS+TEWOS1sw3Qn8F+T6xtWValGtTdOWzNKVSVKaqR3R59pOja9rjA6dYfYrQ/8vmoq0YP+5Dw7fjsHua7LRfhzpVpJHcaw8mtXiHcrXYHko3qkI+UfU7m967aiuXC5bh8LrCOvd7/16HRiMfXxGk3p2WwdKKKK7zjCsPxT4Z0/xLawx34ljmgYvb3MDbJYWIwSp5GCOCCCD3BrcopSipKz2Gm4u6PLrnwBr9v/AMeOrafer6Xdu0L/APfSEj/x0VmXHhDxVdu2ntZWtqkx2PqEd2JEjQj5mVSquXxnAxjOMnFeyUV50spwkpKXJ+Z3RzPEqPLznKeMreK18I2+hWKmNb14dKhRf4Y2wH/KJXP/AAGpvBQKSeIYj1j1ab/x5UcfowpqZ1fx074zZ6JF5a8cNdSqC3/fERUf9tj6Vo6Vp1xZa1rVwzxta30sU8ajO5XESxtntjCKR+NekcBrUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWP4u1628M+HL/AFe9I8q2jLBc4Lt0VR7k4H41sV8+/tAatc+JPFej+B9GbfL5ivOoPHmv90H2VSWPs3tXp5Rgfr2KjTlpFayfaK3/AMjDE1fZU3Jb9PU6b9n7V/E/iDT9V1TxBevPp8k5FssijO/OX2nqEGQAOnXGMV65Wb4a0e28P6DY6VYjFvaRCNTjBY92PuTkn3NaVY5jiYYnEzq0oqMW9ElbTp/wSqEHTpqMndhVPUNL0/Uih1GxtLspnZ58Kybc9cZHHSrlFcRqYbeEfDrAhtD0wg9jbJ/hVWbwL4dkcsun+ST/AM8JniH5KwFdNRTTa2YrI5n/AIQXw5nLacWPq08rH9Wq1ZeFNBspTJBpNp5pAHmPGHbAzgZbJHU1uUUOTe7CyGRRRwoFiRUUdlGBT6KKQwooooAKKKKACiiigAooooAK5qPI+JNwE6NpMfmj6TPs/nJXS1zXhr/SvEfia/3FgLmOxjz2SKME4/4HLJQB0tFFFABRRRQAUUUUAFFFFAHN+BtptdXYcynVrvzPXIlIX/xwJ+GK6Sub0EG08XeJLLACTGDUEA/20MbfrBn8a6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM3xJq9voGg3+q3hxBaRNKw7sQOFHuTgD614h+zxo9xrviPWfG2rjfM0rxwsehlfmQj2AIUdvmI7Vd/aZ1+VrfSvCthue5vZBPMinllB2xr+LZP/ARXq/gbQIvC/hPTdIiwTbxASMP4pDy7fixP4V9HD/hPypy+3Xdv+3Fv97/AAOJ/vsRbpD8zdooor5w7QooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACua+Hh83w0LrGGu7q6uW/wCBzuR+QwPwrpT0rmfh2yv4cZoMGyN5dG1cdHhM7lGHsQeD3GDQB01FFFABRRRQAUUUUAFFFFAHN3SiD4iafIP+XrTJ42+scsRX/wBGPXSVlSabLJ4oh1N5VMEFm9vHFjkM7qzNn6RoPzrVoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkYhVJYgAckmlrhfjXrx8P/DrVJo323N0os4T/tPwce4XcfwrfC4eWJrQow3k0vvIqTUIuT6HlfgBT8QvjlqHiGUF9O05zLDkcYX5IR7Hjf8AVTX0dXln7Onh/wDsfwCl7Km251SQ3BJ6+WPlQfTgt/wKvU69TP8AERqYt0qfwU0oL5b/AI3MMHBxp80t5av5hRRRXiHUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBHcwxXNvLBcRrJDKpR0YZDKRgg+2KWGJIYUihRY4kUKqIMBQOAAB0FPooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+b/ANqXXDNrGk6JG3yW8RuZQD/G5woPuApP/Aq+kK+JviVqEviLxr4g1eMGS1W68pZB0CDKR/mEzX1nB+FVXGutLaC/F6L9TzsyqctLlXU+zdHhgttJsYLNdlrFAiRL6IFAUflirlYXgS7+3+CdAus5MthAzf72wZ/XNbtfMV4uFSUZbps74O8U0FFFFZFBRRRQAUUUUAFFFFABRRRQAUUUUAFFcn4w+IHh/wAKbo9RvBJeAZFrAN8v4jov/AiK8uuPij4y8WXD23grRWgjzt81U851+rMNi/iPxrmq4qnTfLe77LVntYHIMbjIe1UeWH80nyr8d/ke+MwVSzEBQMknjFYGo+NPDWnEi713TkYdVE6sw/AZNeRx/Cnxl4lYTeLfEHlqefLaRrhl/wCA5CD8DXRab8CvDsCg315qN2/fDrGp/ADP61n7bET+CFvV/odn9m5Th9MRinJ9oRv/AOTPRm7cfFzwVDwNXMhBxhLaU/rtxUP/AAuPwZ/0EJv/AAFk/wAKsW/wl8FwD/kDeY3rJcSn9N2Kn/4Vd4M/6AUP/f2T/wCKp2xf938Sb8PrS1Z/+ADbT4qeDLkgJrcaE9pYZEx+JUCuk0vXtJ1XjTNTsrs+kE6uR9QDXHXfwd8GTg+Xp01uT3iuZP8A2YkVymv/AAN0q2t5rqw164sY4VMjNdqrqoHJJYbcD3pc+KhrKKfo7fmUsLkWIfLTrVIN/wA0VL/0k9SHifTh4qk8PTyeTqPlLNEr8CZTnO0+owcj8u+NyviC+vrs6ksg1Ge6ktm2QXO99wVSdpUnlR3HTGa+i/hD8RLjXo00nX4Jo9SjXCXJjIScf7XGFb9D+lZ4bHqrJwlp2O3O+EqmAoRxFB8yS95dfVLt3W69NvVKK57xl4rs/C9kslwjTXEiPJHErBBtQDfI7thY413Llif4gACSAfMB4q8Z+Knd9Msr6OxB+9C4sIWBx92SSOSeXqPmWOMYBPpn0T4w9worxux8P+Onlhk/4SGO0zGHZFvJ5yDycZcMp4A5we/tlkPj3xf4ajjufFOl/a9H+QtdI0Zcq3IYMpXt0DxR5PGQcUAez0VmaFruma7bedpV5FcKAN6qcPGfR0PzKfYgGtOgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMDx7q39heC9a1JW2yQWrmM/7ZGF/8eIr5x8MeGvN+AfinVTH+/kuonjP+xEy5P/j8n5V6l+0xqf2P4epZq3zX12kZHqq5c/qq1t+DvDX/ABZW00PaA93pj5B7PMpbn3Bf9K+ry+v/AGfl0K3WdSP/AIDDX8zz60PbVnHtF/exnwCvxffC7SQWBktjJbtjthyR/wCOla9Drwv9lfUS2j67pTnDW9wlwFPX512n/wBFj8690rys9oewzCtDzv8Afr+p0YSfPRi/L8goooryToCiiigAooooAKKKKACiiqWsanZ6NplxqGpTrBaQLud27e3uSeAO5NJtJXZUISnJRirtkmoXttptlNd388dvbRLueSRsBRXhviT4k694z1RtD+H9tPHC3DXKjbK4/vZ6Rr79fcdKzru5174z+JTbWZksfDtq2Tu5VB2ZgOGkPYdvzJ9y8J+GdM8LaYtjpEAjTgySNy8rf3mPc/oO1cHPPFO0HaHfq/Q+rWHwuQxUsVFVMQ9VH7MP8Xd+X/AZ534L+C2nWOy88Uy/2nfE7jCCRCp9+7nPrgexr1i1toLOBILSGKCBBhY4lCqo9gOBTNQuHtbczRwPOFI3KhG4L3IB649KyINWtjDqmr20pu4IisbLG33QgywA9fmJx1PArqp0adFWgrHgZhmuJzCfPiZt+XRei2OgoqodQtBHaSeehS7IWAg58wlSwx68An6CnfbIzqJshuMwi84kDgLnAyfU8/ka1ucF0WaKKKYwpkkaSoUlRXQ9QwyKfRQGwyKKOEERRogPUKAKx/GOtNoOhyXMEcc17I6W9rFI21Xmdgq7j2UZ3MeyqT2rbryf4/XLx2OmQZYRSJcbtrhSC6pb7gTwCFuXIJ7gUA3fcwdN0PXPFs9p4pa7tNSsZrqEpaahC0YvLZTlZMDIjG7EkceCMEPIWbG30XV11mzvNLitI7NbWWYQSzHKiCPK7MDPUgOg4PzFCcDIqbwnBf2cmoWTaXb2Gj2jxwabtlLM0AjUcrk7cEYC4Hy496q3fjPSdMspZ70rDFEkivLMFi+0CMAEoDjdnOOOhyDgA0AaOp6TFf8Ahm6sre+uLBZRiK7gyrQtgbXQjGQGweeDzng1O4s4NAYzI2o29rbtbMnliXz8AKy8jkkjaRnGc56VQi1W91T7O+ix28tvJKC808m3YmByqgkk84P3cEH61r3M2oWtwrRRwXFiY2ZiXYSCTJOBnI2ngDOMY60AePeJtP8A+EG8U6P4i0O2lttJlQn7IwbfG6AtLCA3KxvArkJ0EkKYAzz7nDKk8McsTB43UMrDoQeQRXA/EaAXfhqV7udwsN7BPCJOGRhMibcL1VgxHPZ+cjFbnw0mabwDoW85aO1SEn12fJn/AMdoAz9P8ReKdWS7uNK0DQ2sYr26tEe51mWKR/InkhLFVtWC5MZONx4PWs+98beIoPCeoeI7XSPC2o6XZW01y8lj4ikmDrErFwpFptLfKRjI564qz4XXT38BasutWX27Tzq+redbfZGu/MH9pXHHlKrF+ccAH1rzj4ewXOnfsteJtJ1LT9R0+/tNL1Iyw3llLb4DrMy7S6gNx/dJx3xQB9B0Vx/xVtLu88KiO2tbu9tlu4HvrS0YiWe1EgMqKBgtleqgjcMjvXH6hqdj4S0+fXfA/h6807T4LqFL6xOmtYpqAkVo4xDHIqsrrK0eSFXcCfvcYAPYKK8c1ifxrb6tpuk3Oo6vfG4tIobk6fp6xokzK3mSNI9q8RQEjAEqEBcYYmur+C0VxbfDfRLS9l1Vrq1tYbeWLUbP7M9u6xIDEg8tN0akEB/mzz8zUAdxRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfPf7Sbvq3i/wAKeH4id8gzgdzLIEH/AKAa+gYY0hiSKJQsaKFVR2A6Cvn3Xv8AieftQafbEbo7FosHHA8uIzf+hH86+ha+gzj91hcJh+0Ob/wJ3/Q48N71SpPzt9x87+Af+KT/AGhtZ0h/kt78zJGDwMNiZP0GPxr6Ir56/aEgk8PePfDXiu1U5BUPju8ThufqrY+i19AWlxHd2sNxA26GZBIjeqkZB/Knnn7+lh8avtxs/wDFHRiwnuSnS7P8GS0UUV88doUUUUAFFFFABRRRQAjMFUsxAUDJJ4xXzx4t1a/+LHjeLw/oUhTRLVizS4+UgcNM3qOcKPftk46/4++LX0vRo9A09m/tDUh+82feWHOMfVjx9Aa6P4TeDk8I+GI45kX+07oCW6fuD2T6KDj65PeuCs3iKnsV8K3/AMj6vLYxyjB/2nUV6s7qmn07z+XT/gnR+G9DsfDuj2+m6XEI7eIdf4nbuzHuT61pHpmloruSUVZHy9SpKrNzm7t6tnLf8JNNqNzcQeHreG7mtyRIk0hj5A4zwSuT0yCevAxXBW1+7L4msdSjk0b7VMXUMVYwzHDROuOG+YbPqoHHb0TxRpzzlbyGGPzIoyPPjT/SIu+VP8Q9UOM9jmvKQmt+KI7a5axX7I1608tw3CuqjbJCi/eZdwLq/HXHUGsKl7pdThrN3S3Z0HhGSDQbe41LxTqcQj0SJbWCASbhD/AWXpksFAAHQ7wOtavh/wAQX9z4heVbKWVb4hhboFV4IcfLJJuORnACrweWJwcCvOZ4Zr6/0yCVIBc2Svc3JaLzPLcH5mQD7xO4lQeM7Scc17V4N0SLRtMJ2KLq6YTXDghiWwAF3dwoAGfqe9KneWi6CouUnZaJf1/wDfooorpOwKKKKACvL/jzpEupaJYmBFeRzNZqrA4LyxExKSOm6aOJfqwrvbfXtNufEN5ocFyJNTs4Y7ieFVJ8tHJC5OMAnBOM5xz0qTXNLtta0i6069DeRcJtJQ7WU9QynswIBB7EA0Aeeanrs9z4P/4Sm31O4GhR6VJerYCGMfaCYnYK0hG5WXIHHGV5JORXzF8RfFV3o2sSWd9pOiatql5FDdajdX9r58rySoJPLUk5jjVSqqE2kYJzyDXv63F74Re40HxVAJdM1IzQtOYS0YEgYs8YHBjbc7NEcNGWYjdGMryMnwz1jWrKwhl8N6L4iitbEf2Zr9xfNE0kA2iOKRIziRtvQkgbT1yDkAufBHxHqEF9exXenWdnpZs4JbO78zzfsMc2BDbOWwzLhAA2QPkAJY4r3rT71r/SRJBMkZmhBjkhxJs3D5SvGGHIIPQgjgV5/wDCnwloTaRrNtqYsda1G4mJ1B3s1RfvACLaMrtVoiABwNoHUZO7r3iBPDviA3F9qdullPbmC10iO1LXc9wH4ZAMF12jAGMDrnFAGB8U9UGi6Fpnh6O7GoXU0qXt7JdfM6WkcodpPlGA24IiA4yTgZYDPfeBbCXTPBui2lypS4jtI/OU9RIVBcf99E1578LtMvvEfiC78Ua+sU0YYG3VGLwLKAFAhJJ3LGoPzjKmSWXbkAMfXqAOPt/Bl1Ztcrpni/xBY2011Pd/Z4o7JkjeaVpXCl7dmxudsZY1Fq3ge91fSr3TdQ8beJJrK8he3nj8qwXfG6lWGRagjIJ5BBrtaKACoLuztrwRC7t4ZxFIs0YlQNskU5VhnowPQ9RU9FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHz18MR/av7Q3ii96rbG6Kt9JFjH6E19C18+fsz/6d4p8W6mfm3bPm/wCuju3fn+GvoOvoOJfdxvsv5IxX4X/U48DrS5u7bPPPjxoP9ufDjUDGu64sCL2P/gGd/wD44W/Sof2ftf8A7b+HVpDI2bjTWNm+f7o5Q/TaQP8AgJr0eWNJY3jkUNG4Ksp6EHqK+dfhPK/gP4xav4VumK2l4xiiLHqRl4W/FSR9WFVgv9syythftU3zx9Npf5+oqv7qvGp0ej/Q+jKKKK+dO0KKKKACiiigApk0qQQySzOEijUuzNwFAGSTT64D44a0dH+Ht8sbYmviLNPo2S3/AI6GH41FWapwc30OrBYWWMxEMPHeTS+886+Hlu/xC+LF/wCJL1SbCxcSxI3Y9IV/ADd9R719CV5/8DdEGj/D+ykZcT35N259m4T/AMdCn8TXoFYYOm4U+aW71fzPU4jxccRjXTp/w6fuRXlHT8WQtcwK+xp4lf8AulwDTft1plB9qgy4yv7wfN9PWuE8c6A9rv1HT4tymY3ErfMzxv6qB1BzggkADrx05S4ghkOyPETP8kqA4dvl3bA3RUAycDg4x3NcdfMalGbhKH4niqCaPZVv7Nhlbu3I45Eg7nA/WvGfiNdpaXM2lRSo1tNdoYiJ2zZMzBt6qOMBmDc9iQOlTXCRBU8iMEyxxmIbdgk2EOqoeg4zx/hUVw0TO1zayI+4CU+Y4RI2HAaTJJ4xgLjg7u/Nc0s1c1bl/Ezq4f2kbJ2HPBeR+K7Cxl1GKVLqRWjtlJH2ZgN7v5inJUNGyAH+Hapr1bSGs7KyRRdw/vGyQLgugY9QhY5xkHivJ7WCFZf7QEwUSkkqQEj+6Q33iDhjtP1FF55cO26QbZBHiGXarQREgAqpHC+uTgHgE44pxzTlekfxCnh+S7uez/bLXGftMOM4zvHXOMfnxSNe2qhi11AApwxMg4+v514z5S24uAUS5Owqvmy/J5Q+8T1LHPLEAnLAdq1dB0G61mKJ0QxuhwLmaL5RjjeFJOXA4BY59QOlawzSdSXLCF36mjgl1PWFIYAggg8gjvWD478TW/hHwxeatcI0zxgJb26ffuJmOI41HcsxA/M9q2bO3W1tIbdGd1iQIGc5YgDGSe5rzXTv+Lg/El9SYb/DPhWZoLP+7dahjEkvusQO1T/eJIPFewr21MzoPhh4ZufD2gyT6y6z+ItVlN9qk45DTMPuL/sIMIo6YGe9dHq8M81k32OQx3MZDxnsSOx9iMirtFXGXK00TOKnFxfU4u/u/wC3LB9N1nRLqQsVOYdyFHByHVuCjA4IYHj1rAXwZ4k062Z9EvFSSXdvH2kW743AqSoieBn67m8tS2eTnr6nRWk6sXrCNjGnRmtKk+b7keR2fhv4iuCsmrpbqTyTcQfNyDuYJaAs2RnO4d/WtXQfhXY29xJd6/fXGr3UwAmDlgko67ZCzNJIuf4Gcp/sivR6KxOghia3haO0iMUbLHlIVIBCDA4X0HAqavAtTLeEv2iLe4LEW2qMpOe4lGw59hIM/hXvtYUa3tOZNWadj08yy76kqU4y5o1IqV7W33XyCiiitzzAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqrqs32fS7ybLDy4XfK9eFJ4q1WR4vdo/CetSIcOtjOwPoRG1aUo81SMe7RMnZNnjv7KUO3TfEU+B880KZ7/Krn/2avea8T/ZXRR4U1iQfea9Cn6CNcfzNe2V7HEkubM6z81+SObAq1CIV4L+0poc9ldaP4w0zclxbSLDK6/wkHdE/wCe4Z/3RXvVZXirRLfxH4dv9JvAPKuoim7GdrdVYe4IB/CuTKcb9RxcKz22fo9GaYil7Wm49RnhDXYPEvhrTtXtcbLqIOyg52P0ZfwYEfhWxXz/APs8a7c6Jr2q+CNZzHMkrvArHpIvEiD2IG4fQnvX0BTzbA/UcVKkvh3i+6e3+QYar7WmpPfr6hRRRXmm4UUUUAFeFftHzyXureG9EgJ3ylnI65LsqL/Jvzr3WvB/iGPt/wAf/Ddu3Kw/ZuD7SM9ceO1pcvdpH0nCqUcf7Z/YjKX3L/gnuVnbx2dnBbQjbFDGsaD0AGB/KpqKK7Nj5xtt3Y10WRGR1DIwwVIyCPSua1Dwbp9xGotS9oyghfL5ABQqOD6A8c109FZVaMKqtNXBNrY8f8QWFxo8y2NzCkkMiYWQghXCjjBzxtALE9fugcnNQPOq3qQOlqpGGbzpVADH+JR95m68kDmvYLy1iu7d4Z1yjDtwR7g9jXG6n4PvjkaffROhG1kuVxkd+VAIP0/KvDxOWThK9JXX4min3ONkCzlMkJcRxg7Tbx7mdtxwN3QnYx4+ualJhju1eEkyyo6vLC3LFAdxZQNpI4A46n8/QNK8IWFrcG7u1FzdsOd3KLwBwD7KBn6+proIbaCDPkQxR5OTsQDJ/CnTymclebt+IOojzPwvoNzqV1DcSLLBarK8jh0K5WRQxUEgZO7uMivT4Y0hjWOJQqKMADoKfUGoXlvp1jcXt7MkFrbxtLLK5wERRkk+wAr1sNhIYZWjq2RKVzi/itrt7a2Fl4d8OybfEuvubW0cc/ZowMy3B9kXn/eK103hXQbHwx4dsNF0qPy7OziESA9W7lj6kkkk+pNcH8ObbUdZv774g31iHu9WQQ6bbTSbGtNPU5jA4PzSH9431Wu2N1rkoxHp1vAfWWbd/wCg13RpOSvdfejCdZQdrN+if/DG0SACSQAOSTXM3/ipYrkC1t2mtEcJLPzt/wCA/wCeavLpE90c6veNcLnPkxjZH+OOTV+ewtprF7MxKtuwxtUAAe4rWHsqb9/3vy/4JjU9vVj7nu+urf8AkiypDKCDkHkGlrmILrUdDxZz2ct7bLxFNCCTt9CP8/jWhFqN9dcWumyRA/8ALS5bYB+A5NTLDyWqaa73Q4YqMtGmpdrM1ZHWNCzkBR1JpwqFISdpnbzHU5HGAD7CpqxdjpV+p4b+0tZNCdA1iA7ZYneEsPXhk/LDV7Rpd2moaZaXkf8Aq7iFJl+jKCP5155+0Paif4dtJj/j3u4pfzyn/s9dF8Kbk3fw60CRuq2qxf8AfGV/9lrhp+7iZruk/wBD6bGfvskw9R7wnKP3+8dXRRRXafNBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWP4z/wCRP13/AK8J/wD0W1bFY/jIE+ENcAGSbGcAf9s2rbD/AMWHqvzJn8LPLf2WP+RP1b/r/wD/AGmle1V4p+ywQfCOrgEZF9kj/tmte116nEX/ACMq3r+iOfBfwIhRRRXinUfP37QWhXOgeJNL8c6L8kqyolwQOkq/cY+xUbT9B617V4S1618TeHbHV7E/urmMMVzko3RlPuDkfhU3iPR7XX9DvdKv13W11GY29R6MPcHBHuK8H+C2tXfgfxzf+BtfbZHNNiBjwomwNpGe0i4x77fWvpY/8KmXcv8Ay9ofjD/7X8vU4X/s9e/2Z/n/AME+iaKKK+aO4KKKKACvCPFn/Jxujf8AbH/0E17vXg3xWP2D43+FbxseW/2YsT2xMwP6Yrjx3wRfZo+l4X1xNWHWVOa/A95ooorsPmgooooAKKKKACiiigArzDx8zeN/F9p4EtWP9l2wj1DxBIp48oHMVrn1kI3EcHYvvXW+PvE8HhHwxdapLG0842w2tsnL3Nw52xxKOpJYjp0GT2qn8MvDE3hrw8x1WUXGv6jK19qlyP8AlpcPyVH+yowqjphe2aAOg1G5On20ckUBeBCFdYxyq46ge3H4VXt9ct7z5dPSa5fuAhUL/vMeBWtUVxPDaxGSeRIox3Y4FaRcbWcbsxnGad1Ky9P1/wCAx0QcRr5pUvjkqMD8KfXN6jq9+8Ju9Mt/9Bhw7ySDBlXvtB5A966C3mS4gjmiO6N1DKfY050pQSk+oqVeFRuMen4+nckooJA68VHFJ5gJAO3sfWsje5JRWBDNqunzvbtZteWoY+VIjgMFJ4Bz6VpW5vZmV51S2jGD5atvY/U9B+GfrWsqXLrdW9f6ZhCup6Wd/T9djkPjmAfhbrWR08j/ANHx0vwN/wCSW6J/23/9HyVD8eJhF8MdTQ4zK8KD/v6rf+y1a+CsJg+GOho3UpI/Ixw0rt/WvO/5i/8At39T6t6cPJPrW/8AbDt6KKK7D5sKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKpa3GZtGv4gcF7eRc+mVNXaQgMCCMg9qqMuVpiaurHhX7KcmdH8QRY+7PE2fqrD+le7V89/su5tNZ8V2D/fAhzkc/I0in/wBCr6Er3OJo2zOq11s//JUcmAf7iPz/ADCiiivBOwK8b/aH8FvqelR+JtKVl1LTVzN5fDPCDncCO6Hn6Z9BXslIyh1KsAVIwQRnNdmAxtTA4iNenuvxXVfMyrUlVg4M4b4P+Nk8aeFY5ZnX+1bTEN4g4y3ZwPRgM/UEdq7qvmjxJZ3fwa+JkOsaZE7+Hr8kGIdNhOXi9ipwV/DrzX0ZpeoWuq6dbX+nzLNaXCCSORehB/z07V3ZzgYUpRxWG/hVNV5PrH5f1sZYaq5J05/FHf8AzLdFFFeKdQV4f+0vZvGnh/Vocq0MjwlgOhOGX/0Fq9wrhfjVo51j4d6ksa7prQC7T22fe/8AHC1c2Lhz0ZJf1Y9rh3ErC5lRqS2vZ/8Ab2n6nYaTeJqOl2d7F/q7mFJl+jKCP51arzv4D6wNV+H1rC7bprB2tWz1wPmX/wAdYD8K9ErWlP2kFPucOYYV4PFVMO/str/L8AooorQ4wooooAKKKKAPMtNgm8cfE2fVbuKRfD3heV7WwjkUqLi+xiWfB6qgOxT6liDXptFFAFK708XLlvtV3FnqIpio/wDrfhUdto9nC4cxmaUf8tJ2Mh/Xp+FaNFX7WaVkzJ0abfM1qH1rFGiy28j/ANnahNawsc+UEDqp9s9K2u9c9F4gSzuZLPV90c0bYWUKdsi9mx2/lWlFVHf2evlv+BniHSTj7XTs9vxNS1sFhIaaaa5l/vStkD6L0H5Zq7WUmsxXZMelq11KO+CqL7sxH8smtC3WRYVE7h5f4mAwM+w9KipGa1nv/XQulKD0p6rv/wAHqS0UUVmbHj/7S1+IfCmm2IOHubvzMeqopz+rrXo3gqxOmeENFs2Xa8NnErjGPm2jd+ua8b+J7Dxd8ZdF8PR/vLe1KRzAc9f3kn/jgA/Cvfq4qHv16k+1l/mfTZqvq2V4TCveV5v5/D+AUUUV2nzIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfPfwfxpnx28W6eQFST7UEHTpOrL/wCO5r6Er56b/iS/tTA52w3h/PzLf/4sV9C19BxF79WjW/npxf6HHgtIyj2bCiiivnzsCiiigDD8aeGrLxZ4dutJ1FfklGY5AMmKQfdce4/UZHevEPhN4nvfh94suPBPitvKs3mxBKx+WKRuhB/uPx9Dzxlq+i683+NHw9j8Z6L9psUVdbs1Jgbp5q9TGT/L0P1Ne7lONpcssDi/4U+v8sukl+pyYmlK6q0/iX4rsekUV418CviI+pxf8Iv4ido9ZswY4Wm4aZV4KNn+NcfUj3Br2WvOx+Bq4Gs6FXddejXRo2o1Y1o80Qpk0aTQvFKoeN1Ksp6EHgin0VxmqdtUfP3wunfwN8VtV8MXjFbW8byombjLDLRN+Kkj6kV9A14x+0L4blNvZeKtNBS6sSsc7J1C7so//AWOP+BD0r0P4e+JofFnha01KMqJ8eXcIP4JR94fQ9R7EVw4V+ynKg+mq9D6nPI/X8PSzWG8lyz8pLr81+h0lFFFdx8sFFFFABRRRQAUVm3s2qRSH7La288fbMhVh9QaqH/hILkEf6HZr68uw/pWsaN1e6Xz/pmEq6i7KLfy/XY2Lq4htYWluJFjjXqzGuR1LxDqO5byzgZNNRwu5l/1v1z0H0rbt9Ch81Zr+WW+nXoZjlR9F6CtSeGOeF4ZVDRuNpU+la050qT25vy+RjVp160dHyem/wA/8l94W8yXEEc0R3I6hgfamXNnbXWPtMEUuOm9AcVzUZ1Lw7IbeK3kv9PY5jK53J6jgf8A1j+daMOrX90QLbSZlz/HcP5YH6ZNEqEovmpvTo7pBHFQkuSqnzdVZv8ATY2Y0SNAsaqqjoFGAKbDKsylozlM4Ddm+lQ28M7KTeyI7NxsjXCD8+T/AJ4qyoAAAGAOmK53ZeZ1RbdtLC1neItWt9C0O91S8OILWIyEf3j2Ue5OAPrWjXg/xs1+48TeI7HwToB81vOX7QVPDS9lJ9FGSff/AHa5sRW9jBy69PU9jJsueYYqNJ6QWsn2it/8iX4AaXcatres+L9TBeWV2iiYjgux3OR9BgD6kV7nWV4W0W38O+H7HSrPmK2jCbsYLt1Zj7kkn8a1aMNS9lTUXv19QzrMFmGMnWjpHaK7RWi/zCiiitzygoorj/FB1K88aaHpFhrd9pNtPp97dytZxQO8jxSWqoCZo5AABM/QDt6UAdhRXK/8Ivq//Q9+JP8Avxp3/wAi0f8ACL6v/wBD34k/78ad/wDItAHVUVyv/CL6v/0PfiT/AL8ad/8AItH/AAi+r/8AQ9+JP+/Gnf8AyLQB1VFcr/wi+r/9D34k/wC/Gnf/ACLR/wAIvq//AEPfiT/vxp3/AMi0AdVRXK/8Ivq//Q9+JP8Avxp3/wAi0f8ACL6v/wBD34k/78ad/wDItAHVUVyv/CL6v/0PfiT/AL8ad/8AItH/AAi+r/8AQ9+JP+/Gnf8AyLQB1VFcr/wi+r/9D34k/wC/Gnf/ACLR/wAIvq//AEPfiT/vxp3/AMi0AdVRXK/8Ivq//Q9+JP8Avxp3/wAi1U0+PVdI8fabptz4i1LVrK80y8uGjvYrVdkkUtqqlTDDGekz5BJHT0oA7WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+evj1/xJfir4T177kYERY54PlTZb9GAr6FrxT9qXTfP8KaVqKrlrW7MRPosinP6oteneBdS/tfwZol+Tl57OJn/39oDfrmvoMw/fZZha38vNF/fdfgcdH3a9SPezN2iiivnzsCiiigAooooA8U+OPw6nupP+Et8LB4tXtiJbiOE4aQLyJEx/GMDjuB6jnpPg58R4PGuli1vWSLXbZP38YGBKvTzF/TI7H2Ir0evAfjB8Pr3QNVHjTwT5kE0Lme6hh6xt3kUd1PO5f6Zx9LgcRSzOisvxbtJfBLt/dfk+n/DHDVhKhJ1qa06r9T36iuE+FfxEsvHOl4Oy31iBR9ptc/8Aj6eqn9Oh7E93Xg4nDVcLVdGsrSR1wnGpFSi9CG9tYb2zntbuNZbedDHIjdGUjBBr560i6uvg/wDESawvjJJ4fviMSEZzHn5ZB/tLkgj0zx0r6LrmfiD4RtPGOgvY3OI7hMvbT4yYn/wPQj+oFediaLmlOHxLb/I9/Jcxp4aUsNilejU0ku3aS81/XQ6OGWOeGOWF1kikUOjqchgRkEHuKfXgXw08Z3ngjV5PCPjINBbRvsgmfpASfXvG3UHt9OnviMrorowZWGQQcgiroV1Wjdb9V2OfNcrqZbV5JawesZLaS7/5i0UUVueWFFNkkSKN5JWVI0BZmY4AA6kmvLvGnxKKXdlpugzRWMF6JG/t29jJgRExvMCdZ3w2R/BwTlgDQB6ctxC1zJbrNG1xGod4gw3KpzgkdQDg4+hqWvK/CGpo+hy3HhOF7HR5P3114n175Xuz3lVGwz+zPsQDAUEDFejaHc295pFpcWd419byRgpctjMo/vcADn2AHpQBeooooAKKKKACiiuA+J/xGsvB9o9tblLnWpF/dwZyI89Gk9B6Dqf1qKlSNOPNJ6HTg8HWxtZUKEbyf9fcR/F7x/F4R0o2tk6vrV0pEK9fJXp5jD+Xqfoayvgf4Gk0i1fxBrSMdWvVzGsnLRRnkk/7TdT6D6kVifCzwBfa1qp8W+NQ80krCaCGf70jcESMOyjsv8gBn3OuSjCVaftqisui/U+gzHEUcswzyzBy5pP+JNdX/KvJdf8AhwoooruPlgooooAK5XUv+Sp+Hv8AsC6n/wCj7CuqrldS/wCSp+Hv+wLqf/o+woA+W9c0jT7zxd4ie4sLWaaTW78F3hVmP+lygcmqnxC8I6f4fTWrI6bBHPbWzEM9tEjqTHuB+RmAPPZj+HSuk1fS9Zt/Feuv/wAI94gkU6xezI0Wk3MiOjXMjKyssZBBBBBBPWmfEptc8WXWt30PhPxJDLewFEg/sm6bB8oIBu8odce3Wg+Nq0cQ685JS+PTR2td38ux9MePdeufDHhW91i0sob57UBmgluDACpIBwwR+eemPxqrN480O01dtIv7iWPVIpYredIrS4lijnkRXSPzhHsJYMNuSC2cYzxWh4w8PxeKPD9zpFxeXdnBcYEklr5e8gHOPnRhg4HbNZ0vgbT5rm5uJ7u+knuNRtNUlcsg3TW6RonAQAKREpYepOMcAB9kc54S+KVldaH/AGn4huHh+0GWaG2ttHvN8Fuh5eQ4beoBXMoCpnI6g1seI/iRoulaZrVxZC71OfTLWS4dbW0neAssXmBGuEjaNCRjOTxnkVn6n8IPD2oWWkQSPPv0yBraKaW3tblmjZt2GWeF0yD0KqDyecVoj4eWSw6rZw6pqkOj6pFJHd6ZH5AgcyQ+UzL+63oSMNhWC5HTHFAD7L4g6TNeW8Vy7WaTwWzoLmC4ilDzyyRIrI8ShVLR4Vi3JPQAqWlvPiJ4Ys/MMuoSusTSrK0NnPMIhE5SR3KIQqKwI3nC5B54NV3+HdhcW19HqOp6pfS3mnRaY9xK0SSKkckkkbr5cagOrScHH8K5BOSc7V/hB4c1KLSlYypLp9oLNJZLe1umkTcWy4uIZF3FizFlAJLH6UAdfr3iPTNBhtJNQmm/0uTyreO2tpLmSZtpbCpErMflVjwOAM1gaf8AETT7rWdasX0/WUXThC4kTSruRpFkjVuUEOVYbwNp+bgnHBxqeLvCdp4n0SLSrmd7e0jZW2x21tKGwMAbZopFGOoIAI7GufvfhXplzaXFoNX1qOzuIbaKaDzIZFlaAKqO/mRsXO1AGViUYZypoA05fiP4YjtIbg3t0/mtMghj0+5edTCcS74VjMiBSRksoAyPWp4/HvhyS+tLWO/keS68kI62sxiVplDRK8mzZGzBlIVyCdw45FcRqXwmm0jS47fwPdSQ3brdRzXE11Fajy59hZPLS1dCu5AQqiMr/Cwzxr6d8ItCtdW07VS26/to7USsbO1lWZ4I0RW3SxPJHkIv+rdfXrzQB6RXK6l/yVPw9/2BdT/9H2FdVXK6l/yVPw9/2BdT/wDR9hQB1VFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBxvxh0v8Atf4a69bquXjtzcL65jIfj8FI/Guc/Zs1X7f8OVtGPz6fcyQgd9rfOD+bkfhXqU0STwyRSqGjkUqynoQeCK+fP2fZX8O/ELxN4WuGI+9s3fxNC5Xj6qxP4V9Dgv8AaMqxFDrBqa/J/gcVX3MRCfe6Poaiiua8R65qtnr+maRoemWN9c3lrc3bNeXz2yRpC8KkArFIWJM47D7pr547TpaK4ebxN4lg1a30ufTvB8ep3CGSGzfxLKJpVGSWVDabiBg8gdjWx4S1u+1d9Zt9VsLaxvdMvRZyJbXTXEb5ghmDBmjjPSYDG3qOpoA6CiisfxJ4m0fw1aifWr6K2U/cUnLv/uqOT+VKUlFXbNKVKdaahTi230WrNigjI5rxfVfj3psMpXS9GurpB/HNKsOfoAGqvafHyITBNR8PTQgHDGK5DMP+AlR/OuV46gnbm/M92PCmbSjzKj+Mb/de5n/FT4eX3hbVf+Ey8B77fyGMtxbQj/U+rqO6Hncvb6dPQvhV8SLHxzYGJgttrMCgz22eGH99PVc/iO/YnT8JePvD3ioiLTL0LdEZNrONkn4A8N+BNcda/Djw7ffE6TWdEvZLM6XcA3ljB8gMxUMpQg/KpycjvhgMV9RTzTDZjhfZY2XvxXuTWrdvsvv5P+n81Xy3FYKtL3GrfEmrW1tc9coqK6uIrS1mubmRY4IUMkjt0VQMkn8K5O1XXPEdt/aF1eXGiaVIvmQWdqi/anjxkNK7A7CRzsQAjOCxPA8I0LHjnwNpHjKCBdTR0nhYFLiEgSBc8rkjkH9OtdFY2sFhZwWlpGsVvAgjjjXoqgYArx3Vdcsha3X/AAicmva1FDk3OqS61Pb2VqM7SxmLHfggkiNW6c4qroWmXupXgh1r4ja7bvKoMNra+ZZJg4OVluFLS8emPoOahQipOSWrN54qtUpRoSk3CN7Lor7nt880VvE0txIkUSjLO7BQB7k1xuvfELT7NZl0sRXskS73lkmEFsgyBzKw+Y8jhAxrk9OsGNpbvNpN68xuBGn9rXX2u6u0AJaRPMOEXgMCADgEbRkVFrluqaptu7S2ks5UWALjLvlgXVtu4Mu0YCHYRjOcE4swLPl674kk/tDWby2vNLVl8m0swptz0+fa2TKc5AVgeVyAN2FpXIjmk8R6LearJqNle3UyAbABagKzhZJc7t25SoH/AE0QbcYFbV3rNnpHiLTdKnuRZ3txbz/ZQiNhEXlxIobaqDC4PzHJOMd8nRJI9Slu7LwR4a0yeynbzZ9UCCO288kFyXK5lI4HyqcFASRnCgGJ4M0O51+I6z4n1Kxj8mRsz6rdteSQMpwwjgk2xQYIIDOrscZ4zXrvhFtKd530q8u9TkYAS6hM7yrLgnhX+4e/CYA9K860b4Y/D3wTdtqXiy9tNS1gnf5mpyhhH3AjiJPTjk7m4zmvUfDHiHTfEdpLcaK7y2cT+UJTEyKxAGQuQCQM+mKnnjflvqb/AFat7P23I+XvZ2+82aKKxdb8VaFoSsdW1W0tmXrG0gL/AIIMsfypykoq7diKVKpWlyU4uT7JXNqobu5gs7aS4u5o4IIxueSVgqqPUk8CvHvEfxytEc23hbTpb+4Y7VlnBVCe2EHzN9PlrDt/Bnjr4iXMd14su5NP07O5YpRtIH+xCOh92wfrXJLGRb5aK5n+H3n0FHhurTiq2YzVGHn8T9I7/wBbGt42+L0t7cf2N4CgluruU+WLsRknP/TNO5/2j+Xernw3+E/2S6XW/GLfbdUdvMW3dvMVGPO5yfvt+g9+3eeDfBWieEbbZpNt+/YYkuZfmlf6nsPYYFdLShhpTl7Su7vt0Q8TnVLD0nhMqi4Qe8n8cvn0Xkvw1Ciiiu0+aCiiigAooooAK5XUv+Sp+Hv+wLqf/o+wrqq5XUv+Sp+Hv+wLqf8A6PsKAMjUPjH4G0/UbuxutXuFubSaS3mVNNunCyIxVhuWMg4IIyCRxVV/jj8PkRnfWrlUUZLHS7sAD1/1VeC23h2fxT8VNe0q3lSAy6zqLPK4yEVbiUk478DpVr4qabpVp8IfDlxpKLIZ474PdtbLDLOFYgbwC3ToMsePTpW/so2Wp0+xjZa6s+u6K5L4oahf6b4Xjk0q8ksbqbULG1+0RojsiS3McbkB1Zc7WOMg1zB8UanoviO50O61WfWLeC+0+MX+2CKRDcSSK8E22PYdojVvlVGw45BwawOY9UoryGL4ygz3sbaNHKq28dxZT29xMIboPcpbr881vGAu6VCXXeuM8nGDp2vxD1q51D+yovDuntq41SfTCg1VvIBito5y/meRu6SbcbOCKAPS6K8qsvi1JfWCaja6HGNPht7Oe+M1+EliNwxULEmwiXGOpZM9ACeKp+K/iP4gjsdQt7PS7XSdSt7u2WKO7uJVlkha9ihZsNbeWUYOAWR32h8/eGKAPYaK80HjvVYvEt5oaabDcay99HaxwzagEtYiLKKeTbKIN+MuQAVZmOT8o+UdR4q1zVND8OwX1vov9oX7NGk1tbySukWR8zbkiaRlU8fLGScj5RzgA6OivIdP+I2sPrOu3sq6I+g22m2Vymb+ULHJK06YUi18xyzoqEFQV2jAJYqLWi/FS91mWPT7Pw/FFrLXtxaNFeXcttAiwwxys5eS3EgyJVAUxA9T0GaAPVK5XUv+Sp+Hv+wLqf8A6PsK4vTvjHcak2mf2f4VvbkT2lpdXSwCeZoROeiGOBkbauSTI0WcHGcV2mpf8lT8Pf8AYF1P/wBH2FAHVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzr8Rv8AijPj5o+vD5LS+MckrDgAEeVJ/wCO4b8a+iq8f/aa0L+0PBVvqka5l0ycFj/0zkwrf+PbK9zh6tGGMVKp8NROD+f/AAbHJjYt0uZbx1+49grlNSz/AMLT8PY6/wBi6n/6PsKPhZrv/CReAdHv2bdN5IimJPPmJ8rE/UjP41b8Q+G21fVbDUrbWdS0m9s4ZrdZLJYG3xytEzBhNFIOsKEEAHr615FejKhVlSnvFtfcdMJKcVJdTxO18J+M7L48+ENc1nSra8u5mvHvtQtLmaW2jjaMqqZMIEQRDhEJO9s5YbiR7F4N/wCRj8d/9hqP/wBN1nR/wi+r/wDQ9+JP+/Gnf/ItWtC0OTw9Z6vLDe3usX99ObySS8MSPJIIY4lUeWiIo2xIOnqTWRaV3Y5v4r/EWHwfaizsQlxrc65SNuViX++39B3/AJ8T4O+Fuo+Kbn+3vH11clp/nFsxxK47bj/Avoo5+laHw28Bare+L9Q8SeOrZlvY5t0MTkFWk67xgkFVGAuMj8q9qrghSeJl7Stt0X6s+sxOPp5LT+qZdJOo179Ra79Ivsu/6mXougaTokKxaTp1raKBjMUYDH6t1P1Jq3f2FnqMBhv7WC6hPBSaMOv5GrNFdqikrJaHy0q1SU/aSk3LvfX7z5w+Nnhbw94bnhudDj1Cxv2YP5cULG3HuJDjafZSfoKwfhL4yn0Xx4tzqVy8kGpt5N3JI2SSx+VyT6N39Ca+q5ESVGSVFdGGCrDII9xXEeIPhZ4T1oMzaaLKdv8AlrZHyiP+A/d/SvOq4Kaqe1otLy2PtcDxRh54N4HMYyldNc11J6+tnputWa/juI3uhf2Srsh1WZLJivXy25l/8hrJXDfEjVpdb1y90CxEkukaJbLd6za27hJb8srNFZoxGADtBfkZVgozk11OlW0k3imzszdyXUPh208uSWROZbiVQFyem5Yhk+vnCub+Gk1pY+DbzU9evIrS61PWLg3D7/LdpzdSIiF8gHKqiAdsYz6ektj4iSSk0ndGN45u9W/sbSLNLaHTrqTT7mbT4CU+bUEjTyICv3fMUvIyjJG9F9MV4p8PtA8US6nq1tdSasl3c23Ed8siyPe71ZJyrEkCLDO0hA4BTksAfpxrK+1W41G31GwsLnSJI1P2eeIPcNKPmJcb9rJ2Cg5GF96mg06x8Nxy3FjbwQ2aW/mS+XAtsrOoIJJUA/MQDlvu4G3OTTJKPiGxvpbSz8u2iENnAJo72S78pPOYbdmVGQuMrk8YI4yBWH481fUjbW+v2NlBpRtSLbUBd3BG4NIhaNRETvf5QE7kvgckiuiub/UreK0uNXhW0llBgNlbXHnAz7gUYsF43LuHJ/iXqcYd4as5ta8V6rdXyL/ZWlXCQ2USOWjkuVjAllIP9w4jUdFKufvdADF0v4ev4svYdX8bW7LYpuaz0eTlkRgv/Hww6n5F+QcDHOckV23ivwvFr2hrp1tfXmlLGu2JrKQxqoxgKUBAZeBx+WK6KvF9f8afEjT9e1GKx8NfarCO5kjt3+wSvvjDEK2VbnIA56VhXqQhG002merlODxGJrc2GnGMo66tL89zyjx14B13wlO0moQm4smb5b2LLI2f73dT7H8M12nhjwv8SW8PWA0LVo4dKmiWSER3IQKr/N6ZB5OffNX5vix4tgiaPXPCEbRMCsiPbTRhh3BDZ9as+G/jdothaQ2b+H7mxtY87UtphKFySeA23A56dugryYQw0Zt87S+aP0LE4nOq2FjF4eFSSe/uyT03te6fp57EJ+F/j7VDjWfFQ8luqm7mlx/wHAH61raL8B9It2V9X1O7vSOdkSiFT7H7x/Iiuu0T4oeEdXKrFq0dtKf+Wd2DDj8T8v5GuzikSWNZInV0YZDKcg/jXfTwuHn7y9753PksZnuc4f8AdTXsl2UVH9L/AHMxvD3hTQvDqAaNpltbNjHmBd0hHu5yx/Otuiiu2MVFWirHzNWtUrSc6snJvq3dhRRRTMwooooAKKKKACiiigArldS/5Kn4e/7Aup/+j7Cuqrn/ABD4bbV9VsNSttZ1LSb2zhmt1kslgbfHK0TMGE0Ug6woQQAevrQB4tP8JfHtl421PXdAvtBgeXUbq8tpHu5Q6rLK7gMvkMM4fBGSOvWq/ij4UfEzxJo8em6jfeFvssKyiBIpXiWIyfeICWy9+a9n/wCEX1f/AKHvxJ/3407/AORaP+EX1f8A6HvxJ/3407/5Fq/aSNPay2N/VdMsNYsZLLVrK1vrOTBeC5iWWNsHIyrAg4IB/Cq9j4f0awsYbKx0jTrazhlE8UENsiRpIDkOqgYDZ5yOayP+EX1f/oe/En/fjTv/AJFo/wCEX1f/AKHvxJ/3407/AORagzHzeBPDf2G/t9P0XS9Ne+iaGae00+3DsrEEgho2VgSAcMpHA4pPBngbRfCVkINPgWWQXD3QnlhiV1kdAjFRGionyKq4RVGB9ab/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAGifCvh43FjOdB0kz2ChbSQ2ce63AOQIzjKAEk8YqOLwf4ZhS+SHw7o0aXwxdqtjEBcDOf3ny/NzzznmqX/CL6v8A9D34k/78ad/8i0f8Ivq//Q9+JP8Avxp3/wAi0AX5vCXhuewaxm8P6RJZMyObd7KMxlkQIh2lcZVAFHoAAOKsX/h7RtQ0qDS7/SNOutMgCiK0ntkeGPaMLtQjAwOBgcCsj/hF9X/6HvxJ/wB+NO/+RaP+EX1f/oe/En/fjTv/AJFoAvXXhDw3dmH7V4e0ebyIPs0XmWUTeXFgjy1yvC4J+Ucc1k678OfD+paKml2dlaaRZif7QUsdOtCrPt25KywuoOMfMAG4HOKsf8Ivq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAEtr4F8MQWOkWsmh6ddjSoI7ezlu7ZJpYkT7uHYEg5GeO/NRal/yVPw9/2BdT/wDR9hR/wi+r/wDQ9+JP+/Gnf/ItS6T4Wls9fh1e/wDEGr6tcwWstpEt4tsqRpK8TOQIYYySTCnUnv60AdLRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZ/iHS4tb0LUNMuP9VdwPCx9Nwxn6jr+FaFFVCbhJSjuhNJqzPAv2aNVm0/UNf8J6gdlxBIZ0jPZ1Plyj9E/I10XxX8LX/iXxzpMdpoen6nF/Y17D52pB1gtZWeHa4ZY3/eDkqPlJAbDDFcb8TVbwD8bNL8Twqy2N8wll2jj+5MvudpDfVq+i43WRFdGDIwyGByCD3r3uIIKrUp46Hw1Yp/9vLSSOTBtxTpPeL/AA6HkZHjjTdF1gLqmrTLpl/b2EJj0+N5ZLTyrbzrlFKFpnBMxUDPO4EPgKIFvfHeovBDa6jrtrYqmpyRXr6VClxcLGtv9m81HhwhZmmAGxCwXOAenstZ/iATNoOpC2d45zbS+W6EhlbYcEY75r55uyud0I88lHueTmXxqz6db6j9u1OKc6Jfu1xpcRFrK92ftMa4iAHloqtlsunDbh1rP8NyeI9C8O6dpxv/ABbbW0d3eLfyxaIs01u292hEK/ZiJI5MlmcBwDgZQHjZ+F/xdt9ZMWl+JnjttROFjueFjnPoeyt+h9uBXr9Z0a0K0eaDOzMMtxGXVnRxEbP8H5pnjFnrXjiXV9Kj1VdVYXFnF9os7bT9kUMhiJYyu9s6MCcZCTqQTtCnmneEdR8V2+qeELK6XVUsn06yS4srbS/ssVq/2cGTzC1r5e0N/Ck0ZXhQnFey0VqcIUUUUAc34TlWK/8AENnOoju479p3z/HHIoMb+4wNmfWMjtWBqfhTU9KvL+bQ7TT9X0q5vBqh0q7kMDxXYYMXil2sMMw37WAwxJDAHFdP4l0y6nVNR0XyU1u1U+Q0pISZc5aGQjna3rztOGAOMGBfFtqkai9sNXtbs8NbHT5pWB9A0asrDjqCRQBlXH9rX2mCwtPDmo6M9zHIslzFd24NqzKRuUq7Z56fL6cCmWttrdrotr/bWpW+l2trFtlmu7gXEjk4BdpCFAb72DnHzdOK0mvfEerqi6ZZxaPbsPmutQTfL/wCFW4+rsP901YsPCenw3KXmotNq+or926vyJCnOfkXASP/AICooA5vTJZdSSSDws1xcyT5WfxFdQCNEU55hXaokfHRlG3OCzHGDrW/i/wN4fhGkDxR4ftDZEwNBLqUKvGynDBwWzuznOec5zzXX151ospt/h9qdw2ujQbeDWtVknvvLjYxxjUbjcB5gKgnoCQ30NAG3/wsfwP/ANDl4b/8GkH/AMVXVV4VofifWPFfwN+I9/qcs93pq22ox6VfXMCQzXVsIGwzKgVeuRkAZweOK91oAKztT0TStUBGpabZXeeP38CufzIrRopNJ6MuE5U3zQdn5Hm+ufBrwpqQZrWCfTpT/FbSkrn/AHWyPwGK4if4c+OfBjtceDtYa7gU7jDG2xj9YmyjfmT7V7/RXNPB0papWfloe3huJMfRXJUl7SH8s1zL8dfxPE/DXxoltLv+zvHOmy2dyh2tPFEylf8AfjPI+oz9K9h0rUrLVrKO7026hurZ/uyRMGH09j7Vn+KPC2j+J7TyNZso58DCSY2yR/7rDkfTpXimteDfFPwyvZNY8JXkt5pY+aVMZIUdpU6MP9odOfu1k51sP8fvR79UdscPlmcaYf8AcVn9lu8JPyfR+XyR9DUVwnw4+JGm+MoRA2LPVlXL2rNkP6sh7j26j9a7uuynUjUjzQd0fO4vB1sHVdHER5ZL+vmFFFFWcwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAecfHvw0fEPgC5lgTdeacftcWByVA+df8AvnJx6qKZ8AfEw8QeAba3mfdeaYRaSAnkoB+7b/vnj6qa9JZQ6lWAKkYIIzmvm/wi7fDD433WizsY9H1NhHGWPy7HOYW98NlCfdq+jwH+35fVwf2qfvx9PtL9fU4q37mtGr0ej/Q+kaR1DKVYAqRgg9xS0V84dp8TX2g39lZG/ntZRp/2l7UT44Lr1H8/yPpX1Z8L0iHhG0ez1q41ezcZhkuFAeId4zjng+ucfTFbeq6Hp2qaLPpV5axtYTKQ0SjaBznIx0Oec+teDT2Pir4PaxNcacrah4dmbc2RlGH+3j7jgcbuh9+g8mFH6lPn3i9/L/gH6BicyXFGHeGTUKsXeKdrSXa72l+f5fRdFeYaL8a/C17Cp1BrrTZcfMskRkXPsUySPqBUmq/GnwjZxFrSe6v37LDAy8+5fbXd9bo2vzI+WeQZmp+z9hK/o7fft+J6XXiPxb+INxfX0HhjwVcTPfSTBZri0cq2/OBGjD36kHHb1rHv/FvjX4myPp/hmwew0pjslkRiBjvvlOOP9leSM9a9H+HXwz0zwlbNJORe6pMhSS4IwEUjBWMdh79T7dK55VZ4r3KWker/AMj2KGBw+RP6xmDUqq+GmtbPvLpp2M2+8d6d8PfDVnpep382t+IIYv3yCYyN5hJJ3yHO0AnAzk4A4qD4NeJta8Z61rOq6rNss7dEggtovliUsSScd2AUcnn5uK8r8T6HaeKPiFd6V4D05EhgR9zCRisjKCWfJJABOFGODx617L8A9JbS/h/FJNGyTXlxJM6sMMuDsAI/4Bn8ayoVKlWso/Zjfby8+p6Ga4PBYHLJVkr16nLfmtdczb+FXUbpPz6XPR6K4zxL4k8Q6X4n07SrDQ9Ju4dSd0tp59VkhbKRb23oLd9vQgYZs8dM8JD8TPDEum2d6l5dSw3aeZAYNOupfNUKGZkAiyyrkbmAwpIDYPFeqfAHaV5LeaG2o+G7/wAN+KPAWt6xYNq19eq1teWkcciyXc0sbA/akcfLIOCBzniuuHxE8MNfRWqai7tKYAJUtZmgBnCmHdME8td4ZcZYZzjrWR4V+J+kXujtLr10ljexJdTSg2s0cLRwylCY3YbZCBsyFZjlunagDF1LTr2DwD4h8P8Ah7wP4ujOoadNZQrfavbXEcRaJkQDzL1yijdztHQdDgV67XJv8QfDyadc3zSan5Nq5S4UaTdmS3+TfmSPyt6Lt53MAD606y+IHhu9vba1t76ZpLkxKjNZzrGHkQOkbSFAqSFSCEYhuRxzQB1VFedab8VtKm1R7a+jeC1TTI9RN9FFcSwAM8oKljCu0ARDDNjczFQNwwev8P8AiHTvECXJ02ScvbOI5ori2ltpY2KhhujlVWAIIIOMHtQBrUV8lfFnTbG8+LHi2S7sraeQXNuoaWJWIH2O34yR7msvX/Bmm6PJZJLpVsDc2qXI821iXhs9NrNkcdTg+woPExGdxoVJQ5G+Xdn2TRXK/Cf/AJJZ4N/7Atl/6ISuqoPbPG/id8LWknOv+DFNrqcTea9tCdu8jnfHjo/t0P166vwi+JA8SoNI1siLXYQRkjaLgDqQOzDuPxHcD0+vGPjT4ElWU+LvDQeHUbZhNcpFwW28+av+0Mc+o56g54KtJ0Je2pfNd/8Agn1eAx1PNaSy7MHr9ifWL7Pun/XRr2eiuI+FPjeLxloO+YomqW2Euoxxk9nA9D+hyK7euynONSKlHZnzmLwtXB1pUKytKO4UUUVZzhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXjn7SfhY6n4ah16zQ/bNMbEhXqYWPP/fLYPsC1ex1Fd28V3azW1zGssEyNHIjdGUjBB/Cu3L8ZLA4mGIj9l/euq+4yrUlVg4Pqcl8JfFY8X+CrO9kcG+iH2e6HfzFA5/4EMN+PtXZV82+AbiX4W/F288N6hI39laiyxxyN0OT+5k/Uqfcn0r6SrrzvBRwuI5qX8Oa5o+j6fIzwtV1IWl8S0YUjKGUqwBUjBB5zS0V450nI6n8N/CGpymS60K2Dk5JhLQ5P/ACKbp/w08HWEgeDQbVmBz+/LTD8nJFdhRWXsKd78q+47v7UxvLye2nbtzO35jIYo4IkigjSOJBhURQoA9gK4X40eKG8M+DZvs0mzUL4/Z4CDyoI+Zx9B39SK72vn7x5u8dfGqw0BSWsLEiOQDpgDfKfY/w/UCssXUcKdo7vRHfw9hIYnGe0r/BTTnL0X+bsdr8CPCg0Hwouo3MeNQ1MCViRykX8C/iDu/EelelqqqMKAo5OAKFUIoVAFUDAAGABS1tSpqlBQXQ87H42pjsRPEVN5O/+S+S0MzUdFt7/AFjSdSmeVZ9NeR4VUjaxdCh3cZPB4wRzXOr8O7GDSNBstN1XV9Om0W0ext722ki85oXChkfdGynOxDkKCCoIIrtaK0OM8z074WQwardRy6hdJ4dV7BrfTIXQpKLWNAnnFo95w0anCuAcDI7VqXnwy0S70yysJ5r9oLSG7ijIlUN/pDiRmJC/eVlBXHTHOa7iigDgr/4aW9/byrdeIteluZ7mO6uLhzbMZzGu2NHQw+WUXqF2fe5OTViD4e2iamt3NrGr3EZu4tQntnaFYri6jVVWZwsYIPyISqlUJUHbXa0UAeey/CjRZLMWZvtUFm2nDTJ4N8RW4hV5HTfmMkMryswKlc8A5HFbvgfwdYeDrS5t9NcOs7h3b7Ha254GAMW8UYP1YE+9dLRQB8wfE/StWPxO8UTQ6Hrdxbz3EDxTW2mXE0bgWkCkh0Qg4ZWHXqKreKrvWNem05/+EU8SW/2Oyis8f2Rdvv2Z+b/VDGc9P1r6oooPJrZNRrSnJyfvb7f5HNfDK2ns/ht4TtbyGWC5g0m0jlilQq8brCgKsDyCCCCDXS0UUHrBQeeDRRQB87+MLGf4VfEa013SI2/sa8J3QrwME/vIv5Mv4elfQGn3kGoWNveWcglt50WSNx0ZSMg1h/ELw3H4q8KXumuo88r5lux/hlX7p/ofYmvP/wBnfxFLNp194avyVudPYyQq/DBCcMv/AAFv/QvauCmvq9b2f2Zar16n1WLf9r5YsW9atG0ZecX8L+W33s9kooorvPlQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8k/aH8HHXfDK6zYx51HSgXO0fM8PVh/wH7w/wCBetbvwW8Yjxf4Ohe4kDanZYt7oZ5YgfK//AgPzDeld6yh1KsAVIwQRnNfNN4kvwa+LS3ESv8A8I5qWeAMjymPKj/ajOCO+MetfS4D/hTwUsA/4kLyh5/zR/Vf8A4a37iqqy2ej/Rn0vRUcEsc8Ec0DrJFIodHU5DAjIINSV801bQ7gooooAhvrmOzsri6mOIoI2kY+yjJ/lXh/wCzraSalrviLxHdjM0h8sH1aRi7/wAl/OvSfi1eGx+HGvyg43W5h/7+EJ/7NXP/ALPNkLX4dxz4wbu5llz64IT/ANkriqe/iYR7Jv8AQ+lwT+r5LiKy3qSjD7vef3o9NooortPmgooooAKKKKACiiigAooooAKKKKACiiigAooooAK+ffFg/wCEF+OdlqsWY7DUWWWXH3dsh2S/XB+f8RX0FXkH7Smli58LafqSrmSzudjH0SQc/qq/nXHjYv2fOt46n0XDFaKxv1ep8FVOD+a0/E9forC8C6mdZ8HaPfs26Sa1QyH/AGwMN+oNbtdUZKSUl1PBrUpUakqUt4tr7goooqjMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5D4peD4fGnhS4sCFW9j/fWkp42yAcAn0PQ/XPYV19FbYevPD1Y1qbtKLuiZwU4uMtmeH/s9+M5sTeDNdLRahYlhaiXhiqn5oj7qc49s+le4V4P8fPCN1puo2/jrw5uhurZ0a78vqCCAsuPyVvw969O+G3jC18a+GYNRg2pdL+7uoAf9VIBz+B6g+nuDXt5xh4YinHM8Mvdn8S/ll1+T3X/BOTDTcG6E91t5o6qiiivnjtPOvj7L5fw0vlyw8yWFOO/zg8/lWj8G4vJ+GehJt25id8D/AGpGP9azfj/GH+Gt4xONk0LD3+cD+tanwel834a6CxxxCy8ezsP6Vxr/AHt/4f1PpJ/8k/G3/P1/+knZUUUV2HzYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcd8X7MXvw212MgfJCJh7bGDf0rsawvHi7/AAN4iXjnTrjqcD/VtWdZXpyXkzsy6bp4ulNdJRf4o5T9n66a4+G9tG3/AC7XEsQ+hbf/AOz16RXkf7NLg+CdQTByNRc57cxx/wCFeuVnhHejH0O3iGChmddL+Zv79QoooroPGCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCO5hiubeWC4jWSGVSjowyGUjBBHoRXzTqVvf8AwS+IyXtmss/hu/JBTOd0eeUP+2mcg9x9TX01WJ4y8NWHizQLjStTTMUoykgHzROOjr7j9eR3r1spzGOEm6dZc1Kekl5d15o5sRRdRJx0ktjQ0rULXVtNtr/T5lntLhBJHIvQg/19u1W6+bfh94l1H4U+LZ/CfiwkaRLJmOb+GLd0lU/3G7jscnqCD9II6uiujBkYZDA5BHrUZpl0sDVVnzQlrGXdf59ysPXVWOujW6OP+MNqbz4a69GP4YVl/wC+HV//AGWsr9n+7+0fDa1iz/x7TzRfTLb/AP2eu61qxXU9HvrBzhbqCSAk+jKV/rXjv7NF80cOvaRNlZIpUnCHrkgq/wCW1a+fqe7iovumv1PrMJ+/yOvTW9OcZfeuU9vooortPmgooooAKKKKACiiigAooooAKKKKACiiigAooooAK5z4jTLB4B8RO3Q2EydccshUfzro688+PWoCx+G99Huw93JHbr/31uP/AI6jVlXly05PyZ35VRdbG0aa6yj+Zmfs3RNH4CuWbpJqEjr9NkY/oa9Wrh/grYGw+Gujqy4eZXnb33uSP/HdtdxU4WPLRivI3z2qquY15rbmf4OwUUUVueSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBxvxP8AAll450M28u2HUYcta3JH3G7qfVTjn8+1eV/Crx/e+DdXfwb45Jt4LdvKguJf+WB7KT3jPUN247dPoauG+KHw80/xzpvz7bfVoVItrsDp/sP6rn8R1HcH3ctzGl7J4HHa0ns+sH3Xl3X/AAb8lejLm9rS+L8zuFIZQVIIPIIrwLTz/wAIZ+0JPC/7uy1RyATwCJvmGP8AtoMfhVDwN8QdY+HGpjwt48gnNjFhYZsbmhTOAVP8cfp3HQdMDoPjvpset6Lo/irw9Mt15DiLzrY7yysfkII9H4+rV5OfZTWwCVT4op3jJbNf10PpuE8bSrYieEqOyqxcHfo+j+/b1PbaKzfDd5c6hoGn3V/bSWt3LCrTQyLgo+ORj61pVzp3Vzx6kHTk4PdaBRRRTICiiigAooooAKKo65q9hoOlXOpaxdxWljbrvlmkOAo/qT0AHJJwK4y2ufGPjAi4tH/4RPQn5iMsCy6jcL/eKtlIAewIdvUL0oA9BrE1zxTo+iyrBeXiNfP/AKuygBluJT6LEuWP1xj1xWG3wz0S6QDWrrXNYfOS17qs5B/4AjKg+gWuh0Dw3ovh6Jo9D0qzsA33zBEFZ/8Aebq34k0AYx0vUvFbI/iGJtP0YMHTSlcGSfByDcOpxjjPlqSP7zN92uvoooAKKKKACvCP2hL2XV/EWgeF7E7pmYSMo/vyNsQH6DJ+jV7ff3cFhZT3l3IsVvAhkkduiqBkmvCfhLbT+NfiZqni6+Q/ZrZy0Qbs7Dai++1B+ePWuLGPnUaK3k/wPpuG4LDyq5lU+GjF285PRL+vI9206zi0/T7WytxiG3iWFB6KoAH6CrFFFdqVtD5qUnJuT3YUUUUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMHxh4T0fxdpv2LW7USqMmOVTtkiPqrdvp0PcGmeBPCtn4N8OxaTYM0iK7SSSuMNI5P3j+AA+gFdDRXR9arex+r8z5L3t0uR7OPNz21CivPdY8dT3a6l/wjX2KLT7BjHc6zfyBLcyA7TFCCy+Y275dxZUB4yxBFed674g1dxouqXXi/xFpuk6imxJEsow0cuONyhAoUsCoDEHI6HrXOWfQ1FeN6TceIJn1SwsviHJd6jpR8u7QWEUpiYMfvKY0PKjPBIyDzjmrWn+LPEc1nrT6Drmi+KbjTbg25tYtOlhlZlTLKzK5CnIZQdpXO3JGTgA9aorh4fHN1DDDJqXh3UPLkMi+ZYEXG3YSCxj4k2nBwQp6djxWv4c8aeHfEczwaNq1tPdRkq9sSY5kI6ho2wwx3yKAOhqO5nitbeW4uZUigiQvJI7bVRQMkknoAKS6uIbS2kuLqWOGCNSzySMFVQO5J6V5LquqJ8QTNd6lKNL+GWnt5k9xdHyv7XdT05xi3BHOfvnjpQBp+H7WX4ia7beKdWjdPDNk+/Q7CVSPtDjj7bIp9f+WYPQfNgEiumv/GNlHqMmm6Tb3WtanEdssFgoZYD6SyMQkZ9i272NYNvLqvxAC/ZPteh+DcfK4BhvNSXtt/ighPrw7DptHJ7nStNstIsIbLS7WG0tIhhIoUCqPwH8+9AGC+teJ4wHfwmskfdYdSjaQD6Mqrn/AIFVjSPF+k6lfDT2kksdVxn7BfIYJyPVVPDj3QsPeuhrP1vRdN12zNrrFjb3tvncEmQNtPqp7H3HNAGhRXJf8I1rOmf8i54jnSEZItNVjN7GPYPuWUD6u30rY8PjXBFN/wAJC+mtLuHlfYVkAx33byefpQBq0UV5x8WviLB4TsmsNOdZdcnX5FGCIAf429/Qd+vTrnVqxpRcpbHXgsFWx1aNCgryf9Xfkcx8dfFU2o3dv4L0HdNdXEiC6EZ6sSNkX54J/D3r0zwD4ah8J+GLTS4irSqN88g/5aSn7x+nQD2Arhvgr4Cm00N4k8Qq7axdZaJJcl4lbqzZ/jb8wD6kivW658NCUpOvU3e3kj2c6xVGhSjleEd4Qd5P+afV+i2X/DMKKKK7D5sKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK8yg8J6PruvfEG6u/D+hanqyakkdtLqdmkoBGnWhVWYqWCbiTgepoA9NrD8czTweD9YktJGimFq+JVODGMYLA9iBk/hXkngHTtD1X4h6z4a1jwb4MlisbJLlbiPw7/Z8jMzbSBDNuZ0HP7wfL09RXpHwwgiuvhH4Tt7hFkhl0O0jdG6Mpt0BB/CgDzuK30RPAer6H4k0+wtPBcN2lpaPNK8UkhVlG9sgbSXwAOoAOTgE11WgeJ9P0rwf9g8UvdXN0kt1bNHPal/tQV5CMAAptKAYBIABUEjjOBc2EUFvd+FvEtm2pG1xcW63H7xL6GM5jwD0bIRGwfv8Yw43HhfU5tdsdMvLgaottqcLj+z7sSRLAU+aQ78gnJkCB8fwcewAzwU50nwZp1nf6fDbXV9chnt3k8uWKIqM7pSAXKqQgbgfMi5OdxwPGHxAeeK7udDGoaNpNlYvqeqSfZlgv3k84RRwgEHyyzjl2BO0Hg4Fdlpsdj4kk0fVLXxDcT6YqvbiO3mWS3LhgCjq5LEqwyjgKRx3254nxPY6p4g8SXF/wCEdPn0qaIXGn3EWt2yx6dqVqp5X5VIYE9CSDjkGgDynwPqFrrOs31xokWtaJ4n07TpdQgvBqbXQnRF3yRSll+QOOjDoTyDmu00azvdW+FM3jC5vTePbwf2lJcW9kI7o3Syl3IlVuduAuccAtkBQop+j+BdUa4n8IrH4a8KxX29dQi0p5bi/uolQOIg8rE7SSQcFV4PJ6HpF0a3h1O20bTIrufSdNf7PaeGbPDR6jAyHM12xOFy7EkyBRgcByaAIvDXinWvidpFnezaZcazIMf6CiG206GUd5XPMhB5xwOwNej6R8OptQ1G11Xx7fjV7m1Ia002NfLsLMjoVi/jYDozZx+tdT4G0JvDnhi002V43nUvLMYgQnmSOzsEB5CgsQM84AreoAKKKKACiio55oreFpZ5EiiQZZ3YBQPcmgaV3ZElISFBJIAHJJrznxT8YPDWih47KZtVuhwEtfuA+8h4x9M1561x4++KzeXCn9m6C55IzHCR7t96Q+w4z2FclTGQi+WHvPsj38Jw7iasPb4m1Gn/ADS0+5bvy7nV/ET4uQWTtpXhDF/qbny/tCDfHGTxhAPvt+n16Uz4XfDKeC+HiPxkWudVkbzY4JW3mNjzvcnq/oO316dV4A+HGjeD0WaJftmpkYa8lXkeyD+Efr6mu3qYYedSSqV9+i6I1xWbYfCUZYPKk1F/FN/FL/Jf13uUUUV2nzQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVy1/wCMDD4oudBsNB1fU7u2ghuJ5LVrZY40lLhcmWZCT+7boD0oA6mvNZNQt9P1fxzYalF4ktf7Q1BJYLrTdKu5jsNjapvjliiZchkcdeq8itvRPH+h3ml2Fxq2o6bpF3evKkNpc3qK8myZogVDbS2SvYdTitj/AISbQf7a/sf+29M/tfn/AEH7XH5/Clj+7zu4UE9OgzQBwHh+Xw7pXie58RXU3jbV9bmtVsvtV94dvAY4A27YqxWqKAW5JxnPeux+GVtPZ/Dbwna3kMsFzBpNpHLFKhV43WFAVYHkEEEEGob3x1o/kWcuiXthrCzajBp8v2S8RxA0rYy23dyOuDjNM8PeP9E1HStIn1LUdN0vUNTjEkNhcXqCVgXKjaDgtkqRwOvFAGz4i0Gx1+2jivVdZYH823uIW2S28n99G7H25BHBBHFcrd+GvEqxXURuNG1hLlNkr3KzWcsigYG5omZSQOMhV/CtDSfiR4T1Gyv7r+3dNtIbG7ks5zdXkMe1ldkDfe4V9jFScbhzil8YePdF8OaXBcf2hp1zdXXktaWn21Ee5SSRU3x9SwwxOQDnFAHKf8Il47eV3N3o0KmTekcdwwSMZU7dqwLkZRT17e9XLvwF4i1GOSKfxBp+n2s3mCaG1sDOX8z7/wA0zkDdjJwvXkYroPHPjODwxfaHYD+z2v8AVrhoYVvr4WkaqqksxbaxJztUAKcswHFalr4p8P3a3TWmu6VOto4S4MV5GwhYttCvg/KSeMHvxQBzmn/DLS4udT1HVtTYgBhLOIVbChRkQhM/KqjnPAFdhpemWOk2ottLs7eztwc+XBGEGfXA7+9ZEnjrwlG8ayeKdBRpASgbUIQWAJBI+bnkEfga19I1XT9ZslvNHv7S/s2JVZ7WZZYyQcEBlJHBoA4fxr8WND8Mzy2ax3F7qUfDQIpRUOP4nIx+QNeTXXxf1fV9ctDqU0tjoiSq01vpwxJIgOdpckE56HBAwelfROveH9J8QW3kazp8F3H2Mi/Mv+6w5H4GvMbv4LWtjrdpqWgzRTQwyq8mn6igkjkXPzKGwe2cZB5715uJp4mTvF6eX9an2mR43I6VNqvTaqW3eqv5aWj5O2ncbN8e9GA/caTqLnP8ZRf5E1mTfHe7un8vSfDW6TtvnMhP/AVUfzr2KHw5ocGPI0bTY8DA2WqDA/AVpRRRwoEhjSNP7qjArX2OIe9S3yOD+0cmp6wwbl6zf6HgzeKPix4h+TTtHfT0bgMtr5XH+9MT+YpYfhJ4s8QypN4v8QkL12GRrh19gDhV/Amve6KPqUZfxJOXz0D/AFmq0dMFRhS81G8vvf8AkcH4Y+FPhbQWSX7Gb+5Xnzb0iTB9lxtH5Z967sAAYHAFLRXVCnCmrQVjw8VjK+Mnz4ibk/N/1YKKKKs5gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5GbwHpN546vPEuq2tjqEslvbQ28dzZpI1q0TSNvR2zgneOgGNg5PbrqKAPIdd+EOo6no0ekx+LZodOETo0HkTBN7TvLvCxzopPzquJA4+XIAzVSXwHrd74xGnvFPF4VW+1K+e5eKFJC13BLGQkizu74ac43RJgDknAr2migDyzQPhQ+mvbSXOsR3E1vPZSJN5d0ztHbuzCNvOuZFAO7jYFC5PBzgVNR+EOo3elWGmDxbMunW0UMfkGCYJujlMm9VSdUJY7QfMWTG0FdtevUUAeW6n8Lb26kZofEKwLDqlzqdnst542jNwztKkjw3EbOMv8pUpgAg7s1GvwnuLazkstM1mztLK5itI7uP7BJKSbeTevlO85ZFPQhjJ6gjNerUUAYWv+Hl1jWNHvXuWiXTzPmNV5kEsRj4bPy43Zzg1xMfwomk0pLDUNbt54bfT4dLtPL04R7beOaOX96PMPmOfKUZG0DJO3k16nRQBw/iHwBFrF1rUzXiRf2lLpz7TbBvKFpMJNv3hkPjHbGe/St7w1oQ0STWWE4mGo6hJfYEe3y96qNvU5+7nPHXpW1RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <em>",
"     Naegleria fowleri",
"    </em>",
"    has three stages, cysts",
"    <strong>",
"     (1)",
"    </strong>",
"    , trophozoites",
"    <strong>",
"     (2)",
"    </strong>",
"    , and flagellated forms",
"    <strong>",
"     (3)",
"    </strong>",
"    , in its life cycle. The trophozoites replicate by promitosis (nuclear membrane remains intact)",
"    <strong>",
"     (4)",
"    </strong>",
"    .",
"    <em>",
"     N. fowleri",
"    </em>",
"    is found in fresh water, soil, thermal discharges of power plants, heated swimming pools, hydrotherapy and medicinal pools, aquariums, and sewage. Trophozoites can turn into temporary nonfeeding flagellated forms, which usually revert back to the trophozoite stage. Trophozoites infect humans or animals by penetrating the nasal mucosa",
"    <strong>",
"     (5)",
"    </strong>",
"    and migrating to the brain",
"    <strong>",
"     (6)",
"    </strong>",
"    via the olfactory nerves causing primary amebic meningoencephalitis (PAM).",
"    <em>",
"     N. fowleri",
"    </em>",
"    trophozoites are found in cerebrospinal fluid (CSF) and tissue, while flagellated forms are occasionally found in CSF. Cysts are not seen in brain tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites: Naegleria. Available at:",
"     <a href=\"file://www.cdc.gov/parasites/naegleria/biology.html\" target=\"_blank\">",
"      file://www.cdc.gov/parasites/naegleria/biology.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27719=[""].join("\n");
var outline_f27_4_27719=null;
var title_f27_4_27720="Approach to the patient with dyspepsia";
var content_f27_4_27720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with dyspepsia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/4/27720/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27720/contributors\">",
"     George F Longstreth, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/4/27720/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27720/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/4/27720/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27720/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/4/27720/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspepsia is a common symptom with an extensive differential diagnosis and a heterogeneous pathophysiology. It occurs in approximately 25 percent of the population each year, but most affected people do not seek medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/1\">",
"     1",
"    </a>",
"    ]. Although dyspepsia does not affect survival, it is responsible for substantial health care costs and significantly affects quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the definition, etiology, and general approach to the evaluation and management of the patient with dyspepsia. The evaluation and recommendations are largely consistent with the American Gastroenterological Association (AGA) guideline for the evaluation of dyspepsia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the Rome III criteria, dyspepsia is defined as one or more of the following symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Postprandial fullness (classified as postprandial distress syndrome)",
"     </li>",
"     <li>",
"      Early satiation (inability to finish a normal sized meal, also classified as postprandial distress syndrome)",
"     </li>",
"     <li>",
"      Epigastric pain or burning (classified as epigastric pain syndrome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 25 percent of patients with dyspepsia have an underlying organic cause (",
"    <a class=\"graphic graphic_table graphicRef65698 \" href=\"UTD.htm?3/22/3436\">",
"     table 1",
"    </a>",
"    ). However, up to 75 percent of patients have functional (idiopathic or nonulcer) dyspepsia with no underlying cause on diagnostic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H59603517\">",
"     'Diagnostic strategies and initial management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1915206322\">",
"    <span class=\"h2\">",
"     Dyspepsia secondary to organic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are several organic causes for dyspepsia, the main causes are peptic ulcer disease, gastroesophageal reflux, gastric malignancy, and NSAID-induced dyspepsia (",
"    <a class=\"graphic graphic_table graphicRef65698 \" href=\"UTD.htm?3/22/3436\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Peptic ulcer disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper abdominal pain or discomfort is the most prominent symptom in patients with peptic ulcers. Although discomfort from ulcers is usually centered in the epigastrium, it may occasionally localize to the right or left upper quadrants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/10\">",
"     10",
"    </a>",
"    ]. While the pain may radiate to the back, back pain as the primary symptom is atypical of peptic ulcer disease.",
"   </p>",
"   <p>",
"    While classic symptoms of duodenal ulcer occur when acid is secreted in the absence of a food buffer (ie, two to five hours after meals or on an empty stomach), peptic ulcers can be associated with food-provoked symptoms.",
"   </p>",
"   <p>",
"    Peptic ulcers can also be associated with postprandial belching, epigastric fullness, early satiation, fatty food intolerance, nausea, and occasional vomiting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13609?source=see_link\">",
"     \"Clinical manifestations of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Gastroesophageal reflux",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptoms of gastroesophageal reflux disease (GERD) are retrosternal burning pain and regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/11\">",
"     11",
"    </a>",
"    ]. GERD should be suspected when these symptoms accompany dyspepsia and are the predominant complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Gastroesophageal malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal malignancy is an uncommon cause of chronic dyspepsia in the Western hemisphere but the incidence is higher in patients of Asian, Hispanic, or Afro-Caribbean extraction. The incidence of malignancy also increases with age. When present, abdominal pain tends to be epigastric, vague and mild early in the disease but more severe and constant as the disease progresses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4661?source=see_link\">",
"     \"Epidemiology of gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Biliary pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic biliary pain is characterized by episodic acute and severe upper abdominal pain, usually in the epigastrium or right upper quadrant. It is not colicky. The pain typically lasts for at least one hour and may persist for several hours. The pain may radiate to the back or scapula, and is often associated with restlessness, sweating, or vomiting. Episodes are typically separated by weeks to months and patients are completely pain free between attacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link&amp;anchor=H7#H7\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Biliary disease'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Drug-induced dyspepsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) and COX-2 selective inhibitors can cause dyspepsia even in the absence of peptic ulcer disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link&amp;anchor=H4#H4\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Gastrointestinal effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several other drugs have been implicated as causes of dyspepsia. However, data to support the role of these medications in drug induced dyspepsia are limited. These medications include calcium channel blockers, methylxanthines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    , potassium supplements,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    and certain antibiotics, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1915205522\">",
"    <span class=\"h3\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease and chronic pancreatitis may rarely present with dyspepsia alone. Other rare causes for dyspepsia include infiltrative diseases of the stomach (eg, eosinophilic gastritis, Crohn&rsquo;s disease, sarcoidosis), diabetic radiculopathy, metabolic disturbances (eg, hypercalcemia, heavy metal), hepatoma, steatohepatitis, and intestinal angina (",
"    <a class=\"graphic graphic_table graphicRef65698 \" href=\"UTD.htm?3/22/3436\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link&amp;anchor=H23610802#H23610802\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Gastrointestinal manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\", section on 'Gastrointestinal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/58/33702?source=see_link&amp;anchor=H4#H4\">",
"     \"Granulomatous gastritis\", section on 'Crohn's disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33206?source=see_link\">",
"     \"Chronic mesenteric ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33206?source=see_link&amp;anchor=H2#H2\">",
"     \"Chronic mesenteric ischemia\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1915206385\">",
"    <span class=\"h2\">",
"     Functional dyspepsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional (idiopathic or nonulcer) dyspepsia is defined as the presence of one or more of the following: postprandial fullness, early satiation, epigastric pain or burning, and",
"    <strong>",
"     no",
"    </strong>",
"    evidence of structural disease to explain the symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/1\">",
"     1",
"    </a>",
"    ]. These criteria should be fulfilled for the last three months with symptom onset at least six months before diagnosis.",
"   </p>",
"   <p>",
"    A diagnosis of functional dyspepsia can therefore only be established exclusion of other causes of dyspepsia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/15\">",
"     15",
"    </a>",
"    ]. The pathophysiology and treatment of functional dyspepsia are discussed in detail, separately. (See",
"    <a class=\"local\" href=\"#H59603517\">",
"     'Diagnostic strategies and initial management'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=see_link\">",
"     \"Functional dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75708801\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history, physical examination, and laboratory evaluation are the first steps in the evaluation of a patient with new onset of dyspepsia. (See",
"    <a class=\"local\" href=\"#H59602395\">",
"     'History'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H59602487\">",
"     'Physical examination'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H59602579\">",
"     'Laboratory tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One important goal of the initial evaluation is to identify alarm features for gastroesophageal malignancy (",
"    <a class=\"graphic graphic_table graphicRef56585 \" href=\"UTD.htm?9/2/9259\">",
"     table 2",
"    </a>",
"    ), which will direct the diagnostic approach. (See",
"    <a class=\"local\" href=\"#H59603517\">",
"     'Diagnostic strategies and initial management'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59602395\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed history is necessary to narrow the differential diagnosis and to identify GERD and NSAID-induced dyspepsia, as well as patients with alarm features (",
"    <a class=\"graphic graphic_table graphicRef56585 \" href=\"UTD.htm?9/2/9259\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A dominant history of heartburn, regurgitation, or cough is suggestive of GERD [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NSAID use raises the possibility of NSAID dyspepsia and peptic ulcer disease. Radiation of the pain to the back, a personal or family history of pancreatitis may be indicative of underlying chronic pancreatitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link&amp;anchor=H4#H4\">",
"       \"Nonselective NSAIDs: Overview of adverse effects\", section on 'Gastrointestinal effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Significant weight loss, anorexia, vomiting, dysphagia, odynophagia, and a family history of gastrointestinal cancers suggest the presence of an underlying malignancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical features, diagnosis, and staging of gastric cancer\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of severe episodic epigastric or right upper quadrant abdominal pain lasting more than an hour or pain that occurs at any time is suggestive of symptomatic cholelithiasis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=see_link&amp;anchor=H7#H7\">",
"       \"Pathogenesis, clinical features, and diagnosis of acute cholecystitis\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59602487\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination in patients with dyspepsia is usually normal, except for epigastric tenderness. Abdominal tenderness on palpation should be evaluated with the Carnett sign to determine if it is due to pain arising from the abdominal wall rather than due to inflammation of the underlying viscera. The presence of increased local tenderness during muscle tensing (positive Carnett&rsquo;s sign) suggests the presence of abdominal wall pain. However, if the pain is decreased (negative Carnett&rsquo;s sign), the origin of pain is not from the abdominal wall and likely from an intra-abdominal organ, as the tensed abdominal wall muscles protect the viscera. The Carnett sign is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31030?source=see_link&amp;anchor=H6#H6\">",
"     \"Chronic abdominal wall pain\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other informative findings on physical examination may include: a palpable abdominal mass (eg, hepatoma) or lymphadenopathy (eg, left supraclavicular or periumbilical in gastric cancer), jaundice (eg, secondary to liver metastasis) or pallor secondary to anemia. Ascites may indicate the presence of peritoneal carcinomatosis. Patients may have evidence of muscle wasting, loss of subcutaneous fat, and peripheral edema due to weight loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59602579\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine blood counts and blood chemistry including liver function tests should be performed to identify patients with alarm features (eg, iron deficiency anemia) and underlying metabolic diseases that can cause dyspepsia (eg, diabetes, hypercalcemia) (",
"    <a class=\"graphic graphic_table graphicRef56585 \" href=\"UTD.htm?9/2/9259\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of hypercalcemia\", section on 'Gastrointestinal abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24985?source=see_link\">",
"     \"Diabetic autonomic neuropathy of the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59603517\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC STRATEGIES AND INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to and extent of diagnostic evaluation of a patient with dyspepsia is based on the presence or absence of alarm features (",
"    <a class=\"graphic graphic_table graphicRef56585 \" href=\"UTD.htm?9/2/9259\">",
"     table 2",
"    </a>",
"    ), patient age, and the local prevalence of",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    (",
"    <em>",
"     H. pylori",
"    </em>",
"    )",
"    <em>",
"    </em>",
"    infection",
"    <em>",
"    </em>",
"    (",
"    <a class=\"graphic graphic_algorithm graphicRef67791 \" href=\"UTD.htm?20/17/20766\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87622 \" href=\"UTD.htm?9/12/9421\">",
"     table 3",
"    </a>",
"    )",
"    <em>",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with GERD and NSAID-induced dyspepsia should be treated with an empiric trial of proton pump inhibitors (PPI) for eight weeks and NSAIDs should be discontinued (",
"    <a class=\"graphic graphic_table graphicRef65374 \" href=\"UTD.htm?28/19/28988\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further evaluation should be pursued if these patients continue to have symptoms after eight weeks of PPI therapy or earlier if they have alarm features (",
"    <a class=\"graphic graphic_table graphicRef56585 \" href=\"UTD.htm?9/2/9259\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H63380082\">",
"     'Evaluation of persistent symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63379815\">",
"    <span class=\"h2\">",
"     Patient with alarm features or age &gt;55 years",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63379823\">",
"    <span class=\"h3\">",
"     Early upper endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper endoscopy should be performed for the evaluation of new onset dyspepsia in patients with alarm features (",
"    <a class=\"graphic graphic_table graphicRef56585 \" href=\"UTD.htm?9/2/9259\">",
"     table 2",
"    </a>",
"    ) or those over age 55 years. Upper endoscopy provides a gold standard for establishing a specific cause in patients with upper abdominal pain. Biopsies of the stomach should be obtained to rule out",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    . Patients with",
"    <em>",
"     H. pylori",
"    </em>",
"    should receive",
"    <em>",
"    </em>",
"    eradication therapy in addition to treatment based on the underlying diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple studies have evaluated the yield of upper endoscopy in patients with dyspepsia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. A meta-analysis of nine studies with 5389 patients found that the most prevalent findings in patients with dyspepsia were erosive esophagitis and peptic ulcer disease (pooled prevalence 6 and 8 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic yield of upper endoscopy increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. In the absence of alarm features, we perform early endoscopy (within two weeks) in patients over the age of 55 years. These recommendations are consistent with the American Gastroenterological Association (AGA) and American College of Gastroenterology (ACG) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/6,23,24\">",
"     6,23,24",
"    </a>",
"    ]. However, the optimal age cut-off for endoscopic evaluation in patients with dyspepsia (without alarm features) is controversial and is supported by limited evidence that suggests that the risk of malignancy in most United States populations prior to 55 years is low. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Guidelines also suggest that the age cutoff may vary between countries, depending upon the prevalence of gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/25\">",
"     25",
"    </a>",
"    ]. The AGA guidelines suggest that it may be reasonable in some populations in developed nations to consider the age of 60 or 65 years as the threshold age at which endoscopy should be offered to all new dyspeptic patients and an age cutoff of 45 or 50 years may be more appropriate for United States patients of Asian, Hispanic, or Afro-Caribbean extraction or in populations with a high incidence of gastric cancer in young individuals. A European consensus statement recommends endoscopy in adults older than 45 years old who present with persistent dyspepsia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the upper endoscopy is normal, patients with alarm features or persistent symptoms of dyspepsia should undergo further evaluation to exclude other etiologies. However, most patients with a normal upper endoscopy and routine laboratory tests have functional dyspepsia. (See",
"    <a class=\"local\" href=\"#H59602579\">",
"     'Laboratory tests'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H63380082\">",
"     'Evaluation of persistent symptoms'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=see_link\">",
"     \"Functional dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63377954\">",
"    <span class=\"h2\">",
"     Patient without alarm features and age &le;55 years",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two main strategies in patients &le;55 years without alarm features are to test and treat for",
"    <em>",
"     H. pylori",
"    </em>",
"    and to provide empiric antisecretory therapy. The efficacy of the",
"    <em>",
"     H. pylori",
"    </em>",
"    test and treat strategy varies based on whether it is employed in primary or secondary care settings and the local prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients &le;55 years of age without alarm features should be tested and treated for",
"    <em>",
"     H. pylori",
"    </em>",
"    if the local prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    is high (&gt;20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/28\">",
"     28",
"    </a>",
"    ]. Empiric treatment with a proton pump inhibitor (PPI) should be recommended in areas with prevalence &lt;5 percent (",
"    <a class=\"graphic graphic_table graphicRef87622 \" href=\"UTD.htm?9/12/9421\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65374 \" href=\"UTD.htm?28/19/28988\">",
"     table 4",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    In areas with a prevalence of 5 to 20 percent, the strategies of test and treat",
"    <em>",
"     H .pylori",
"    </em>",
"    or empiric PPI therapy may be equivalent in terms of dyspepsia resolution, patient satisfaction, and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/6\">",
"     6",
"    </a>",
"    ]. It is therefore reasonable for clinicians to use clinical judgment in deciding upon noninvasive",
"    <em>",
"     H. pylori",
"    </em>",
"    testing or an empiric trial of a PPI. The decision should include consideration of the patient's age, past history, nonsteroidal antiinflammatory drug use, comorbidities, symptom duration, risk factors for gastric or esophageal malignancy and",
"    <em>",
"     H. pylori",
"    </em>",
"    infection, availability and cost of diagnostic testing, and patient preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63377961\">",
"    <span class=\"h3\">",
"     Test and treat for Helicobacter pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for",
"    <em>",
"     H. pylori",
"    </em>",
"    testing in patients with dyspepsia is based upon the recognition of",
"    <em>",
"     H. pylori",
"    </em>",
"    as an etiologic factor in peptic ulcer disease. Testing for",
"    <em>",
"     H. pylori",
"    </em>",
"    should be performed with a urea breath test or stool antigen assay. Serologic testing should not be used due to their low positive predictive value [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who test positive for an infection with",
"    <em>",
"     H. pylori",
"    </em>",
"    should undergo treatment with eradication therapy.",
"   </p>",
"   <p>",
"    Patients who have continued symptoms after successful eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    should be treated with antisecretory therapy with a proton pump inhibitor for four to eight weeks (",
"    <a class=\"graphic graphic_algorithm graphicRef67791 \" href=\"UTD.htm?20/17/20766\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65374 \" href=\"UTD.htm?28/19/28988\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/6,30\">",
"     6,30",
"    </a>",
"    ]. However, some patients may continue to have symptoms of dyspepsia and may require additional evaluation. (See",
"    <a class=\"local\" href=\"#H63380082\">",
"     'Evaluation of persistent symptoms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63380043\">",
"    <span class=\"h3\">",
"     Antisecretory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric antisecretory therapy without",
"    <em>",
"     H. pylori",
"    </em>",
"    <span class=\"nowrap\">",
"     testing/treatment",
"    </span>",
"    should be recommended in areas of very low prevalence for",
"    <em>",
"     H. pylori",
"    </em>",
"    (&lt;5 percent) and may also be considered in areas with prevalence of 5 to 20 percent (",
"    <a class=\"graphic graphic_table graphicRef65374 \" href=\"UTD.htm?28/19/28988\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/6\">",
"     6",
"    </a>",
"    ]. Proton pump inhibitor therapy is more effective in relieving symptoms of dyspepsia as compared with H2 antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=see_link&amp;anchor=H15#H15\">",
"     \"Pharmacology of antiulcer medications\", section on 'Comparative efficacy of antisecretory agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63380074\">",
"    <span class=\"h3\">",
"     Upper endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic evaluation of patients with dyspepsia without alarm features provides a very small additional benefit over a strategy to test and treat for",
"    <em>",
"     H. pylori",
"    </em>",
"    and is unlikely to be cost-effective. It is therefore reserved for patients with persistent symptoms despite antisecretory therapy and",
"    <em>",
"     H. pylori",
"    </em>",
"    <span class=\"nowrap\">",
"     testing/treatment",
"    </span>",
"    (",
"    <a class=\"graphic graphic_algorithm graphicRef67791 \" href=\"UTD.htm?20/17/20766\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef80468 \" href=\"UTD.htm?16/8/16526\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One of the most comprehensive systematic reviews included 17 controlled trials that involved comparison of 20 variations in the treatment strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/33\">",
"     33",
"    </a>",
"    ]. Initial endoscopy was associated with a small reduction in the risk of recurrent dyspeptic symptoms compared with a strategy of initial empiric treatment.",
"    <em>",
"     H. pylori",
"    </em>",
"    testing with endoscopy for a positive result increased costs but did not improve symptoms.",
"    <em>",
"     H. pylori",
"    </em>",
"    testing followed by eradication appeared to be as effective as initial endoscopy, but reduced costs by decreasing the proportion of patients that ultimately required an endoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63380082\">",
"    <span class=\"h1\">",
"     EVALUATION OF PERSISTENT SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the approaches described above, some patients continue to have symptoms of dyspepsia. Patients with continued symptoms of dyspepsia fall into the following categories: patients with persistent",
"    <em>",
"     H. pylori",
"    </em>",
"    infection, patients with an alternate diagnosis, and patients with functional dyspepsia.",
"   </p>",
"   <p>",
"    Patients with continued symptoms of dyspepsia should be carefully reassessed, paying specific attention to the type of ongoing symptoms, the degree to which symptoms have improved or worsened, and compliance with medications. &nbsp;",
"   </p>",
"   <p>",
"    An upper endoscopy should be performed in patients with persistent dyspepsia (",
"    <a class=\"graphic graphic_algorithm graphicRef80468 \" href=\"UTD.htm?16/8/16526\">",
"     algorithm 2",
"    </a>",
"    ). Upper endoscopy allows for testing for",
"    <em>",
"     H. pylori",
"    </em>",
"    with biopsy for histology in patients who have not previously been tested and culture and sensitivity testing in patients who have previously been treated. Biopsies of the duodenum should also be performed to rule out celiac disease.",
"   </p>",
"   <p>",
"    In patients with a normal upper endoscopy further evaluation should be performed based on the type of ongoing symptoms (",
"    <a class=\"graphic graphic_algorithm graphicRef60586 \" href=\"UTD.htm?31/11/31934\">",
"     algorithm 3",
"    </a>",
"    ). An ultrasound of the gallbladder should be performed only in patients with pain suggestive of biliary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/34\">",
"     34",
"    </a>",
"    ]. Distinguishing between patients with true biliary pain and those with coincident but unrelated dyspepsia and cholelithiasis is important, as it may lead to an unnecessary cholecystectomy that is unlikely to relieve dyspepsia.",
"   </p>",
"   <p>",
"    Delayed gastric emptying has been found in 30 to 80 percent of patients complaining of dyspeptic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/7\">",
"     7",
"    </a>",
"    ]. A gastric emptying study for gastroparesis should be considered in patients with persistent postprandial fullness, nausea and vomiting, and in patients with risk factors for delayed gastric emptying (eg, diabetes mellitus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=see_link\">",
"     \"Etiology and diagnosis of delayed gastric emptying\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diarrhea, constipation, bloating, and flatulence may be associated with irritable bowel disease and a colonoscopy and small bowel radiography may be indicated. A diagnosis of chronic intestinal ischemia should be considered in patients with severe peripheral vascular disease or coronary artery disease. In patients with chronic mesenteric ischemia, CT and MR angiography may demonstrate high grade stenoses in mesenteric vessels. Symptoms suggestive of an anxiety or panic disorder should be sought and treated if present [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 75 percent of patients have functional (idiopathic or nonulcer) dyspepsia with no underlying cause on diagnostic evaluation. The management of patients with functional dyspepsia is presented in detail, separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=see_link\">",
"     \"Functional dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics",
"     </li>",
"     <li>",
"      Beyond the Basics topics",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63380126\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dyspepsia is defined as one or more of the following symptoms: postprandial fullness, early satiation, epigastric pain, or burning. Approximately 25 percent of patients with dyspepsia are found to have an underlying organic disease on diagnostic evaluation (",
"      <a class=\"graphic graphic_table graphicRef65698 \" href=\"UTD.htm?3/22/3436\">",
"       table 1",
"      </a>",
"      ). However, approximately 75 percent of patients have functional (idiopathic or nonulcer) dyspepsia.",
"     </li>",
"     <li>",
"      A detailed history, physical examination, and laboratory studies are necessary to narrow the differential diagnosis, identify GERD and NSAID-induced dyspepsia, and patients with alarm features (",
"      <a class=\"graphic graphic_table graphicRef56585 \" href=\"UTD.htm?9/2/9259\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The approach to and extent of diagnostic evaluation of a patient with dyspepsia is based on the presence or absence of alarm features, patient age, and the prevalence of",
"      <em>",
"       Helicobacter pylori",
"      </em>",
"      (",
"      <em>",
"       H. pylori",
"      </em>",
"      ) infection",
"      <em>",
"      </em>",
"      (",
"      <a class=\"graphic graphic_table graphicRef56585 \" href=\"UTD.htm?9/2/9259\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef67791 \" href=\"UTD.htm?20/17/20766\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with dyspepsia who have alarm features (",
"      <a class=\"graphic graphic_table graphicRef56585 \" href=\"UTD.htm?9/2/9259\">",
"       table 2",
"      </a>",
"      ) and patients &gt;55 years of age should undergo an early upper endoscopy, preferably within two weeks (",
"      <a class=\"graphic graphic_algorithm graphicRef67791 \" href=\"UTD.htm?20/17/20766\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with GERD and NSAID-induced dyspepsia should be treated with an empiric trial of proton pump inhibitors (PPI) (",
"      <a class=\"graphic graphic_table graphicRef65374 \" href=\"UTD.htm?28/19/28988\">",
"       table 4",
"      </a>",
"      ) for eight weeks and NSAIDs should be discontinued. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"       \"Medical management of gastroesophageal reflux disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"       \"Overview of the natural history and treatment of peptic ulcer disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Further evaluation should be pursued if these patients continue to have symptoms after eight weeks of PPI therapy or earlier if they have alarm features (",
"      <a class=\"graphic graphic_algorithm graphicRef55044 \" href=\"UTD.htm?11/60/12238\">",
"       algorithm 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef56585 \" href=\"UTD.htm?9/2/9259\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients &le;55 years of age without alarm features should be tested and treated for",
"      <em>",
"       H. pylori",
"      </em>",
"      if the prevalence of",
"      <em>",
"       H. pylori",
"      </em>",
"      is high (&gt;20 percent). Patients who test positive for an infection with",
"      <em>",
"       H. pylori",
"      </em>",
"      should undergo treatment with eradication therapy.",
"     </li>",
"     <li>",
"      We suggest empiric treatment with a PPI (",
"      <a class=\"graphic graphic_table graphicRef65374 \" href=\"UTD.htm?28/19/28988\">",
"       table 4",
"      </a>",
"      ) in areas of low",
"      <em>",
"       H. pylori",
"      </em>",
"      prevalence (&lt;5 percent) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Either strategy (test and treat",
"      <em>",
"       H. pylori",
"      </em>",
"      or empiric PPI therapy) may be employed in areas of intermediate H. pylori prevalence (5 to 20 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testing for",
"      <em>",
"       H. pylori",
"      </em>",
"      should be performed with a urea breath test or stool antigen assay. &nbsp;",
"      <br/>",
"      <br/>",
"      Patients who test positive for an infection with",
"      <em>",
"       H. pylori",
"      </em>",
"      should undergo treatment with eradication therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=see_link\">",
"       \"Treatment regimens for Helicobacter pylori\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In patients who test negative for an infection with",
"      <em>",
"       H. pylori",
"      </em>",
"      and those who have continued symptoms after eradication of",
"      <em>",
"       H. pylori,",
"      </em>",
"      we suggest treatment with antisecretory therapy with a proton pump inhibitor for four to eight weeks (",
"      <a class=\"graphic graphic_table graphicRef65374 \" href=\"UTD.htm?28/19/28988\">",
"       table 4",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27720/abstract/6\">",
"       6",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      In patients with continued symptoms of dyspepsia, endoscopic evaluation should be considered in patients who have not previously undergone an upper endoscopy and biopsies should be obtained for",
"      <em>",
"       H. pylori",
"      </em>",
"      and to rule out celiac disease (",
"      <a class=\"graphic graphic_algorithm graphicRef80468 \" href=\"UTD.htm?16/8/16526\">",
"       algorithm 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Further evaluation for an alternate diagnosis should be considered based on the patient&rsquo;s symptoms (",
"      <a class=\"graphic graphic_algorithm graphicRef60586 \" href=\"UTD.htm?31/11/31934\">",
"       algorithm 3",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Patients with continued symptoms of dyspepsia for three months with symptom onset at least six months before diagnosis and no evidence of structural disease to explain the symptoms should be diagnosed and treated as functional dyspepsia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=see_link\">",
"       \"Functional dyspepsia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/1\">",
"      Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/2\">",
"      Kurata JH, Nogawa AN, Everhart JE. A prospective study of dyspepsia in primary care. Dig Dis Sci 2002; 47:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/3\">",
"      Ford AC, Forman D, Bailey AG, et al. Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol 2012; 107:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/4\">",
"      van Zanten SV, Wahlqvist P, Talley NJ, et al. Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole--results from the STARS II study. Aliment Pharmacol Ther 2011; 34:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/5\">",
"      Talley NJ, American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005; 129:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/6\">",
"      Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/7\">",
"      Bytzer P, Talley NJ. Dyspepsia. Ann Intern Med 2001; 134:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/8\">",
"      Koch KL, Stern RM. Functional disorders of the stomach. Semin Gastrointest Dis 1996; 7:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/9\">",
"      Malagelada JR. Functional dyspepsia. Insights on mechanisms and management strategies. Gastroenterol Clin North Am 1996; 25:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/10\">",
"      Earlam R. A computerized questionnaire analysis of duodenal ulcer symptoms. Gastroenterology 1976; 71:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/11\">",
"      Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/12\">",
"      Klauser AG, Schindlbeck NE, M&uuml;ller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990; 335:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/13\">",
"      Hallas J, Bytzer P. Screening for drug related dyspepsia: an analysis of prescription symmetry. Eur J Gastroenterol Hepatol 1998; 10:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/14\">",
"      Talley NJ. Dyspepsia. Gastroenterology 2003; 125:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/15\">",
"      Lacy BE, Talley NJ, Locke GR 3rd, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 2012; 36:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/16\">",
"      Moayyedi P, Axon AT. The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease. Am J Gastroenterol 1999; 94:3122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/17\">",
"      Hunt RH, Xiao SD, Megraud F, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011; 20:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/18\">",
"      Williams B, Luckas M, Ellingham JH, et al. Do young patients with dyspepsia need investigation? Lancet 1988; 2:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/19\">",
"      Wiklund I, Glise H, Jerndal P, et al. Does endoscopy have a positive impact on quality of life in dyspepsia? Gastrointest Endosc 1998; 47:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/20\">",
"      Vakil N, Talley N, van Zanten SV, et al. Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms. Clin Gastroenterol Hepatol 2009; 7:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/21\">",
"      Adang RP, Vismans JF, Talmon JL, et al. Appropriateness of indications for diagnostic upper gastrointestinal endoscopy: association with relevant endoscopic disease. Gastrointest Endosc 1995; 42:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/22\">",
"      Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/23\">",
"      Talley NJ, Vakil N, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005; 100:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/24\">",
"      Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/25\">",
"      Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/26\">",
"      Manes G, Menchise A, de Nucci C, Balzano A. Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. BMJ 2003; 326:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/27\">",
"      Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996; 110:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/28\">",
"      Grad YH, Lipsitch M, Aiello AE. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol 2012; 175:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/29\">",
"      Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/30\">",
"      Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/31\">",
"      Jones RH, Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1997; 11:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/32\">",
"      Mason I, Millar LJ, Sheikh RR, et al. The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. Aliment Pharmacol Ther 1998; 12:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/33\">",
"      Delaney BC, Innes MA, Deeks J, et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2001; :CD001961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/34\">",
"      Talley NJ. Gallstones and upper abdominal discomfort. Innocent bystander or a cause of dyspepsia? J Clin Gastroenterol 1995; 20:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27720/abstract/35\">",
"      Goodwin RD, Cowles RA, Galea S, Jacobi F. Gastritis and mental disorders. J Psychiatr Res 2013; 47:128.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 20 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-71969A6E96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27720=[""].join("\n");
var outline_f27_4_27720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H63380126\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1915206322\">",
"      Dyspepsia secondary to organic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Gastroesophageal reflux",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Gastroesophageal malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Biliary pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Drug-induced dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1915205522\">",
"      - Other causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1915206385\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H75708801\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59602395\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59602487\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59602579\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H59603517\">",
"      DIAGNOSTIC STRATEGIES AND INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63379815\">",
"      Patient with alarm features or age &gt;55 years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63379823\">",
"      - Early upper endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63377954\">",
"      Patient without alarm features and age &le;55 years",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63377961\">",
"      - Test and treat for Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63380043\">",
"      - Antisecretory therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63380074\">",
"      - Upper endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63380082\">",
"      EVALUATION OF PERSISTENT SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63380126\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/20\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/20|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/17/20766\" title=\"algorithm 1\">",
"      Management of dyspepsia based on age and alarm features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?16/8/16526\" title=\"algorithm 2\">",
"      Endoscopy in patients who have failed empirical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/11/31934\" title=\"algorithm 3\">",
"      Management of functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/60/12238\" title=\"algorithm 4\">",
"      Initial management of dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/20|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/22/3436\" title=\"table 1\">",
"      Differential diagnosis of upper abdominal pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/2/9259\" title=\"table 2\">",
"      Dyspepsia alarm features AGA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/12/9421\" title=\"table 3\">",
"      Helicobacter pylori infection globally",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/19/28988\" title=\"table 4\">",
"      PPI recommended doses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31030?source=related_link\">",
"      Chronic abdominal wall pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33206?source=related_link\">",
"      Chronic mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13609?source=related_link\">",
"      Clinical manifestations of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24985?source=related_link\">",
"      Diabetic autonomic neuropathy of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4661?source=related_link\">",
"      Epidemiology of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/28/35272?source=related_link\">",
"      Functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/58/33702?source=related_link\">",
"      Granulomatous gastritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29208?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/47/13049?source=related_link\">",
"      Pharmacology of antiulcer medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_4_27721="Epidemiology, prevention and control of vancomycin-resistant enterococci";
var content_f27_4_27721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, prevention and control of vancomycin-resistant enterococci",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/4/27721/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27721/contributors\">",
"     Deverick J Anderson, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/4/27721/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27721/contributors\">",
"     Anthony Harris, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/4/27721/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27721/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/4/27721/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    -resistant enterococci (VRE) are an increasingly common and difficult to treat cause of hospital-acquired infection. The epidemiology of VRE and strategies for preventing its spread will be reviewed here. The infection control measures described are applicable to all resistant enterococci.",
"   </p>",
"   <p>",
"    The mechanisms of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    resistance, infections caused by VRE, and the treatment of VRE are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26506?source=see_link\">",
"     \"Mechanisms of antibiotic resistance in enterococci\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20229?source=see_link\">",
"     \"Microbiology of enterococci\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=see_link\">",
"     \"Treatment of enterococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    inhibits enterococci by binding to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of cell wall precursors, compromising the subsequent enzymatic steps in the synthesis of cell wall. High-level resistance to vancomycin is encoded by different clusters of genes referred to as the vancomycin resistance gene clusters (eg, vanA, vanB, and vanD gene clusters).",
"   </p>",
"   <p>",
"    The end result is the replacement of D-Ala-D-Ala-ending peptidoglycan precursors with D-alanyl-D-lactate termini, to which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    binds with significantly lower affinity. The replacement of D-alanine by D-lactate, which disrupts one of the five hydrogen bonds required for the interaction of vancomycin with its target, increases the minimum inhibitory concentration (MIC) of vancomycin almost 1000-fold. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26506?source=see_link&amp;anchor=H8#H8\">",
"     \"Mechanisms of antibiotic resistance in enterococci\", section on 'Vancomycin resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the 2006 report from the Clinical and Laboratory Standards Institute, the following MIC definitions were used for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    susceptibility and resistance in enterococci [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      susceptible &mdash; &le;4",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      resistant &mdash; &ge;32",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An MIC of 8 to 16",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    was considered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    intermediate, but we do not recommend vancomycin therapy for such isolates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonization and clinical infection with VRE were first described in Europe in the 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] and soon thereafter in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/4\">",
"     4",
"    </a>",
"    ]. The presence of VRE in Europe was related to the use of glycopeptides such as avoparcin as a food additive for growth promotion in animals for more than 20 years, a practice that was subsequently banned by the European Union.",
"   </p>",
"   <p>",
"    Multiple epidemics of VRE infection have been described in diverse hospital settings (eg, medical and surgical intensive care units, and medical and pediatric wards) and, like methicillin-resistant Staphylococcus aureus, VRE is endemic in many large hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/5-12\">",
"     5-12",
"    </a>",
"    ]. In 2008, the National Healthcare Safety Network (NHSN) published summary data on multidrug resistant organisms suggesting that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    resistance had increased to 33 percent among enterococci that caused healthcare-associated infections in 2006 and 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/13\">",
"     13",
"    </a>",
"    ]. In fact, the rate of hospitalization with VRE essentially doubled during 2003-2006 from 4.60 to 9.48 hospitalizations per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Modern techniques have expanded our knowledge of the epidemiology of VRE. Pulsed-field gel electrophoresis (PFGE) has been utilized in analyses of both epidemic and endemic clusters of VRE infection and colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/3,5,8,15,16\">",
"     3,5,8,15,16",
"    </a>",
"    ]. These studies demonstrated that a single VRE clone can spread within an institution or a patient care unit. In addition, VRE strains can transfer resistance horizontally to unrelated strains. Both methods of spread can occur simultaneously in a single institution. One report using PFGE found 45 different profiles in a single medical center where VRE had become endemic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of VRE isolates are E. faecium. This was illustrated in a prospective analysis from the SCOPE (Surveillance and Control or Pathogens of Epidemiologic Importance) database of 24,179 nosocomial bloodstream infections occurring in 49 hospitals in the United States between 1995 to 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/17\">",
"     17",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    resistance was found in 60 percent of E. faecium isolates compared to 2 percent of E. faecalis isolates. Data from the NHSN suggest that resistance trends are worsening; 80 percent of the 987 isolates of E. faecium and 6.9 percent of the 1497 isolates of E. faecalis reported in 2006 and 2007 were vancomycin resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VRE infections have been associated with worse outcomes. The magnitude of this effect was illustrated in a meta-analysis of nine studies of 1614 enterococcal bloodstream infections, 42 percent of which were due to VRE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/18\">",
"     18",
"    </a>",
"    ]. The mortality rate was significantly higher in patients with VRE compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    susceptible enterococcal isolates (summary odds ratio 2.5, 95% CI 1.9-3.4).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After VRE has been introduced into a healthcare setting, transmission is determined by selective pressure due to antimicrobial use, the proportion of colonized patients, the availability of susceptible patients, and adherence to prevention efforts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/19\">",
"     19",
"    </a>",
"    ]. The risk increases significantly in an intensive care unit once the proportion of patients exceeds 50 percent.",
"   </p>",
"   <p>",
"    VRE colonize the gastrointestinal tract and can be found on the skin due to fecal shedding. Colonization with VRE generally precedes infection, but not all patients with colonization become infected. Persons either colonized or infected with VRE can serve as sources for secondary transmission.",
"   </p>",
"   <p>",
"    VRE colonization is identified through the use of rectal or perirectal swab cultures or stool cultures. The overall sensitivity of rectal swab cultures for detection of VRE was 58 percent in one report, but varied directly with VRE density in stool from 100 percent at high densities (&ge;7.5 logs per gram) to 0 percent at low densities (&le;4.5 logs per gram) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/20\">",
"     20",
"    </a>",
"    ]. Both prior antibiotic exposure and skin colonization with VRE were more common in patients with high stool densities. The authors speculated that the high false-negative rate of rectal swab cultures may contribute to the increasing prevalence of VRE.",
"   </p>",
"   <p>",
"    PCR techniques for identification of vanA and vanB genes from",
"    <span class=\"nowrap\">",
"     stool/rectal",
"    </span>",
"    samples have been developed but their impact on surveillance for VRE has yet to be determined.",
"   </p>",
"   <p>",
"    Transmission can occur by both direct contact (eg, the hands of health care workers) and indirectly from environmental surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/21\">",
"     21",
"    </a>",
"    ]. The following observations come from different studies that have evaluated VRE transmission:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study in which VRE were inoculated in different places, the strains survived for five to seven days on countertops, 24 hours without a reduction in counts on bedrails, 60 minutes on a telephone handpiece, and 30 minutes on the diaphragmatic surface of stethoscopes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rectal electronic thermometer probes were the means of transmission of VRE in an ICU [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Environmental cultures for VRE were more likely to be positive when the stool density of the organism exceeded four logs per gram [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Healthcare workers can become colonized in their gastrointestinal tracts but the rate of acquisition of stool colonization appears to be low and transmission to patients from this source has not been demonstrated [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors for VRE colonization and infection. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous antimicrobial therapy",
"     </li>",
"     <li>",
"      Patient characteristics",
"     </li>",
"     <li>",
"      Colonization pressure",
"     </li>",
"     <li>",
"      Exposure to contaminated surfaces",
"     </li>",
"     <li>",
"      Residence in long-term care facilities",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Previous antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most consistently observed risk factor for hospital acquisition of VRE is previous treatment with antimicrobials, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and cephalosporins. As an example, a prospective study of 126 adult intensive care units (ICUs) in 60 hospitals found that vancomycin and cephalosporin use were significantly higher in patients with VRE, after controlling for the type of ICU and rates of VRE elsewhere in the institution [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/25\">",
"     25",
"    </a>",
"    ]. In another report, colonization or infection was associated with a longer duration of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    (13.2 versus 4.6 days in noninfected controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/22\">",
"     22",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    Use of multiple agents with a broad-spectrum of activity may predispose patients to colonization with resistant enterococci, probably via alteration of the normal bowel flora [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, among patients with VRE in stool, the administration of antibiotics active against anaerobic organisms can increase the density of stool colonization with VRE, which decreases after discontinuation of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patient characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of patient characteristics other than antimicrobial therapy have been associated with a high risk of VRE colonization. These include hospitalization longer than 72 hours, significant underlying medical conditions (end-stage renal disease requiring dialysis, cancer, transplant recipient), requirement for ICU, and invasive devices [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Colonization pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonization pressure, defined as the daily point prevalence of VRE colonized patients, is another important risk factor for acquisition of VRE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/19\">",
"     19",
"    </a>",
"    ]. Colonization pressure in hospitals can lead to substantial increases in VRE colonization. A review of 1039 patients admitted to a general medicine ward demonstrated that colonization with VRE increased from 3.8 percent on admission to 32 percent during hospitalization; 60 percent of the VRE isolates were the same strain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/27\">",
"     27",
"    </a>",
"    ]. Indeed, hospitalization is strongly correlated with risk of VRE colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Colonization pressure may outweigh other risk factors including antibiotic use once 50 percent or more of patients within the unit are colonized with VRE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Exposure to contaminated surfaces",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to contaminated surfaces in patient rooms, even after routine discharge cleaning, may be associated with VRE acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. For example, several outbreaks caused by transmission of VRE from contaminated medical equipment have been reported. Implicated medical equipment included rectal thermometers, tympanic thermometers, and contaminated EKG leads [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/22,31,32\">",
"     22,31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission of VRE from environmental surfaces to the hands or gloves of healthcare workers has been well documented. Forty-six percent of healthcare workers who touched bedrails and bedside tables in rooms of colonized patients in turn contaminated their gloves with VRE in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/33\">",
"     33",
"    </a>",
"    ]. Another study demonstrated that gloves or hands contaminated through contact with contaminated environmental surfaces can transfer VRE to approximately 10 percent of uncontaminated surfaces that are subsequently touched by other healthcare workers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific education of environmental services personnel leads to improved compliance with cleaning protocols and decreased environmental contamination with VRE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/35\">",
"     35",
"    </a>",
"    ]. A prospective quasi-experimental study showed that improved environmental cleaning significantly reduced the rate of VRE acquisition in a medical ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/36\">",
"     36",
"    </a>",
"    ]. This study was divided into four phases; a baseline period, a period including education to improve cleaning practices, a \"washout\" period and a period including a multimodal hand hygiene initiative. Patients were screened for VRE on admission to ICU and daily thereafter. Enhanced cleaning with a detergent-disinfectant was found to reduce environmental and hand contamination as well as VRE acquisition. Novel technologies such as steam vapor may further decrease environmental contamination with VRE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Residence in long-term care facilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Residents of long-term care facilities (LTCFs) appear to be a reservoir for VRE. In a prospective cohort study, 45 percent of patients admitted to an acute care hospital from an LTCF had rectal colonization with VRE; risk factors included prior use of antibiotics and the presence of a decubitus ulcer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of infection with VRE, as with any multidrug-resistant organism, requires a multifaceted approach including general infection prevention (eg, optimal management of vascular and urinary catheters), accurate and prompt diagnosis and treatment, prudent use of antimicrobial drugs, and prevention of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/39\">",
"     39",
"    </a>",
"    ]. Methods for prevention will be summarized here.",
"   </p>",
"   <p>",
"    Several different strategies for the prevention, control, and eradication of VRE have been studied. These include hand hygiene, contact precautions, cohorting of colonized patients, decolonization, surveillance cultures, and source control.",
"   </p>",
"   <p>",
"    Judicious use of antimicrobial drugs (called antimicrobial stewardship) is another modality, but its relative importance for control of VRE is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/40\">",
"     40",
"    </a>",
"    ]. Agents that would be targeted include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , third-generation cephalosporins, and anti-anaerobic drugs.",
"   </p>",
"   <p>",
"    The majority of published studies on the control of VRE have included multiple approaches. As a result, it is often difficult to determine the attributable efficacy of individual interventions. Judicious use of antimicrobial drugs is another modality, but its relative importance for control of VRE is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hand hygiene",
"    </span>",
"    &nbsp;&mdash;&nbsp;VRE is primarily transmitted from patient to patient on the hands of healthcare workers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/41\">",
"     41",
"    </a>",
"    ]. Thus, hand hygiene is the most important and most practical means of preventing spread of these organisms within the hospital. Antimicrobial soaps (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    containing) may be more useful than plain soap for patients with VRE in contact precautions or during an epidemic. Alcohol-based hand rubs are as effective as soap and water and may improve compliance with hand hygiene among healthcare workers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The duration of handwashing and the use of soap appear to determine efficacy. This was illustrated in a study in which VRE isolates were placed onto the hands of healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/21\">",
"     21",
"    </a>",
"    ]. A 30 second wash with water plus soap was necessary to complete eradicate the VRE hand carriage. In contrast, a five second wash with water alone produced virtually no change in VRE recovery",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Contact precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wearing gown and gloves when entering a patient room and removing them prior to exiting may decrease VRE transmission. The efficacy of this approach compared to gloves alone has been evaluated in three observational studies in medical ICUs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, gloves and gowns were used in two time periods, while only gloves were used in a third period between the other two [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/43\">",
"       43",
"      </a>",
"      ]. The rate of acquiring VRE with gloves and gowns was significantly lower compared to gloves alone (9.1 versus 19.6 cases per 1000 ICU days).",
"     </li>",
"     <li>",
"      In a second study of similar design, the rate of VRE acquisition was significantly higher after gown and gloves precautions were changed to gloves alone (3.8 versus 1.8 per 100 ICU days, hazard ratio 2.5) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The third study compared gowns and gloves in eight beds in a medical ICU to gloves alone in another eight beds [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/45\">",
"       45",
"      </a>",
"      ]. Daily rectal surveillance cultures were obtained. There was no difference between the two groups in the rate of VRE acquisition in the ICU, but the authors noted that gown use might lead to additional benefits of enhancing awareness and increasing compliance with other infection control strategies such as hand hygiene.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 1995 Healthcare Infection Control Practices Advisory Committee (HICPAC) guideline recommended that three negative",
"    <span class=\"nowrap\">",
"     stool/rectal",
"    </span>",
"    cultures obtained at weekly intervals are required to remove a previously colonized patient from contact precautions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/46\">",
"     46",
"    </a>",
"    ]. These criteria have been generally reliable; in one series, for example, 95 percent of patients with three negative cultures remained culture-negative [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some studies have shown that VRE colonization frequently reemerges, particularly in patients who receive subsequent antimicrobial therapy, and persistent or intermittent carriage for more than one year has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. One report, for example, described 13 patients who had an initial positive VRE stool culture and then three consecutive negative stool cultures obtained at least one week apart [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/49\">",
"     49",
"    </a>",
"    ]. After subsequent antimicrobial therapy, eight developed recurrent high-density VRE stool colonization. Three of the five strains tested were different from the original strain on pulsed field gel electrophoresis.",
"   </p>",
"   <p>",
"    Patients with known VRE colonization are presumed to remain colonized for at least one year after a positive culture. Screening for recurrent colonization may be warranted after antibiotics are given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cohorting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cohorting of patients with VRE",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    staff who care for colonized patients can help reduce rates of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. In one study, for example, the prevalence of VRE in all hospitalized patients decreased from 8.1 to 4.7 percent after the establishment of a cohort ward [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/51\">",
"     51",
"    </a>",
"    ]. While this decrease was not statistically significant (p = 0.14), an interesting additional finding was that staff were observed to be significantly more compliant with contact precautions recommendations (22 percent prior to establishment of cohorting versus 88 percent after establishment of cohorting).",
"   </p>",
"   <p>",
"    Using private rooms has been shown to decrease the risk of acquiring multidrug-resistant organisms, although this relationship has not been specifically studied with VRE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/53\">",
"     53",
"    </a>",
"    ]. Unit closure may be necessary to control further transmission during severe outbreaks or when usual control measures fail.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Decolonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effective methods for decolonization of VRE have been identified, as attempts to eliminate intestinal VRE carriage with nonabsorbable oral antibiotics have been generally disappointing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Thus, treatment specifically directed at decolonization of VRE is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Surveillance cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance cultures for VRE are usually obtained from rectal swabs, perirectal swabs, or stool samples [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/40,54\">",
"     40,54",
"    </a>",
"    ]. Samples for culture should also be obtained from areas of skin breakdown and draining wounds.",
"   </p>",
"   <p>",
"    The standard approach to surveillance of hospitalized patients for VRE carriage has been active surveillance of patients deemed to be at high risk. However, legislation mandating active surveillance cultures to screen all hospitalized patients for VRE carriage has been introduced in least one state in the United States. Such an approach remains controversial. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Proposed mandatory surveillance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Surveillance cultures are not needed from patients known to have been colonized or infected with VRE within the past 6 to 12 months. Such patients typically remain culture-positive regardless of the therapy that has been given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Rationale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for surveillance cultures to detect VRE carriage is threefold:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients colonized with VRE on admission or during hospitalization are at increased risk for VRE infection in-hospital or after discharge. The rate of infection varies with the health status of the patient, with an increased risk in severely ill or immunocompromised patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/57\">",
"       57",
"      </a>",
"      ]. The magnitude of infection risk was assessed in a report from a university hospital over a five-year period [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/58\">",
"       58",
"      </a>",
"      ]. Ninety VRE infections (60 urinary tract, 11 primary bloodstream, and 10 surgical site) occurred in 83 of 1050 patients who were colonized with VRE for an attack rate of 7.9 percent. A similar rate of infection (annual incidence 8.2 percent) was noted in 73 colonized children on a pediatric oncology ward [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      VRE colonization may be spread to other patients, most often by healthcare workers whose hands or gloves have become transiently contaminated [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/21,41\">",
"       21,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intervention may reduce both the development of VRE infection and spread to other patients. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Impact of infection control'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Active surveillance of patients at high risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active surveillance reduces transmission of VRE when performed in outbreak settings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/10,58,60,61\">",
"     10,58,60,61",
"    </a>",
"    ] or in high-risk patient units such as ICUs and hematology-oncology wards [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. The following observations illustrate the range of findings, some of which included combining surveillance cultures with other infection control measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an outbreak in The Netherlands, surveillance cultures revealed that 27 patients in six wards were colonized, 93 percent with the outbreak strain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/60\">",
"       60",
"      </a>",
"      ]. The detection rate of non-outbreak VRE was only about 3 percent, which was comparable to a 2 percent prevalence in non-hospitalized persons. Surveillance cultures with isolation of carriers, preemptive isolation of patients at high risk for VRE colonization, and increased hand hygiene compliance controlled the outbreak. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Impact of infection control'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The impact of screening hospitalized high-risk patients on admission and then weekly for rectal colonization with VRE was evaluated in 14 units at four academic medical centers in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/65\">",
"       65",
"      </a>",
"      ]. Ten units were ICUs; the other four cared for immunocompromised and transplant patients. The study population consisted of 8266 admissions and approximately 61,000 patient-days over 165 unit-months. The following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The admission prevalence of VRE colonization varied from 2 to 27 percent, with admission surveillance cultures increasing the detection rate 3.3-fold (range 2- to 17-fold).",
"     </li>",
"     <li>",
"      The monthly incidence of VRE acquisition was 1 to 10 percent, with weekly surveillance cultures increasing the detection rate 6.1-fold (range 3- to 15-fold).",
"     </li>",
"     <li>",
"      Active surveillance prevented the misclassification of 43 percent of \"incident\" carriers on the basis of clinical cultures alone and increased precaution days 2.4-fold.",
"     </li>",
"     <li>",
"      By advancing the initiation of contact precautions, active surveillance consistently reduced VRE transmission over a 12 month period (0.22 percent per month).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Proposed mandatory surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to selective surveillance limited to patients at high-risk for VRE as described in the preceding section, legislation has been introduced in numerous state in the United States mandating surveillance cultures to screen all hospitalized patients for carriage of methicillin-resistant Staphylococcus aureus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    VRE. These laws also require treating or offering treatment to carriers and, in some states, segregating the patient from those who test negative.",
"   </p>",
"   <p>",
"    Concerns with this approach led the Society for Healthcare Epidemiology of America (SHEA) and the Association of Professionals in Infection Control and Epidemiology (APIC) issued a joint position statement in March 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/54\">",
"     54",
"    </a>",
"    ]. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Patient bathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient bathing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    has been shown to be useful for reducing enterococcal colonization and infection; this issue is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Impact of infection control",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have demonstrated the beneficial clinical effects of infection control [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/12,52,58,60,64-66\">",
"     12,52,58,60,64-66",
"    </a>",
"    ]. The following observations illustrate the potential benefits of infection control measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The impact of screening for VRE on the rate of VRE bacteremia was evaluated in a study of two similar neighboring hospitals, one of which actively screened high-risk patients and one of which did not [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/67\">",
"       67",
"      </a>",
"      ]. Over a six year period, the hospital that did not screen had a 2.1-fold higher rate of VRE bacteremia (17.1 versus 8.2 per 100,000 hospital days) with a higher incidence of clonally related isolates, suggesting more horizontal transmission.",
"     </li>",
"     <li>",
"      In a VRE outbreak in The Netherlands cited above, the outbreak was retrospectively divided into three periods of different infection control measures [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/60\">",
"       60",
"      </a>",
"      ]. The use of alcohol-based hand rubs was enforced during all periods. Period I (duration four months) involved active surveillance cultures, isolation of carriers and cohorting; preemptive isolation of high-risk patients for VRE colonization was added in period II (duration seven months); and cohorting and preemptive isolation were discontinued in period III (duration 18 months). Compared to period I, the relative risk (RR) of detecting epidemic VRE was 0.67 (95% CI, 0.41-1.10) in period II and 0.02 (95% CI, 0.002-0.6) in period III, demonstrating control of the outbreak.",
"     </li>",
"     <li>",
"      In a study in an oncology unit in which VRE was endemic, 184 patients received standard infection control measures and 259 received an enhanced infection control strategy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/52\">",
"       52",
"      </a>",
"      ]. Both regimens included surveillance rectal swab cultures on admission and weekly, handwashing before and after patient contact, and contact precautions for VRE colonized and infected patients. The enhanced regimen included gown and glove use on room entry rather than for patient contact, cohorting with VRE unknown patients being placed on a separate unit until culture results were available, and more Infectious Diseases input with emphasis of reducing all antimicrobial drugs. Enhanced infection control was associated with reductions in the incidence of both VRE colonization (10.3 versus 20.7 patients per 1000 patient-days) and VRE bacteremia (0.45 versus 2.1 patients per 1000 patient-days). A side benefit of the program was a significant decrease in the use of all antimicrobial drugs except for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In a system-wide study, a comprehensive infection control intervention was evaluated for the control of endemic colonization and infection in 30 acute care and long-term facilities in Iowa, Nebraska, and South Dakota [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/12\">",
"       12",
"      </a>",
"      ]. The prevalence of VRE colonization fell from 2.2 percent at baseline to 1.4 percent at one year and 0.5 percent at two years after intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Guideline recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Society for Healthcare Epidemiology of America (SHEA) in 2003 and the Hospital Infection Control Practices Advisory Committee (HICPAC) of the Centers for Disease Control and Prevention in 2006 published recommendations to prevent transmission of multidrug resistant organisms including VRE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the two guidelines agree in large part, they offer different recommendations regarding the use of surveillance cultures. The SHEA guideline strongly recommends that facilities implement a program of active surveillance cultures in patients at high risk and contact precautions to reduce the transmission of VRE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/41\">",
"     41",
"    </a>",
"    ]. In contrast, the HICPAC guideline contains a two-tiered set of recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tier-1 level recommendations, which represent general measures for all healthcare facilities, do not include the use of active surveillance cultures.",
"     </li>",
"     <li>",
"      Tier-2 level recommendations include intensified interventions that should be implemented when the incidence or prevalence of multidrug resistant organisms such as VRE is not decreasing despite implementation of and adherence to routine control measures. Active surveillance cultures of high-risk patients are recommended as part of Tier-2 level interventions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As described above, the main components of a program aimed at reducing the transmission of VRE in healthcare facilities include hand hygiene, contact precautions (gloves, gowns, and isolation or cohorting) for infected and colonized patients, active surveillance cultures of patients at high risk, and decontamination of the environment and equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/40\">",
"     40",
"    </a>",
"    ]. In contrast, attempts to eliminate intestinal VRE carriage with nonabsorbable oral antibiotics have been generally disappointing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/54-56\">",
"     54-56",
"    </a>",
"    ] and the 2006 HICPAC guidelines concluded that no recommendation for such therapy can be made [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific components of these infection control measures and the definition of patients at high risk are similar to those used for the prevention of transmission of methicillin-resistant Staphylococcus aureus (MRSA) and are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only major difference is the site of culture which, as noted above, consists of rectal, perirectal, or stool cultures as opposed to nares cultures for MRSA surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/40\">",
"     40",
"    </a>",
"    ]. A mathematical model suggested that, in intensive care units, active surveillance cultures alone could reduce VRE transmission by 39 percent and by 65 percent when combined with preemptive isolation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/64\">",
"     64",
"    </a>",
"    ]. The 2006 HICPAC guidelines also concluded the judicious use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , third-generation cephalosporins, and antianaerobic antibiotics may reduce that rate of VRE colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27721/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/19/39217?source=see_link\">",
"       \"Patient information: Vancomycin-resistant enterococci (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VRE is differentiated from other strains of Enterococcus by an increased minimum inhibitory concentration for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      and the presence of vancomycin resistance gene clusters such as vanA. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adherence to protocols for cleaning of patient rooms should be monitored to decrease the environmental contamination with VRE. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk Factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Healthcare-associated VRE is transmitted on the hands of healthcare workers; as a result, good hand hygiene is considered an essential measure for reducing the spread of this pathogen. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hand hygiene'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colonization with VRE typically precedes infection. Colonization most commonly occurs in patients with previous antimicrobial therapy and residents in long-term care facilities. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Risk Factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are colonized with VRE have approximately an 8 percent rate of developing a VRE infection in-hospital or after discharge, with a higher rate in patients who are severely ill or immunocompromised. In addition, VRE colonization may be spread to other patients, most often by healthcare workers whose hands or gloves have become transiently contaminated. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that contact precautions be followed for patients with VRE infection or colonization (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Contact precautions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H11#H11\">",
"       \"General principles of infection control\", section on 'Contact precautions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surveillance cultures for VRE are usually obtained from rectal swabs, perirectal swabs, or stool samples. Samples for culture should also be obtained from areas of skin breakdown and draining wounds. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Surveillance cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine active surveillance cultures are not warranted to identify patients colonized with VRE in non-epidemic situations. Active surveillance cultures in high risk patients can be used if the incidence or prevalence of VRE in the facility is not decreasing despite implementation of and rigorous adherence to routine control measures (eg, hand hygiene, contact precautions). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Guideline recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT attempting to decolonize VRE carriers (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Decolonization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Sixteenth Informational Supplement. M100-S16 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved Standard. Vol 26. No 3. CLSI, Wayne, Pennsylvania, USA, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/2\">",
"      Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/3\">",
"      Uttley AH, George RC, Naidoo J, et al. High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989; 103:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/4\">",
"      Sahm DF, Kissinger J, Gilmore MS, et al. In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1989; 33:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/5\">",
"      Boyce JM, Opal SM, Chow JW, et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance. J Clin Microbiol 1994; 32:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/6\">",
"      Boyle JF, Soumakis SA, Rendo A, et al. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci. J Clin Microbiol 1993; 31:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/7\">",
"      Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/8\">",
"      Handwerger S, Raucher B, Altarac D, et al. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin. Clin Infect Dis 1993; 16:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/9\">",
"      Karanfil LV, Murphy M, Josephson A, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992; 13:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/10\">",
"      Montecalvo MA, Horowitz H, Gedris C, et al. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 1994; 38:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/11\">",
"      Rubin LG, Tucci V, Cercenado E, et al. Vancomycin-resistant Enterococcus faecium in hospitalized children. Infect Control Hosp Epidemiol 1992; 13:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/12\">",
"      Ostrowsky BE, Trick WE, Sohn AH, et al. Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med 2001; 344:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/13\">",
"      Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/14\">",
"      Ramsey AM, Zilberberg MD. Secular trends of hospitalization with vancomycin-resistant enterococcus infection in the United States, 2000-2006. Infect Control Hosp Epidemiol 2009; 30:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/15\">",
"      Miranda AG, Singh KV, Murray BE. DNA fingerprinting of Enterococcus faecium by pulsed-field gel electrophoresis may be a useful epidemiologic tool. J Clin Microbiol 1991; 29:2752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/16\">",
"      Morris JG Jr, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995; 123:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/17\">",
"      Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/18\">",
"      DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005; 41:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/19\">",
"      Bonten MJ, Slaughter S, Ambergen AW, et al. The role of \"colonization pressure\" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med 1998; 158:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/20\">",
"      D'Agata EM, Gautam S, Green WK, Tang YW. High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci. Clin Infect Dis 2002; 34:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/21\">",
"      Noskin GA, Stosor V, Cooper I, Peterson LR. Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces. Infect Control Hosp Epidemiol 1995; 16:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/22\">",
"      Livornese LL Jr, Dias S, Samel C, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992; 117:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/23\">",
"      Donskey CJ, Chowdhry TK, Hecker MT, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 2000; 343:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/24\">",
"      Baran J Jr, Ramanathan J, Riederer KM, Khatib R. Stool colonization with vancomycin-resistant enterococci in healthcare workers and their households. Infect Control Hosp Epidemiol 2002; 23:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/25\">",
"      Fridkin SK, Edwards JR, Courval JM, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units. Ann Intern Med 2001; 135:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/26\">",
"      Weinstein JW, Roe M, Towns M, et al. Resistant enterococci: a prospective study of prevalence, incidence, and factors associated with colonization in a university hospital. Infect Control Hosp Epidemiol 1996; 17:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/27\">",
"      Cohen MJ, Adler A, Block C, et al. Acquisition of vancomycin-resistant enterococci in internal medicine wards. Am J Infect Control 2009; 37:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/28\">",
"      Riedel S, Von Stein D, Richardson K, et al. Development of a prediction rule for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus carriage in a Veterans Affairs Medical Center population. Infect Control Hosp Epidemiol 2008; 29:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/29\">",
"      Mart&iacute;nez JA, Ruthazer R, Hansjosten K, et al. Role of environmental contamination as a risk factor for acquisition of vancomycin-resistant enterococci in patients treated in a medical intensive care unit. Arch Intern Med 2003; 163:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/30\">",
"      Trillis F 3rd, Eckstein EC, Budavich R, et al. Contamination of hospital curtains with healthcare-associated pathogens. Infect Control Hosp Epidemiol 2008; 29:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/31\">",
"      Falk PS, Winnike J, Woodmansee C, et al. Outbreak of vancomycin-resistant enterococci in a burn unit. Infect Control Hosp Epidemiol 2000; 21:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/32\">",
"      Porwancher R, Sheth A, Remphrey S, et al. Epidemiological study of hospital-acquired infection with vancomycin-resistant Enterococcus faecium: possible transmission by an electronic ear-probe thermometer. Infect Control Hosp Epidemiol 1997; 18:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/33\">",
"      Ray AJ, Hoyen CK, Taub TF, et al. Nosocomial transmission of vancomycin-resistant enterococci from surfaces. JAMA 2002; 287:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/34\">",
"      Duckro AN, Blom DW, Lyle EA, et al. Transfer of vancomycin-resistant enterococci via health care worker hands. Arch Intern Med 2005; 165:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/35\">",
"      Hota B, Blom DW, Lyle EA, et al. Interventional evaluation of environmental contamination by vancomycin-resistant enterococci: failure of personnel, product, or procedure? J Hosp Infect 2009; 71:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/36\">",
"      Hayden MK, Bonten MJ, Blom DW, et al. Reduction in acquisition of vancomycin-resistant enterococcus after enforcement of routine environmental cleaning measures. Clin Infect Dis 2006; 42:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/37\">",
"      Tanner BD. Reduction in infection risk through treatment of microbially contaminated surfaces with a novel, portable, saturated steam vapor disinfection system. Am J Infect Control 2009; 37:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/38\">",
"      Elizaga ML, Weinstein RA, Hayden MK. Patients in long-term care facilities: a reservoir for vancomycin-resistant enterococci. Clin Infect Dis 2002; 34:441.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Campaign to prevent antimicrobial resistance in healthcare settings, 2007. Available at: file://www.cdc.gov/drugresistance/healthcare/. (Accessed May 7, 2007).",
"    </li>",
"    <li>",
"     Siegel, JR, E, Jackson, M, Chiarello, L, et al. Management of multidrug-resistant organisms in healthcare settings, 2006. Centers for Disease Control. Available at: www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf (accessed May 6, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/41\">",
"      Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003; 24:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/42\">",
"      Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee, HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/43\">",
"      Puzniak LA, Leet T, Mayfield J, et al. To gown or not to gown: the effect on acquisition of vancomycin-resistant enterococci. Clin Infect Dis 2002; 35:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/44\">",
"      Srinivasan A, Song X, Ross T, et al. A prospective study to determine whether cover gowns in addition to gloves decrease nosocomial transmission of vancomycin-resistant enterococci in an intensive care unit. Infect Control Hosp Epidemiol 2002; 23:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/45\">",
"      Slaughter S, Hayden MK, Nathan C, et al. A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Ann Intern Med 1996; 125:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/46\">",
"      Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/47\">",
"      Byers KE, Anglim AM, Anneski CJ, Farr BM. Duration of colonization with vancomycin-resistant Enterococcus. Infect Control Hosp Epidemiol 2002; 23:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/48\">",
"      Baden LR, Thiemke W, Skolnik A, et al. Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of \"clearance\". Clin Infect Dis 2001; 33:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/49\">",
"      Donskey CJ, Hoyen CK, Das SM, et al. Recurrence of vancomycin-resistant Enterococcus stool colonization during antibiotic therapy. Infect Control Hosp Epidemiol 2002; 23:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/50\">",
"      Christiansen KJ, Tibbett PA, Beresford W, et al. Eradication of a large outbreak of a single strain of vanB vancomycin-resistant Enterococcus faecium at a major Australian teaching hospital. Infect Control Hosp Epidemiol 2004; 25:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/51\">",
"      Jochimsen EM, Fish L, Manning K, et al. Control of vancomycin-resistant enterococci at a community hospital: efficacy of patient and staff cohorting. Infect Control Hosp Epidemiol 1999; 20:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/52\">",
"      Montecalvo MA, Jarvis WR, Uman J, et al. Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting. Ann Intern Med 1999; 131:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/53\">",
"      Mulin B, Rouget C, Cl&eacute;ment C, et al. Association of private isolation rooms with ventilator-associated Acinetobacter baumanii pneumonia in a surgical intensive-care unit. Infect Control Hosp Epidemiol 1997; 18:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/54\">",
"      Weber SG, Huang SS, Oriola S, et al. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. Infect Control Hosp Epidemiol 2007; 28:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/55\">",
"      Mondy KE, Shannon W, Mundy LM. Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2001; 33:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/56\">",
"      Hachem R, Raad I. Failure of oral antimicrobial agents in eradicating gastrointestinal colonization with vancomycin-resistant enterococci. Infect Control Hosp Epidemiol 2002; 23:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/57\">",
"      Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc 2006; 81:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/58\">",
"      Calfee DP, Giannetta ET, Durbin LJ, et al. Control of endemic vancomycin-resistant Enterococcus among inpatients at a university hospital. Clin Infect Dis 2003; 37:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/59\">",
"      Henning KJ, Delencastre H, Eagan J, et al. Vancomycin-resistant Enterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996; 15:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/60\">",
"      Mascini EM, Troelstra A, Beitsma M, et al. Genotyping and preemptive isolation to control an outbreak of vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2006; 42:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/61\">",
"      Singh N, L&eacute;ger MM, Campbell J, et al. Control of vancomycin-resistant enterococci in the neonatal intensive care unit. Infect Control Hosp Epidemiol 2005; 26:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/62\">",
"      Hachem R, Graviss L, Hanna H, et al. Impact of surveillance for vancomycin-resistant enterococci on controlling a bloodstream outbreak among patients with hematologic malignancy. Infect Control Hosp Epidemiol 2004; 25:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/63\">",
"      Siddiqui AH, Harris AD, Hebden J, et al. The effect of active surveillance for vancomycin-resistant enterococci in high-risk units on vancomycin-resistant enterococci incidence hospital-wide. Am J Infect Control 2002; 30:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/64\">",
"      Perencevich EN, Fisman DN, Lipsitch M, et al. Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. Clin Infect Dis 2004; 38:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/65\">",
"      Huang SS, Rifas-Shiman SL, Pottinger JM, et al. Improving the assessment of vancomycin-resistant enterococci by routine screening. J Infect Dis 2007; 195:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/66\">",
"      May AK, Melton SM, McGwin G, et al. Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. Shock 2000; 14:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27721/abstract/67\">",
"      Price CS, Paule S, Noskin GA, Peterson LR. Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis 2003; 37:921.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4045 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27721=[""].join("\n");
var outline_f27_4_27721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Previous antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patient characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Colonization pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Exposure to contaminated surfaces",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Residence in long-term care facilities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hand hygiene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Contact precautions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cohorting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Decolonization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Surveillance cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Rationale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Active surveillance of patients at high risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Proposed mandatory surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Patient bathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Impact of infection control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Guideline recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26506?source=related_link\">",
"      Mechanisms of antibiotic resistance in enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/48/20229?source=related_link\">",
"      Microbiology of enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/19/39217?source=related_link\">",
"      Patient information: Vancomycin-resistant enterococci (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17338?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_4_27722="Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis";
var content_f27_4_27722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/4/27722/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27722/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/4/27722/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27722/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27722/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27722/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/4/27722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/4/27722/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/4/27722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 23, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatomyositis (DM) and polymyositis (PM) are classified as idiopathic inflammatory myopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Both disorders, as defined clinically, have prevalence rates estimated at approximately one per 100,000 in the general population. There is a female to male predominance of about 2:1. The peak incidence in adults occurs between the ages of 40 and 50, but individuals of any age may be affected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of the many clinical and serologic features of DM and PM varies widely among affected individuals, depending upon the patient's immunogenetic profile and presumably a host of potential environmental triggers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of DM and PM in adults will be reviewed here. Treatment approaches to these diseases and of the related disorders that occur in children (known as juvenile DM and PM) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=see_link\">",
"     \"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENCES BETWEEN DM AND PM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although DM and PM share the clinical feature of muscle weakness, there are both clinical and pathogenetic differences between these disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DM is associated with a variety of characteristic skin manifestations, including Gottron's sign, the shawl sign, the heliotrope rash, and a generalized erythroderma. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Skin findings'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      DM is more likely to be associated with cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=see_link\">",
"       \"Malignancy in dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      DM is characterized by immune complex deposition in the vessels and is considered to be in part a complement-mediated vasculopathy. In contrast, PM appears to reflect direct T cell-mediated muscle injury. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Immunopathogenesis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several sets of classification criteria have been developed for DM and PM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bohan and Peter criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The original Bohan and Peter criteria, formulated in 1975, included the following features [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symmetric proximal muscle weakness",
"     </li>",
"     <li>",
"      Typical rash of DM, which was the only distinguishing feature between DM and PM",
"     </li>",
"     <li>",
"      Elevated serum muscle enzymes",
"     </li>",
"     <li>",
"      Myopathic changes on electromyography",
"     </li>",
"     <li>",
"      Characteristic muscle biopsy abnormalities and the absence of histopathologic signs of other myopathies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria were formulated before testing for myositis-specific autoantibodies was available. In addition, inclusion body myositis, which shares clinical features with DM and PM, was not recognized until the 1980s. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Autoantibodies'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H30\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As a result, patients who were classified as DM or PM according to these criteria may have some other disorder. This was illustrated in a retrospective review of 160 patients with \"myositis\" who were seen between 1977 and 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/8\">",
"     8",
"    </a>",
"    ]. When the patients were reevaluated one year after presentation, 59 (35 percent) were classified more precisely as DM and only 4 (2 percent) were categorized as PM (compared to nine with this diagnosis at presentation, with the other five having inclusion body myositis) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/8\">",
"     8",
"    </a>",
"    ]. At least 65 patients (40 percent) were recognized to have a connective tissue disorder that was often not identifiable at the time of the initial myositis diagnosis.",
"   </p>",
"   <p>",
"    The main reason so few patients were classified as PM in this study was that the investigators required a strict histologic definition of PM, rather than myositis specific autoantibodies or inclusion body myositis.",
"   </p>",
"   <p>",
"    Similar findings were noted in another report [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/9\">",
"     9",
"    </a>",
"    ]. In this review of 100 patients with idiopathic inflammatory myopathy, 45 percent were classified as PM by the Bohan and Peter criteria, compared to only 14 percent with a modified classification.",
"   </p>",
"   <p>",
"    In summary, when compared to the Bohan and Peter criteria, under more recent classification systems and definitions, the percentage of inflammatory myopathy cases classified as pure adult PM has declined, while the percentage of cases classified as \"overlap\" myositis (ie, related to a connective tissue disorder) has increased substantially [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Alternative classification schemes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two alternative classification schemes have emerged since 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The two new systems address significantly different populations. In addition, one relies heavily on histologic criteria while the other relies heavily on clinical features.",
"   </p>",
"   <p>",
"    One approach, based upon a longitudinal study of 100 French-Canadian patients, classified patients according to a \"clinicoserologic\" approach that relied upon extensive testing for autoantibodies. Excluding inclusion body myositis, four categories of inflammatory myopathy were recognized:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pure PM",
"     </li>",
"     <li>",
"      Pure DM",
"     </li>",
"     <li>",
"      Overlap myositis, which was defined as myositis plus any associated clinical overlap feature other than rash",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      any overlap autoantibody. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Autoantibodies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Cancer-associated myositis, which was defined as myositis with clinical paraneoplastic features and without an overlap autoantibody or anti-Mi-2 antibodies. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Myositis-specific autoantibodies'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The second scheme, proposed by an international workshop of myositis experts focused on criteria for the inclusion of patients in clinical trials, excluded myositis associated with either a connective tissue disease or malignancy but included the following categories [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inclusion body myositis",
"     </li>",
"     <li>",
"      Definite PM",
"     </li>",
"     <li>",
"      Probable PM",
"     </li>",
"     <li>",
"      Definite DM",
"     </li>",
"     <li>",
"      Probable DM",
"     </li>",
"     <li>",
"      Amyopathic DM, also called dermatomyositis sine myositis",
"     </li>",
"     <li>",
"      Possible dermatomyositis sine dermatitis",
"     </li>",
"     <li>",
"      Nonspecific myositis",
"     </li>",
"     <li>",
"      Immune-mediated necrotizing myopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These categories were based upon clinical, histopathologic, and laboratory findings, including autoantibody determinations.",
"   </p>",
"   <p>",
"    Both newer approaches to the classification of inflammatory myopathies allow greater accuracy in predicting the course of the disease and response to treatment than do the Bohan and Peter criteria. Future studies of DM and PM are likely to employ one of these newer classification systems [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IMMUNOPATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the histologic features of both DM and PM include muscle fiber necrosis, degeneration and regeneration, and an inflammatory cell infiltrate, certain characteristic findings in these two different diseases reflect their distinct pathophysiologic pathways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DM is considered to be a humorally&ndash;mediated disorder in which the cellular infiltrate, located principally in perifascicular regions, is often focused around",
"      <strong>",
"       blood vessels",
"      </strong>",
"      &nbsp;(",
"      <a class=\"graphic graphic_picture graphicRef76448 \" href=\"UTD.htm?4/49/4888\">",
"       picture 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. The terminal complement C5b&ndash;9 membrane attack complex is detectable in vessel walls before the appearance of inflammatory cell infiltration in DM but not in PM (",
"      <a class=\"graphic graphic_picture graphicRef56483 \" href=\"UTD.htm?34/13/35038\">",
"       picture 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although DM is clearly associated with a vasculopathy in which complement is involved, it is not known if the vasculopathy is mediated purely by complement or if the deposition of complement proteins and other immune complexes associated with this diagnosis is secondary to other pathophysiologic events [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The inflammatory infiltrate is composed of B cells and plasmacytoid dendritic cells that are CD4+. Other typical features include perifascicular atrophy and fibrosis. Abnormal muscle fibers are usually grouped in one portion of the fascicle, suggestive of microinfarction mediated by blood vessel dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In PM, the cellular infiltrate is predominantly",
"      <strong>",
"       within the fascicle",
"      </strong>",
"      with inflammatory cells invading individual muscle fibers (",
"      <a class=\"graphic graphic_picture graphicRef69212 \" href=\"UTD.htm?0/43/696\">",
"       picture 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/14\">",
"       14",
"      </a>",
"      ]. In contrast to DM, abnormal muscle fibers are scattered throughout the fascicle, not limited to one portion. There are no signs of vasculopathy or immune complex deposition. There is, however, evidence of cell&ndash;mediated immune mechanisms with increased numbers of cytotoxic CD8+ T cells, which appear to recognize an antigen on the muscle fiber surface [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/13\">",
"       13",
"      </a>",
"      ], and enhanced expression of major histocompatibility complex (MHC) antigens by the muscle fibers [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proinflammatory cytokines may contribute to muscle weakness in the absence of overt histologic inflammatory changes. Both interleukin (IL)-1 and tumor necrosis factor (TNF)-alpha are increased in muscle tissue of patients with DM and PM. Both of these cytokines, as well as upregulation of MHC class I molecules on myocytes, may lead to disturbed muscle function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DM and PM are both multisystem disorders with a wide variety of potential clinical findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Muscle weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle weakness is the most common presenting feature of DM and PM. The onset is usually insidious, with gradual worsening over a period of several months before medical attention is sought. However, an acute onset has been described.",
"   </p>",
"   <p>",
"    The distribution of weakness is typically symmetric and",
"    <strong>",
"     proximal",
"    </strong>",
"    . Distal muscle weakness, if present, tends to be mild and usually does not cause significant functional impairment. Rare patients present with focal myositis that usually but not always progresses to the typical generalized form over time [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link\">",
"     \"Approach to the patient with muscle weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myalgias and muscle tenderness occur in 25 to 50 percent of cases. These symptoms tend to be mild, unlike the more prominent muscle pain that occurs in polymyalgia rheumatica, fibromyalgia, and viral or bacterial myositis.",
"   </p>",
"   <p>",
"    Muscle atrophy is generally not seen in early cases, even in patients with marked weakness, but may occur in severe, long-standing disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Skin findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several distinct rashes, generally present at the time of clinical presentation, occur in DM but not PM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gottron's sign &mdash; Gottron's sign is an erythematous, often scaly eruption that occurs in a symmetric fashion over the metacarpophalangeal and interphalangeal joints (",
"      <a class=\"graphic graphic_picture graphicRef70904 graphicRef50909 graphicRef51110 \" href=\"UTD.htm?9/0/9226\">",
"       picture 4A-C",
"      </a>",
"      ). Similar lesions can be seen over the extensor aspects of the elbows and knees, mimicking psoriasis.",
"     </li>",
"     <li>",
"      Heliotrope rash &mdash; The heliotrope rash is a violaceous eruption on the upper eyelids, often accompanied by eyelid swelling (",
"      <a class=\"graphic graphic_picture graphicRef73090 graphicRef53713 \" href=\"UTD.htm?20/29/20953\">",
"       picture 5A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Shawl sign and V sign &mdash; The shawl sign is a diffuse, flat erythematous lesion occurring over the chest and shoulders or in a V&ndash;shaped distribution over the anterior neck and chest (",
"      <a class=\"graphic graphic_picture graphicRef51164 \" href=\"UTD.htm?8/9/8351\">",
"       picture 6",
"      </a>",
"      ). This finding, which corresponds generally to the site covered by a shawl, may be exacerbated by exposure to ultraviolet light.",
"     </li>",
"     <li>",
"      Erythroderma &mdash; Erythroderma refers to erythema that resembles the shawl sign but is seen in a variety of other cutaneous areas, including the malar region (",
"      <a class=\"graphic graphic_picture graphicRef58803 \" href=\"UTD.htm?30/44/31424\">",
"       picture 7",
"      </a>",
"      ) and the forehead (",
"      <a class=\"graphic graphic_picture graphicRef62881 \" href=\"UTD.htm?3/51/3892\">",
"       picture 8",
"      </a>",
"      ). Erythroderma is often associated with extensive areas of skin redness.",
"     </li>",
"     <li>",
"      Periungual abnormalities &mdash; The capillary nailbeds in DM may be erythematous and show vascular changes similar to those observed in other connective tissue disorders (eg, scleroderma and systemic lupus erythematosus). Abnormal capillary nailbed loops may be evident, with alternating areas of dilatation and dropout (",
"      <a class=\"graphic graphic_picture graphicRef60688 graphicRef53495 \" href=\"UTD.htm?23/1/23573\">",
"       picture 9A-B",
"      </a>",
"      ) and periungual erythema (",
"      <a class=\"graphic graphic_picture graphicRef75333 \" href=\"UTD.htm?42/56/43919\">",
"       picture 10",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Mechanic's hands &mdash; Patients with either DM or PM may have \"mechanic's hands,\" a roughening and cracking of the skin of the tips and lateral aspects of the fingers, resulting in irregular, dirty-appearing lines that resemble those of a manual laborer (",
"      <a class=\"graphic graphic_picture graphicRef56057 \" href=\"UTD.htm?41/47/42736\">",
"       picture 11",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/20\">",
"       20",
"      </a>",
"      ]. These lesions are classically associated with the antisynthetase syndrome, but have also been reported with other autoantibodies. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antisynthetase syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Psoriasiform changes in scalp &mdash; Changes in the scalp resembling psoriasis probably occur in a high percentage of patients with dermatomyositis (",
"      <a class=\"graphic graphic_picture graphicRef54249 \" href=\"UTD.htm?25/9/25745\">",
"       picture 12",
"      </a>",
"      ). Dermatomyositis of the scalp is often misdiagnosed as psoriasis.",
"     </li>",
"     <li>",
"      Flagellate erythema &mdash; Flagellate erythema comprises linear, violaceous streaks on the trunk [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/21\">",
"       21",
"      </a>",
"      ]. Because of their truncal location in DM, these lesions are sometimes termed \"centripetal\" flagellate erythema. Recurrent scratching of the skin is believed to play an important role in the etiology of these lesions.",
"     </li>",
"     <li>",
"      Calcinosis cutis &mdash; The deposition of calcium within the skin, a finding known as calcinosis cutis, occurs commonly in juvenile DM, but is unusual in adult DM.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of other, more unusual skin manifestations of DM include ichthyosis, panniculitis, lichen planus, porcelain white atrophic scars, vesicle and bullae formation, follicular hyperkeratosis, malakoplakia, and papular mucinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interstitial lung disease (ILD) is an important complication in at least 10 percent of cases of DM and PM. In addition, respiratory insufficiency may result from diaphragmatic and chest wall muscle weakness.",
"   </p>",
"   <p>",
"    The occurrence of ILD may be associated with rapidly progressive pulmonary failure and death. ILD in the inflammatory myopathies often occurs in the context of antisynthetase antibodies and the antisynthetase syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=see_link\">",
"     \"Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H22\">",
"     'Myositis-specific autoantibodies'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Antisynthetase syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increased rate of malignancy has been described, with a greater risk in patients with DM. The spectrum of malignancies parallels the distribution in the general population with a few possible exceptions. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=see_link\">",
"     \"Malignancy in dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Esophageal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness of the striated muscle of the upper one-third of the esophagus",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    the oropharyngeal muscles) may lead to dysphagia, nasal regurgitation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/23\">",
"     23",
"    </a>",
"    ]. Esophageal involvement is more common in elderly patients and may underlie the increased incidence of bacterial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac involvement with histologic evidence of myocarditis is well described in DM and PM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/25\">",
"     25",
"    </a>",
"    ]. However, myocardial involvement severe enough to cause heart failure is unusual.",
"   </p>",
"   <p>",
"    Patients with myositis may have an elevated serum CK-MB fraction due either to increased expression of CK B chain from inflamed skeletal muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/26\">",
"     26",
"    </a>",
"    ], or to involvement of the myocardium by the myositis. However, the most common reason for increased CK-MB levels is that the fraction of MB is increased in regenerating muscle. Myocardial infarction may be suspected in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\", section on 'Cardiac enzymes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac troponin I, a more specific and sensitive marker of cardiac damage than CK-MB, can be used to assess the cause of elevated serum CK-MB levels in patients with myositis. Normal plasma troponin I concentrations provide some reassurance against cardiac involvement, but the clinical utility of this assay in DM and PM requires further evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe disease may present with a variety of other manifestations, including fever, weight loss, Raynaud phenomenon, and a nonerosive inflammatory polyarthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antisynthetase syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to 30 percent of patients with DM or PM have a constellation of clinical findings termed \"the antisynthetase syndrome.\" These findings include the relatively acute disease onset, constitutional symptoms (eg, fever), Raynaud's phenomenon, mechanic's hands, arthritis, and ILD. Affected patients have antisynthetase antibodies that are highly specific for DM and PM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Myositis-specific autoantibodies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With regard to the anti-synthetase syndrome, several points should be noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Not all patients with antisynthetase antibodies or even those classified as having the antisynthetase syndrome have all manifestations of this syndrome.",
"     </li>",
"     <li>",
"      This group of clinical findings or this general clinical picture is not specific for antisynthetase antibodies. Patients with other types of autoantibodies, eg, anti-PM-Scl, anti-U1RNP, can also present with these types of features.",
"     </li>",
"     <li>",
"      Finally, some patients with antisynthetase antibodies have relatively little myositis but more prominent other features of this disease spectrum, such as ILD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Amyopathic DM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyopathic dermatomyositis and dermatomyositis sine myositis are terms used to describe patients with the typical rash and dermatopathology of DM who do not have clinical evidence of myopathy. Most of these patients eventually develop clinical, histologic, or radiologic evidence of myositis; however, muscle involvement may not be seen as long as six years after disease onset [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Sometimes the term \"clinically-amyopathic DM\" is used if subclinical or asymptomatic muscle disease has not been excluded with the utmost rigor.",
"   </p>",
"   <p>",
"    Antibodies to an uncharacterized protein (called CADM-140) may be seen and may be specific for amyopathic DM. In one report, these antibodies were present in eight Japanese patients with amyopathic DM, four of whom also had rapidly progressive interstitial lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/33\">",
"     33",
"    </a>",
"    ]. Further study in other populations will be needed to assess the diagnostic utility of this test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Overlap syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;DM and PM may overlap with features of other connective tissue diseases, particularly scleroderma, systemic lupus erythematosus, mixed connective tissue disease and, less often, rheumatoid arthritis and Sj&ouml;gren's syndrome. The myopathy associated with the other connective tissue diseases varies from clinically insignificant (with minimal muscle enzyme elevations and minimal inflammatory changes on muscle biopsy) to typically severe PM or DM in which myopathy dominates the clinical picture [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/4,5,34\">",
"     4,5,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of DM or PM is suggested by the above clinical findings. The medical history can help eliminate use of prescription and illicit drugs as a cause of muscle damage (eg, colchicine, statins, hydroxychloroquine, alcohol, cocaine). In addition, risk factors for HIV infection and features of connective tissue diseases should also be sought.",
"   </p>",
"   <p>",
"    Both measurement of serum muscle enzyme levels and testing for the presence of specific autoantibodies play important roles in the assessment of patients with suspected DM and PM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Muscle enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creatine kinase (CK), lactate dehydrogenase (LD), aldolase, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) are the muscle enzymes routinely measured in the evaluation of myopathy. Blood should not be drawn soon after the performance of electromyography (EMG), because the trauma associated with needle insertion into the muscle can lead to elevated serum muscle enzyme levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=see_link\">",
"     \"Muscle enzymes in the evaluation of neuromuscular diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At some point in the course of the disease, almost all patients with DM and PM have an elevation in at least one muscle enzyme; most have elevations in all enzymes. In a review of 153 patients with DM or PM, CK was normal in 5 percent, aldolase in 4 percent, LD in 9 percent and the aminotransferases in 15 to 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/4\">",
"     4",
"    </a>",
"    ]. However, these data may underestimate the frequency of normal CK concentrations, because the Bohan and Peter criteria employed in that study include muscles enzyme elevation as a criterion for the disease. In addition, the study was performed before autoantibodies and magnetic resonance (MR) imaging studies were available to facilitate diagnoses.",
"   </p>",
"   <p>",
"    In severe cases, the serum CK concentration may be elevated 50-fold. Although a correlation between the severity of the weakness and the height of elevation in serum muscle enzymes may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/5\">",
"     5",
"    </a>",
"    ], the degree of muscle dysfunction may be much greater than the enzyme levels would suggest. An important concept in the treatment of DM and PM is that therapy should be guided primarily by patients' strength, not the concentration of their muscle enzymes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"     \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The occurrence of muscle weakness with relatively normal enzyme levels is more likely to occur in DM than PM. Persistently low serum muscle enzyme levels in the setting of obvious muscle weakness may also occur in patients with advanced disease and significant loss of muscle mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antinuclear antibodies (ANA) detected by standard immunofluorescence methods are present in up to 80 percent of patients with DM or PM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Detailed autoantibody testing designed to identify the specific autoantibody responsible for the ANA pattern is much more useful. Specific autoantibody testing in the setting of inflammatory myopathies is useful in two contexts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis of connective tissue disorders associated with myositis.",
"     </li>",
"     <li>",
"      Detection of myositis-specific autoantibodies, which may offer valuable information regarding prognosis and potential future patterns of organ involvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Autoantibodies and connective tissue disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detection of anti-Ro, anti-La, anti-Sm, or anti-ribonucleoprotein (RNP) antibodies strongly suggests a diagnosis of myositis associated or overlapping with another connective tissue disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/35\">",
"     35",
"    </a>",
"    ]. As an example, anti-RNP antibodies are associated with the overlap of myositis with features of either scleroderma or systemic lupus erythematosus, a clinical entity termed mixed connective tissue disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3447?source=see_link\">",
"     \"Definition and diagnosis of mixed connective tissue disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The precise diagnosis of an underlying connective tissue disease is critical to patient management because of the prognostic and treatment implications of specific diagnoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=see_link\">",
"     \"Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link\">",
"     \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Myositis-specific autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several categories of autoantibodies directed against cytoplasmic RNA synthetases, other cytoplasmic proteins, ribonucleoproteins, and certain nuclear antigens are called myositis-specific autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/28,38-40\">",
"     28,38-40",
"    </a>",
"    ]. These autoantibodies occur in approximately 30 percent of patients with DM and PM.",
"   </p>",
"   <p>",
"    It appears increasingly likely that myositis-specific autoantibodies play specific roles in the pathophysiology of DM and PM. Although the exact role of myositis-specific autoantibodies remains unknown, it appears increasingly likely that they reflect important processes in the pathophysiology of DM and PM. In addition, a fuller understanding of myositis-specific autoantibodies is likely to reveal essential information regarding diagnosis and prognosis.",
"   </p>",
"   <p>",
"    There are three major categories of myositis-specific autoantibodies: antibodies to aminoacyl-tRNA synthetases (antisynthetase antibodies), including anti-Jo-1; antibodies to signal recognition particle (anti-SRP antibodies); and antibodies to Mi-2, a nuclear helicase.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-Jo-1 &mdash; Anti&ndash;Jo&ndash;1 antibodies are the most common myositis-specific autoantibody. Anti-Jo-1 antibodies directed against the anti&ndash;histidyl&ndash;tRNA synthetase, one of a group of enzymes that catalyze the attachment of specific amino acids to their cognate tRNAs during the process of protein synthesis. Anti-Jo-1 antibodies are strongly associated with ILD, Raynaud's phenomenon, arthritis, and mechanic's hands (",
"      <a class=\"graphic graphic_picture graphicRef56057 \" href=\"UTD.htm?41/47/42736\">",
"       picture 11",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. One study suggested correlations between anti-Jo-1-antibody levels and disease activity in patients with inflammatory myopathy, but data in the overall literature are conflicting on this point [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/41\">",
"       41",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other antisynthetase antibodies include antibodies to the OJ, EJ, PL-7, PL-12, KS, and Zo antigens [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/29,42\">",
"       29,42",
"      </a>",
"      ]. Patients who possess these other antisynthetase antibodies manifest clinical features similar to those with anti-Jo-1-antibodies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-SRP antibodies &mdash; The signal recognition particle (SRP) is involved in the translocation of newly synthesized proteins into the endoplasmic reticulum. Anti-SRP antibodies occur almost exclusively in PM. Anti-SRP antibodies are associated with severe myopathy and aggressive disease that is difficult to control, even with high-dose glucocorticoids and adjunct immunosuppressive agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=see_link\">",
"       \"Initial treatment of dermatomyositis and polymyositis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anti-Mi-2 antibodies &mdash; Anti-Mi-2 antibodies are directed against a helicase involved in transcriptional activation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/43\">",
"       43",
"      </a>",
"      ]. Among patients with DM, anti-Mi-2 antibodies are present in about 7 percent of Caucasians and 30 percent of those from Central America [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/6\">",
"       6",
"      </a>",
"      ]. They are associated with the relatively acute onset of classic DM with erythroderma and the shawl sign [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of other myositis-specific autoantibodies have been described in different populations of patients with myositis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibodies directed against hPMS-1, a DNA mismatch repair enzyme, is a myositis-specific autoantibody reported to occur in 7.5 percent of patients with myositis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both anti-Ku and anti-PM-Scl antibodies have been identified in patients with overlapping features of myositis and scleroderma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/45\">",
"       45",
"      </a>",
"      ]. Because many of these patients do not have myositis, they are sometimes termed \"myositis-associated autoantibodies\" rather than myositis-specific autoantibodies.",
"     </li>",
"     <li>",
"      Antibodies to a 140 kD polypeptide (anti-CADM-140) may be a serologic feature of amyopathic DM. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Amyopathic DM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibodies to a 155-kD protein were found in sera of 51 of 244 DM patients (21 percent), but in only 1 of 108 patients with other connective tissue diseases and no normal controls [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/46\">",
"       46",
"      </a>",
"      ]. Caucasian patients with this autoantibody had a unique HLA risk factor, DQA1*0301, and an increased frequency of the V sign rash. Patients with this autoantibody were clinically distinct from those with autoantibodies to aminoacyl-transfer RNA synthetases.",
"     </li>",
"     <li>",
"      An MSA reactive with 155 and 140 kD nuclear proteins, now known as the",
"      <span class=\"nowrap\">",
"       anti-155/140",
"      </span>",
"      antibody, has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/47\">",
"       47",
"      </a>",
"      ]. This autoantibody appears to be distinct from the anti-CADM-140 and the 155-kD antibodies described above. The",
"      <span class=\"nowrap\">",
"       anti-155/140",
"      </span>",
"      antibody was detected in 7 of 52 (13 percent) Japanese patients with DM but in none of the disease controls with PM, SLE, SSc, or idiopathic interstitial pneumonia tested. Clinical associations of the",
"      <span class=\"nowrap\">",
"       anti-155/140",
"      </span>",
"      antibody included flagellate erythema and internal malignancy, in addition to the conventional cutaneous DM findings of Gottron's papules and heliotrope rash.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Myositis-specific autoantibodies and histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies that have correlated the presence of myositis-specific autoantibodies with histopathologic features suggest that such autoantibodies are associated with a humorally-mediated immune-complex microangiopathy typical of DM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. However, anti-synthetase antibodies occur in both DM and PM.",
"   </p>",
"   <p>",
"    There also appears to be some histopathological variation according to the specific type of myositis-specific autoantibody [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/45,50\">",
"     45,50",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The histopathologic pattern of anti-Jo-1 antibody-positive patients appears to differ from that of anti-SRP antibody-positive patients.",
"     </li>",
"     <li>",
"      The histopathologic pattern of patients with the clinical phenotype of DM and either antisynthetase or anti-SRP antibodies differs from that of patients with DM who do not have these autoantibodies. For example, anti-Jo-1 antibody-positive patients have the perifascicular atrophy typical of DM but not the characteristic capillary pathology. In contrast, anti-SRP patients have the capillary pathology but not the perifascicular atrophy.",
"     </li>",
"     <li>",
"      Anti-Jo-1 patients are reported to have perimysial connective tissue fragmentation, a finding not observed in DM patients without such autoantibodies but one that is observed in fasciitis.",
"     </li>",
"     <li>",
"      Patients with anti-SRP antibodies are reported to have less intramuscular inflammation than do other patients with DM or PM.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Gene expression profiling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene expression profiling of tissue from patients with DM and controls demonstrates increased expression of various genes that share a responsiveness to induction by interferon-alpha and interferon-beta [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/16,49\">",
"     16,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunohistochemical staining confirmed an increase in the presence one gene production, human myxovirus resistance protein, in muscle fibers and microvasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition, plasmacytoid dendritic cells, were abundant in involved muscle and accounted for 30 to 90 percent of all CD4 positive cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ELECTROMYOGRAPHY AND TISSUE BIOPSIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to laboratory testing for muscle enzymes and autoantibodies, electromyography (EMG) and tissue biopsies of skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    muscle are important facets of the evaluation of patients with possible DM or PM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EMG shows evidence of increased membrane irritability in the form of a classic triad:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased insertional activity and spontaneous fibrillations",
"     </li>",
"     <li>",
"      Abnormal myopathic low amplitude, short&ndash;duration polyphasic motor potentials",
"     </li>",
"     <li>",
"      Complex repetitive discharges",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, an early finding in myopathy is that of early recruitment; ie, an increased number of motor units firing rapidly in order to produce a low level of contraction. The findings of abnormal spontaneous activity such as insertional activity, fibrillation potentials, and complex repetitive discharges can be seen in a wide range of myogenic processes, but are much more frequently seen in inflammatory myopathies.",
"   </p>",
"   <p>",
"    A normal EMG is unusual in a patient with otherwise typical DM or PM, occurring in one study in 16 of 153 patients (11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EMG abnormalities may support the diagnosis of DM or PM but are not diagnostic. Similar findings occur in various infectious, toxic, or metabolic myopathies. However, the EMG is of value in distinguishing weakness of myopathic origin from neuropathic disorders, such as amyotrophic lateral sclerosis, peripheral polyneuropathy, or myasthenia gravis.",
"   </p>",
"   <p>",
"    The EMG is also useful in directing the site of muscle biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=see_link\">",
"     \"Clinical neurophysiology\"",
"    </a>",
"    .) Because muscle involvement may not be generalized, the electromyographer should sample multiple sites before concluding that there are no myopathic changes. Highly localized disease, although atypical, sometimes occurs in DM and PM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Skin biopsy in DM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic confirmation of the diagnosis of DM should be achieved whenever possible. Biopsy of a variety of DM skin findings, including Gottron's sign, the shawl sign, and erythroderma can provide confirmation of the diagnosis in the proper clinical setting. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Skin findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, skin biopsy may seal the diagnosis and avoid the need for muscle biopsy in a patient with weakness in a pattern typical of inflammatory myopathy (symmetric; proximal greater than distal), elevation of serum muscle enzymes, and cutaneous findings characteristic of DM.",
"   </p>",
"   <p>",
"    On light microscopy, DM skin lesions usually demonstrate mild atrophy of the epidermis with vacuolar changes in the basal keratinocyte layer. A perivascular lymphoid infiltrate often prevails in the dermis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assessment by light and immunofluorescence microscopy are essential to make the histologic diagnosis of DM. Immunofluorescence reveals an interface dermatitis (deposition of complement proteins and immunoglobulin at the dermal-epidermal junction) that is generally not distinguishable on light microscopy from systemic lupus erythematosus. (However, in DM, immunoglobulin deposition as opposed to complement is less common than in lupus.) Deposits of the membrane attack complex are found along the dermal-epidermal junction and within the walls of dermal blood vessels (",
"    <a class=\"graphic graphic_picture graphicRef56483 \" href=\"UTD.htm?34/13/35038\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the majority of myositis cases, the definitive test for establishing the diagnosis of inflammatory myopathy and excluding the many other causes of muscle weakness is muscle biopsy. The biopsy should be obtained from a muscle that is weak on clinical examination. The usual muscle targets for biopsy are the quadriceps or the deltoid. Biopsying the muscle contralateral to one demonstrated to be abnormal by EMG increases the likelihood of a diagnostic biopsy.",
"   </p>",
"   <p>",
"    Muscles with severe weakness, marked atrophy, or recent EMG testing should be avoided. In addition, biopsy of the calf muscles is discouraged because of the frequency of artifactual findings in biopsies from that region.",
"   </p>",
"   <p>",
"    If physical examination and EMG fail to identify an appropriate muscle for biopsy, magnetic resonance (MR) imaging may be useful. MR may reveal areas of increased T2 signal in muscles that can then be selected for biopsy. Targeted study of the most accessible muscles (eg, deltoid, biceps, quadriceps) by MR is one approach, but whole-body imaging is another option (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51395 \" href=\"UTD.htm?43/10/44207\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'MR imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An open biopsy is preferred to a closed needle biopsy because larger specimens can be obtained and muscle fiber orientation is better preserved. Muscle biopsy via a small incision using local anesthesia and a sharp-jawed surgical instrument (conchotome) may also yield a diagnostically adequate specimen with a low complication rate.",
"   </p>",
"   <p>",
"    The efficacy of this technique was evaluated in a report in which 149 muscle biopsies were obtained from 122 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/53\">",
"     53",
"    </a>",
"    ]. Only four biopsies (2.7 percent) failed to provide an adequate sample for histologic analysis. Eighty-three percent of patients who met clinical criteria for definite or probable DM or PM had biopsies that revealed myositis.",
"   </p>",
"   <p>",
"    Proper processing of the muscle biopsy is essential. Once obtained, the muscle tissue should be preserved appropriately for later testing. Some tissue should be fixed for routine light and electron microscopy, and some tissue should be frozen in isopentane cooled in liquid nitrogen for biochemical assays. Important biochemical assays include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Testing for glycogen storage disorders and defects in lipid metabolism",
"     </li>",
"     <li>",
"      Testing for mutant proteins (Western blotting for dystrophin)",
"     </li>",
"     <li>",
"      Genetic testing",
"     </li>",
"     <li>",
"      Immunohistologic studies, eg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dystrophin for",
"      <span class=\"nowrap\">",
"       Duchenne/Becker",
"      </span>",
"      dystrophy",
"     </li>",
"     <li>",
"      Merosin for congenital muscular dystrophy",
"     </li>",
"     <li>",
"      Sarcoglycan for limb-girdle muscular dystrophy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The experience of the laboratory in processing muscle biopsy specimens correlates highly with the usefulness of diagnostic information obtained from the procedure. The team performing and processing the biopsy should be provided with detailed clinical information.",
"   </p>",
"   <p>",
"    The clinician requesting the biopsy should communicate directly with the surgeon and pathologist prior to the procedure. A set of detailed instructions for handling of muscle biopsy specimens is available at the following site:",
"    <a class=\"external\" href=\"file://www.medicine.uiowa.edu/Path_Handbook/Appendix/AnatomicPath/ex_muscle_biopsy.html\">",
"     www.medicine.uiowa.edu/Path_Handbook/Appendix/AnatomicPath/ex_muscle_biopsy.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     MR IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;MR imaging has emerged as an important technique in the clinical evaluation of patients with DM and PM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/54\">",
"     54",
"    </a>",
"    ]. MR imaging can demonstrate areas of muscle inflammation, edema with active myositis, fibrosis, and calcification. Unlike muscle biopsy, MR imaging can assess large areas of muscle, thereby avoiding problems with sampling error (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51395 \" href=\"UTD.htm?43/10/44207\">",
"     image 1",
"    </a>",
"    ). Because MR imaging is noninvasive, it has the additional advantage of permitting serial assessments, which may be useful in defining the response to therapy.",
"   </p>",
"   <p>",
"    Some centers now utilize MRI as a routine part of the evaluation of patients with inflammatory myopathy. However, these studies do not replace EMG and muscle biopsy in making the diagnosis.",
"   </p>",
"   <p>",
"    Another MR modality, MR spectroscopy, provides a view of muscle metabolism by comparing the ratio of muscle phosphorus contained in phosphocreatine to the level of inorganic phosphorus. This ratio is decreased in abnormal muscle in which the generation of high energy compounds such as phosphocreatine is reduced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6134?source=see_link\">",
"     \"Energy metabolism in muscle\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MR spectroscopy is very sensitive and has been used to detect muscle abnormalities in amyopathic DM in which muscle strength and muscle enzymes are normal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Amyopathic DM'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The precise utilities of MR spectroscopy in the evaluation and longitudinal follow-up of patients with inflammatory myopathies require further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DM and PM must be distinguished from other conditions that cause muscle weakness, with or without muscle enzyme elevation. The differential diagnosis of DM and PM includes other inflammatory myopathies, motor neuron disease, myasthenia gravis, and the muscular dystrophies. In addition, a variety of inherited, metabolic, drug&ndash;induced, endocrine, and infectious myopathies must also be considered (",
"    <a class=\"graphic graphic_table graphicRef70008 \" href=\"UTD.htm?0/23/381\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=see_link\">",
"     \"Approach to the patient with muscle weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    None of these disorders is associated with the skin lesions that are characteristic of DM. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Skin findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Inclusion body myositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inclusion body myositis (IBM) is the most common inflammatory myopathy to be misdiagnosed as PM and, in cases of \"refractory PM,\" the correct diagnosis often proves to be IBM. Distinction between these two disorders is critical because their prognoses differ significantly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to PM, IBM generally has a more insidious onset and more prominent distal muscle weakness (",
"    <a class=\"graphic graphic_table graphicRef74076 \" href=\"UTD.htm?27/13/27867\">",
"     table 2",
"    </a>",
"    ). Muscle atrophy and weakness of the wrist and finger flexors in the upper extremities and of the quadriceps and anterior tibial muscles in the legs are characteristic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/11,57\">",
"     11,57",
"    </a>",
"    ]. Furthermore, in many patients with IBM, the muscle involvement is asymmetric, particularly in the beginning.",
"   </p>",
"   <p>",
"    On average, serum muscle enzyme levels are lower in IBM than in PM, although substantial elevations may occur. The presence of typical inclusion bodies on muscle biopsy is diagnostic of this disorder, but a single biopsy lacks the characteristic histopathologic features in 20 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MR imaging findings may help to distinguish PM from IBM. Whereas MR changes suggestive of inflammation are noted along fascial planes in PM, such changes are observed throughout the muscle in IBM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/58\">",
"     58",
"    </a>",
"    ]. Fatty infiltration and muscle atrophy are more prominent in IBM than PM, perhaps owing to the longer preclinical phase and the relative refractoriness to treatment exhibited by IBM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myopathy associated with hypothyroidism can mimic the presentation of inflammatory myopathy, causing a subacute onset of proximal muscle weakness and elevated muscle enzymes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link\">",
"     \"Hypothyroid myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Drug-induced myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs can produce a myopathy that can mimic the inflammatory myopathies. These include corticosteroids, statins, antimalarials, antipsychotic drugs, colchicine, penicillamine, alcohol, cocaine, and certain antiretroviral drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"     \"Drug-induced myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=see_link&amp;anchor=H6#H6\">",
"     \"Muscle disease in HIV-infected patients\", section on 'NRTI myopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness in an HIV&ndash;infected patient presents a diagnostic challenge. In addition to causing weakness through chronic disease and cachexia, HIV infection may be associated with an inflammatory myopathy that is identical to PM. The myopathy can be either a presenting manifestation of HIV infection or occur in the later stages of infection. A myopathy may also be induced by certain antiretroviral drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=see_link&amp;anchor=H2#H2\">",
"     \"Muscle disease in HIV-infected patients\", section on 'HIV myopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Amyotrophic lateral sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyotrophic lateral sclerosis (ALS, also called motor neuron disease) has a number of clinical features that differ from DM and PM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ALS may present with distal rather than with proximal weakness, and onset is not usually symmetric.",
"     </li>",
"     <li>",
"      Long-tract signs are typically present in ALS, since there is dysfunction of both upper and lower motor neurons.",
"     </li>",
"     <li>",
"      ALS is not associated with myopathic changes on EMG because the central problem is neuronal death.",
"     </li>",
"     <li>",
"      Serum muscle enzyme levels are usually normal in ALS, although elevations of CK to the range of approximately 1000 may be observed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=see_link\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Myasthenia gravis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis is a disorder of the neuromuscular junction, caused by antibodies to the acetylcholine receptor. Although the classic physical examination finding in myasthenia gravis is muscle fatigability (the development of muscle weakness as exercise proceeds), the disease can occasionally cause diffuse weakness without prominent fatigability symptoms.",
"   </p>",
"   <p>",
"    Myasthenia gravis is distinguished from myositis by the frequent presence of facial muscle weakness, normal muscle enzymes, characteristic EMG changes, and the presence of anti&ndash;acetylcholine receptor antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to myasthenia gravis, DM and PM rarely involve the oculobulbar muscles. A condition related to myasthenia gravis known as the Lambert-Eaton syndrome, can mimic DM and PM more closely, because the oculobulbar muscles are usually spared. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Muscular dystrophy and myotonic dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscular dystrophies are an inherited group of progressive myopathic disorders resulting from defects in a number of genes required for normal muscle function. Patients with muscular dystrophy occasionally have a prominent endomysial inflammatory cell infiltrate.",
"   </p>",
"   <p>",
"    This may cause diagnostic confusion, particularly in dystrophic disorders such as limb-girdle and facioscapulohumeral muscular dystrophies. However, the inflammatory cell infiltrate in muscular dystrophy is typically limited to areas adjacent to necrotic muscle fibers, in contrast to the tendency of PM to involve nonnecrotic muscle fibers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=see_link\">",
"     \"Limb-girdle muscular dystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=see_link\">",
"     \"Oculopharyngeal, distal, and congenital muscular dystrophies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Proximal myotonic myopathy (PROMM), also known as myotonic dystrophy type 2, must also be considered in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Inherited metabolic myopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited metabolic myopathies include such disorders of carbohydrate and lipid metabolism as carnitine deficiency and myoadenylate deaminase deficiency. These diseases are characterized by intermittent episodes of acute muscle pain and tenderness, usually induced by exertion. The episodes are often accompanied by myoglobinuria with red or brown urine. Occasional patients develop chronic weakness after years of repeated acute episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link\">",
"     \"Approach to the metabolic myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other myopathies may be mimics of PM.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute viral or bacterial infections (pyomyositis), immobilization, and trauma can be characterized by acute, fulminant presentations that are often complicated by rhabdomyolysis. However, rhabdomyolysis has been described in case reports in the inflammatory myopathies [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"       \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=see_link\">",
"       \"Pyomyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Muscle weakness occurring in multiple family members is not always due to inherited metabolic defects or dystrophies, but may result from the development of idiopathic myositis in several members of the same family. The clinical features of familial idiopathic inflammatory myopathy are similar to those of sporadic disease, although the frequency of myositis-specific autoantibodies is lower with the familial disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Muscle disease that is clinically and histopathologically similar to PM has been well documented in patients with chronic graft-versus-host (GVH) disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/63\">",
"       63",
"      </a>",
"      ]. The estimated frequency is 0.6 percent. The onset of myositis is typically more than one year after transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/64\">",
"       64",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rare patients present with focal myositis that usually but not always progresses to the typical generalized form over time [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Amyloid myopathy, which can occur in immunoglobulin-related or familial amyloidosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/4/27722/abstract/65\">",
"       65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11623?source=see_link\">",
"       \"Musculoskeletal manifestations of amyloidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sarcoid myopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25752?source=see_link&amp;anchor=H3#H3\">",
"       \"Sarcoid: Muscle, bone, and vascular disease manifestations\", section on 'Myopathy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Parasitic infections, eg, trichinellosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15207?source=see_link\">",
"       \"Trichinellosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=see_link\">",
"       \"Patient information: Myositis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DM and PM are two forms of inflammatory myopathy. Overlap myositis is the occurrence of myositis in association with another connective tissue disease; eg, scleroderma, systemic lupus erythematosus, rheumatoid arthritis, or Sj&ouml;gren's syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Immunopathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic features of DM and PM include muscle fiber necrosis, degeneration and regeneration, and inflammatory cell infiltration.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In DM, the cellular infiltrate is predominantly perifascicular and often perivascular. B lymphocytes and an increased number of plasmacytoid dendritic cells are also typical of DM (",
"      <a class=\"graphic graphic_picture graphicRef76448 \" href=\"UTD.htm?4/49/4888\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In PM, the cellular infiltrate is found predominantly within the fascicle, where there are increased numbers of cytotoxic CD8+ T cells (",
"      <a class=\"graphic graphic_picture graphicRef69212 \" href=\"UTD.htm?0/43/696\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical manifestations of these inflammatory myopathies are muscle weakness and, in DM, rash.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle weakness is typically symmetric and predominantly proximal. Muscle atrophy may be present in severe, long-standing disease. Oropharyngeal and upper esophageal muscle involvement may lead to dysphagia, nasal regurgitation, or aspiration. Respiratory failure may result from weakness of the diaphragm and chest wall muscles. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Muscle weakness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rash is a feature of DM. The most common skin findings are (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Skin findings'",
"      </a>",
"      above):",
"     </li>",
"     <li>",
"      Gottron's sign, which is characterized by symmetric, roughened, erythematous skin changes over the extensor surfaces of the metacarpophalangeal and interphalangeal joints of the fingers, elbows,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      knees (",
"      <a class=\"graphic graphic_picture graphicRef70904 graphicRef50909 \" href=\"UTD.htm?5/47/5879\">",
"       picture 4A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Heliotrope rash, which is a violaceous eruption on the upper eyelids, sometimes accompanied by edema (",
"      <a class=\"graphic graphic_picture graphicRef73090 \" href=\"UTD.htm?0/26/418\">",
"       picture 5A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Shawl sign, which is a diffuse flat erythema in a shawl-like distribution over the chest and shoulder or in a V-shaped pattern over the anterior neck and chest (",
"      <a class=\"graphic graphic_picture graphicRef51164 \" href=\"UTD.htm?8/9/8351\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Erythroderma, a generalized redness that occurs at a variety of other skin sites, including the malar region and forehead (",
"      <a class=\"graphic graphic_picture graphicRef58803 \" href=\"UTD.htm?30/44/31424\">",
"       picture 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Periungual abnormalities in which the capillary nailbeds are erythematous and show vascular changes similar to those observed in other connective tissue disorders. Abnormal capillary nailbed loops may be evident, with alternating areas of dilatation and dropout (",
"      <a class=\"graphic graphic_picture graphicRef60688 graphicRef53495 \" href=\"UTD.htm?23/1/23573\">",
"       picture 9A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mechanic's hands, which are characterized by painful roughening and cracking of the skin and lateral aspects of the fingers (",
"      <a class=\"graphic graphic_picture graphicRef56057 \" href=\"UTD.htm?41/47/42736\">",
"       picture 11",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Interstitial lung disease may occur with DM and PM and also with overlap myositis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Lung disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although CK-MB elevation is not unusual, symptomatic cardiac muscle involvement is uncommon. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cardiac disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of an inflammatory myopathy is made on the basis of a combination of the clinical, laboratory, electromyography,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy findings, and exclusion of other disorders with similar features (",
"    <a class=\"graphic graphic_table graphicRef70008 \" href=\"UTD.htm?0/23/381\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Serum muscle enzyme concentrations and autoantibody tests are useful in making the diagnosis, following disease activity, and defining disease phenotypes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevations in serum creatine kinase, lactate dehydrogenase, aldolase, and aminotransferases occur in most patients. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Muscle enzymes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autoantibodies are found in a majority of patients. Antinuclear antibodies in high titer suggest the presence of another connective tissue disease. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Autoantibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among the myositis-specific antibodies, anti-histidyl-tRNA synthase antibodies (eg, the anti-Jo-1 antibody) has been associated with interstitial lung disease, Raynaud phenomenon, arthritis, and mechanic's hands, a syndrome known as the antisynthetase syndrome. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antisynthetase syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional myositis-specific autoantibodies include other antisynthetase antibodies, anti-signal recognition particle antibodies, and anti-Mi-2 antibodies. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Myositis-specific autoantibodies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyography (EMG) shows evidence of muscle irritability. EMG findings are helpful in confirming the presence of a myopathic process and in indicating which muscle groups are most involved. This information can be valuable in selecting a site for muscle biopsy. However, EMG findings are not specific for either DM or PM and the EMG is normal in about 11 percent of patients. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Electromyography'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Tissue biopsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    muscle biopsies may establish the diagnosis in DM. Muscle biopsy is the definitive test for PM, in which skin lesions are not seen.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin biopsy may be sufficient to confirm the diagnosis of DM in a patient with weakness in a pattern typical of inflammatory myopathy (symmetric; proximal &gt; distal), elevation of serum muscle enzymes, and classic cutaneous findings. A diagnostic skin biopsy in the appropriate clinical setting obviates the need for muscle biopsy. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Skin biopsy in DM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Even in clinical scenarios highly consistent with PM, muscle biopsy is essential to establishing the correct diagnosis and excluding other disorders. Open muscle biopsy is preferred to needle biopsy as the former provides larger specimens. The clinician ordering the muscle biopsy should confer with the surgeon and pathologist before the procedure. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Muscle biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance (MR) imaging may be useful if physical examination and EMG fail to identify a suitable target for muscle biopsy. MR may also be useful in the longitudinal follow-up of patients, as an adjunct test to assess treatment responses and to diagnose disease flares. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'MR imaging'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/1\">",
"      Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/2\">",
"      Plotz PH, Dalakas M, Leff RL, et al. Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med 1989; 111:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/3\">",
"      Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/4\">",
"      Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/5\">",
"      Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985; 12:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/6\">",
"      Shamim EA, Rider LG, Pandey JP, et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 2002; 46:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/7\">",
"      O'Hanlon TP, Carrick DM, Targoff IN, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006; 85:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/8\">",
"      van der Meulen MF, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/9\">",
"      Troyanov Y, Targoff IN, Tremblay JL, et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005; 84:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/10\">",
"      Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/11\">",
"      Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/12\">",
"      Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986; 314:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/13\">",
"      Goebels N, Michaelis D, Engelhardt M, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest 1996; 97:2905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/14\">",
"      Hohlfeld R, Engel AG. The immunobiology of muscle. Immunol Today 1994; 15:269.",
"     </a>",
"    </li>",
"    <li>",
"     Greenberg, SA, Amato, AA. Uncertainties in the pathogenesis of DM. Curr Opin Neurol 2004;13;356.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/16\">",
"      Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/17\">",
"      Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989; 20:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/18\">",
"      Lundberg IE. Idiopathic inflammatory myopathies: why do the muscles become weak? Curr Opin Rheumatol 2001; 13:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/19\">",
"      Sekiguchi K, Kanda F, Oishi K, et al. HLA typing in focal myositis. J Neurol Sci 2004; 227:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/20\">",
"      Stahl NI, Klippel JH, Decker JL. A cutaneous lesion associated with myositis. Ann Intern Med 1979; 91:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/21\">",
"      Yamamoto T, Nishioka K. Flagellate erythema. Int J Dermatol 2006; 45:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/22\">",
"      Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad Dermatol 1998; 39:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/23\">",
"      de Merieux P, Verity MA, Clements PJ, Paulus HE. Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis. Arthritis Rheum 1983; 26:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/24\">",
"      Marie I, Hatron PY, Levesque H, et al. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 1999; 78:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/25\">",
"      Denbow CE, Lie JT, Tancredi RG, Bunch TW. Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis Rheum 1979; 22:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/26\">",
"      Larca LJ, Coppola JT, Honig S. Creatine kinase MB isoenzyme in dermatomyositis: a noncardiac source. Ann Intern Med 1981; 94:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/27\">",
"      Badsha H, Gunes B, Grossman J, Brahn E. Troponin I Assessment of Cardiac Involvement in Patients With Connective Tissue Disease and an Elevated Creatine Kinase MB Isoform Report of Four Cases and Review of the Literature. J Clin Rheumatol 1997; 3:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/28\">",
"      Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep 2006; 8:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/29\">",
"      Betteridge Z, Gunawardena H, North J, et al. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 2007; 46:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/30\">",
"      Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sin&eacute; myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/31\">",
"      Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sin&eacute; myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 1991; 24:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/32\">",
"      Stonecipher MR, Jorizzo JL, White WL, et al. Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: dermatomyositis sine myositis? J Am Acad Dermatol 1993; 28:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/33\">",
"      Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/34\">",
"      Ringel RA, Brick JE, Brick JF, et al. Muscle involvement in the scleroderma syndromes. Arch Intern Med 1990; 150:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/35\">",
"      Reichlin M, Arnett FC Jr. Multiplicity of antibodies in myositis sera. Arthritis Rheum 1984; 27:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/36\">",
"      Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol 1996; 34:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/37\">",
"      Nimelstein SH, Brody S, McShane D, Holman HR. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore) 1980; 59:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/38\">",
"      Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/39\">",
"      Plotz PH, Rider LG, Targoff IN, et al. NIH conference. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 1995; 122:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/40\">",
"      Brouwer R, Hengstman GJ, Vree Egberts W, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001; 60:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/41\">",
"      Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007; 56:3125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/42\">",
"      Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009; 135:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/43\">",
"      Seelig HP, Moosbrugger I, Ehrfeld H, et al. The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum 1995; 38:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/44\">",
"      Casciola-Rosen LA, Pluta AF, Plotz PH, et al. The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum 2001; 44:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/45\">",
"      Jablonska S, Blaszyk M. Scleromyositis (scleroderma/polimyositis overlap) is an entity. J Eur Acad Dermatol Venereol 2004; 18:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/46\">",
"      Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54:3682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/47\">",
"      Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/48\">",
"      Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000; 68:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/49\">",
"      Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology 2002; 59:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/50\">",
"      Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/51\">",
"      Dourmishev LA, Wollina U. Dermatomyositis: immunopathologic study of skin lesions. Acta Dermatovenerol Alp Panonica Adriat 2006; 15:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/52\">",
"      O'Connell MJ, Powell T, Brennan D, et al. Whole-body MR imaging in the diagnosis of polymyositis. AJR Am J Roentgenol 2002; 179:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/53\">",
"      Dorph C, Nennesmo I, Lundberg IE. Percutaneous conchotome muscle biopsy. A useful diagnostic and assessment tool. J Rheumatol 2001; 28:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/54\">",
"      Reimers CD, Finkenstaedt M. Muscle imaging in inflammatory myopathies. Curr Opin Rheumatol 1997; 9:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/55\">",
"      Park JH, Olsen NJ, King L Jr, et al. Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. Arthritis Rheum 1995; 38:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/56\">",
"      Plotz PH. Not myositis. A series of chance encounters. JAMA 1992; 268:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/57\">",
"      Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996; 40:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/58\">",
"      Dion E, Cherin P, Payan C, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol 2002; 29:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/59\">",
"      Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol 1990; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/60\">",
"      Kim HW, Choi JR, Jang SJ, et al. Recurrent rhabdomyolysis and myoglobinuric acute renal failure in a patient with polymyositis. Nephrol Dial Transplant 2005; 20:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/61\">",
"      Caccamo DV, Keene CY, Durham J, Peven D. Fulminant rhabdomyolysis in a patient with dermatomyositis. Neurology 1993; 43:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/62\">",
"      Rider LG, Gurley RC, Pandey JP, et al. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. Arthritis Rheum 1998; 41:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/63\">",
"      Parker P, Chao NJ, Ben-Ezra J, et al. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine (Baltimore) 1996; 75:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/64\">",
"      Stevens AM, Sullivan KM, Nelson JL. Polymyositis as a manifestation of chronic graft-versus-host disease. Rheumatology (Oxford) 2003; 42:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/4/27722/abstract/65\">",
"      Mandl LA, Folkerth RD, Pick MA, et al. Amyloid myopathy masquerading as polymyositis. J Rheumatol 2000; 27:949.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5159 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27722=[""].join("\n");
var outline_f27_4_27722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H41\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENCES BETWEEN DM AND PM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bohan and Peter criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Alternative classification schemes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IMMUNOPATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Skin findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Esophageal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antisynthetase syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Amyopathic DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Overlap syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Muscle enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Autoantibodies and connective tissue disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Myositis-specific autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Myositis-specific autoantibodies and histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Gene expression profiling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ELECTROMYOGRAPHY AND TISSUE BIOPSIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Skin biopsy in DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      MR IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Drug-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Muscular dystrophy and myotonic dystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Inherited metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Immunopathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Tissue biopsies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5159\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5159|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/10/44207\" title=\"diagnostic image 1\">",
"      Polymyositis whole body MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5159|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/49/4888\" title=\"picture 1\">",
"      Muscle biopsy dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/13/35038\" title=\"picture 2\">",
"      Muscle biopsy DM IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/43/696\" title=\"picture 3\">",
"      Muscle biopsy polymyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/36/30273\" title=\"picture 4A\">",
"      Gottrons sign in DM I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/13/40145\" title=\"picture 4B\">",
"      Gottrons sign in DM II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/34/9765\" title=\"picture 4C\">",
"      gottrons sign a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/26/418\" title=\"picture 5A\">",
"      Heliotrope eruption in DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/51/41782\" title=\"picture 5B\">",
"      Heliotrope eruption b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/9/8351\" title=\"picture 6\">",
"      shawl sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/44/31424\" title=\"picture 7\">",
"      Malar rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/51/3892\" title=\"picture 8\">",
"      erythroderma d",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/5/40017\" title=\"picture 9A\">",
"      capillary nail loop a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/28/18895\" title=\"picture 9B\">",
"      capillary nail loop c",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/56/43919\" title=\"picture 10\">",
"      Periungual erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/47/42736\" title=\"picture 11\">",
"      mechanics hands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/9/25745\" title=\"picture 12\">",
"      psoriasiform change in scalp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5159|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/23/381\" title=\"table 1\">",
"      Major causes of myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/13/27867\" title=\"table 2\">",
"      IBM versus polymyositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=related_link\">",
"      Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=related_link\">",
"      Approach to the metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26694?source=related_link\">",
"      Approach to the patient with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23962?source=related_link\">",
"      Clinical manifestations, diagnosis, and grading of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3447?source=related_link\">",
"      Definition and diagnosis of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6134?source=related_link\">",
"      Energy metabolism in muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=related_link\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11626?source=related_link\">",
"      Initial treatment of dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/7/24697?source=related_link\">",
"      Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15881?source=related_link\">",
"      Limb-girdle muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=related_link\">",
"      Malignancy in dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=related_link\">",
"      Muscle disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=related_link\">",
"      Muscle enzymes in the evaluation of neuromuscular diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/22/11623?source=related_link\">",
"      Musculoskeletal manifestations of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/14/41192?source=related_link\">",
"      Oculopharyngeal, distal, and congenital muscular dystrophies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29368?source=related_link\">",
"      Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=related_link\">",
"      Patient information: Myositis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=related_link\">",
"      Pyomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25752?source=related_link\">",
"      Sarcoid: Muscle, bone, and vascular disease manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=related_link\">",
"      The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/48/13065?source=related_link\">",
"      Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15207?source=related_link\">",
"      Trichinellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_4_27723="Potential complications of acute diarrheal disease in adults";
var content_f27_4_27723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential complications of acute diarrheal disease in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Complication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated bacterial agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteremia",
"       </td>",
"       <td>",
"        Shigella species, Nontyphoidal S",
"        <em>",
"         almonella enterica",
"        </em>",
"        ,",
"        <em>",
"         Campylobacter fetus",
"        </em>",
"       </td>",
"       <td>",
"        Particular concern in HIV-infected individuals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemolytic-uremic syndrome",
"       </td>",
"       <td>",
"        Shigella species, Shiga toxin-producing",
"        <em>",
"         Escherichia coli",
"        </em>",
"       </td>",
"       <td>",
"        Shiga toxins are responsible for damage to endothelial cells and hemolytic-uremic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guillain-Barr&eacute; syndrome",
"       </td>",
"       <td>",
"        <em>",
"         Campylobacter jejuni",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reactive arthritis",
"       </td>",
"       <td>",
"        Campylobacter species, Salmonella species,",
"        <em>",
"         Shigella flexneri",
"        </em>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Regina C LaRocque, MD, MPH, and Mark Pietroni, MA, MBBChir, FRCP, DTM&amp;H.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27723=[""].join("\n");
var outline_f27_4_27723=null;
var title_f27_4_27724="ACC AHA HRS fascic block";
var content_f27_4_27724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/HRS guideline summary: Indications for permanent pacing in chronic bifascicular block",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that permanent pacing is indicated in patients with chronic bifascicular block in the following settings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Advanced second-degree AV block or intermittent third-degree AV block. (Level of Evidence: B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Type II second-degree AV block. (Level of Evidence: B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Alternating bundle branch block. (Level of Evidence: C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of permanent pacing in patients with chronic bifascicular block in the following settings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Syncope not demonstrated to be due to AV block when other likely causes have been excluded, specifically ventricular tachycardia (VT). (Level of Evidence: B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Incidental finding at electrophysiological study of a markedly prolonged HV interval (&ge;100 msec) in asymptomatic patients. (Level of Evidence: B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Incidental finding at electrophysiological study of pacing-induced infra-His block that is not physiological. (Level of Evidence: B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of permanent pacing in patients with chronic bifascicular block in the following setting:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Neuromuscular diseases, such as myotonic muscular dystrophy, Erb dystrophy (limb-girdle muscular dystrophy), and peroneal muscular atrophy with bifascicular block or any fascicular block, with or without symptoms. (Level of Evidence: C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that permanent pacing for chronic bifascicular block is not useful in in the following settings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Fascicular block without AV block or symptoms. (Level of Evidence: B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Fascicular block with first-degree AV block without symptoms. (Level of Evidence: B)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27724=[""].join("\n");
var outline_f27_4_27724=null;
var title_f27_4_27725="NonAIDS cancer SIRs";
var content_f27_4_27725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of cancer in immunosuppressed patients compared with the general population",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Cancer",
"      </td>",
"      <td class=\"subtitle1\">",
"       SIR in people with HIV/AIDS",
"      </td>",
"      <td class=\"subtitle1\">",
"       SIR in transplant recipients",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       AIDS-defining cancers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Kaposi sarcoma",
"      </td>",
"      <td>",
"       3640",
"      </td>",
"      <td>",
"       208",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cervical cancer",
"      </td>",
"      <td>",
"       1.0-22.0",
"      </td>",
"      <td>",
"       1.5-2.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Non-Hodgkin lymphoma",
"      </td>",
"      <td>",
"       22.6-353.5",
"      </td>",
"      <td>",
"       5.5-9.9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Non-AIDS-defining cancers",
"      </td>",
"      <td>",
"       1.6-2.8",
"      </td>",
"      <td>",
"       2.5-4.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Anal cancer",
"      </td>",
"      <td>",
"       19.6-50.0",
"      </td>",
"      <td>",
"       2.8-10.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bladder cancer",
"      </td>",
"      <td>",
"       0.4-4.2",
"      </td>",
"      <td>",
"       1.6-3.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Breast cancer",
"      </td>",
"      <td>",
"       0.7-1.4",
"      </td>",
"      <td>",
"       1.0-1.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Brain cancer",
"      </td>",
"      <td>",
"       0.5-4.4",
"      </td>",
"      <td>",
"       0.6-1.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Colorectal cancer",
"      </td>",
"      <td>",
"       0.9-1.4",
"      </td>",
"      <td>",
"       1.4-2.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Esophageal cancer",
"      </td>",
"      <td>",
"       0.5-2.1",
"      </td>",
"      <td>",
"       1.6-3.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Eye cancer",
"      </td>",
"      <td>",
"       1.7-2.0",
"      </td>",
"      <td>",
"       2.0-7.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hodgkin lymphoma",
"      </td>",
"      <td>",
"       3.6-18.0",
"      </td>",
"      <td>",
"       2.2-8.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Laryngeal cancer",
"      </td>",
"      <td>",
"       0.6-2.8",
"      </td>",
"      <td>",
"       1.7-2.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Leukemia",
"      </td>",
"      <td>",
"       1.8-5.3",
"      </td>",
"      <td>",
"       2.3-2.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lip cancer",
"      </td>",
"      <td>",
"       2.3-3.1",
"      </td>",
"      <td>",
"       13.0-53.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Liver cancer",
"      </td>",
"      <td>",
"       1.9-22.2",
"      </td>",
"      <td>",
"       1.1-3.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Melanoma",
"      </td>",
"      <td>",
"       0.2-1.3",
"      </td>",
"      <td>",
"       1.4-2.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Multiple myeloma",
"      </td>",
"      <td>",
"       2.2-5.0",
"      </td>",
"      <td>",
"       2.7-3.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Oropharyngeal cancer",
"      </td>",
"      <td>",
"       1.1-2.9",
"      </td>",
"      <td>",
"       2.8-5.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ovarian cancer",
"      </td>",
"      <td>",
"       0.3-4.4",
"      </td>",
"      <td>",
"       1.2-2.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pancreatic cancer",
"      </td>",
"      <td>",
"       0.7-2.9",
"      </td>",
"      <td>",
"       0.9-1.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Penile cancer",
"      </td>",
"      <td>",
"       3.9-8.0",
"      </td>",
"      <td>",
"       15.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Prostate cancer",
"      </td>",
"      <td>",
"       0.5-1.4",
"      </td>",
"      <td>",
"       0.9-1.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Renal cancer",
"      </td>",
"      <td>",
"       0.8-2.0",
"      </td>",
"      <td>",
"       4.1-8.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Respiratory tract (lower) cancer",
"      </td>",
"      <td>",
"       1.4-4.5",
"      </td>",
"      <td>",
"       1.7-2.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Skin carcinoma",
"      </td>",
"      <td>",
"       1.5-19.6",
"      </td>",
"      <td>",
"       10.7-56.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Small intestine cancer",
"      </td>",
"      <td>",
"       1.3-3.4",
"      </td>",
"      <td>",
"       1.1-11.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Stomach cancer",
"      </td>",
"      <td>",
"       0.4-2.9",
"      </td>",
"      <td>",
"       1.8-2.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Testicular cancer",
"      </td>",
"      <td>",
"       0.7-1.8",
"      </td>",
"      <td>",
"       1.3-2.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Thyroid cancer",
"      </td>",
"      <td>",
"       0.4-3.0",
"      </td>",
"      <td>",
"       0.9-8.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Uterine cancer",
"      </td>",
"      <td>",
"       0.5-0.9",
"      </td>",
"      <td>",
"       0.9-1.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vulva/vaginal cancer",
"      </td>",
"      <td>",
"       4.4-6.8",
"      </td>",
"      <td>",
"       22.2-23.9",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     *SIR = Standardized incidence ratio",
"     <br>",
"      Modified from: Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27725=[""].join("\n");
var outline_f27_4_27725=null;
var title_f27_4_27726="Eval of suspected pericard";
var content_f27_4_27726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 509px\">",
"   <div class=\"ttl\">",
"    Initial clinical and echocardiographic evaluation of patients with suspected acute pericarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 489px; height: 366px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission and modified from: Imazio M, Demichelis B, Parrini I, et al. Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. J Am Coll Cardiol 2004; 43:1042. Copyright &copy; 2004 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27726=[""].join("\n");
var outline_f27_4_27726=null;
var title_f27_4_27727="Approach to oral appliances for OSA";
var content_f27_4_27727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Multidisciplinary approach to oral appliances for obstructive sleep apnea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 594px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_4_27727=[""].join("\n");
var outline_f27_4_27727=null;
